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Hereditary polyposis and colorectal cancer
Colorectal cancer (CRC) is the second and third most common cause of cancer-related 
death in Europe and the United States, respectively [1, 2]. The development of colon and rectal 
carcinomas is strongly associated with genomic alterations and is considered to be a multistep 
process. The development of these carcinomas is initiated by the functional loss of APC activity 
and, consequently, the development of a benign polyp. This polyp has the potential to evolve 
into an in-situ carcinoma by the accumulation of additional somatic mutations in oncogenes 
(e.g. KRAS) and tumor suppressor genes (e.g. TP53) [3] (Figure 1). The development of polyps 
and subsequently CRC is not only associated with age, environmental factors and life-style, but 
also with family history [4-6]. Heritable germline aberrations can predispose to the development 
of cancer and, therefore, entire families may be at increased risk to develop cancer. For most 
cancer predisposing syndromes, patients are at an increased risk to develop specific tumor types, 
which may include CRC [7]. In order to enable proper clinical management of the families and 
individuals involved, these germline aberrations warrant identification.
 The hypothesis that cancer could be caused by heritable factors was put forward 
several centuries after the first report describing cancer as a medical disease. The Edwin Smith 
Papyrus is considered to be the first report describing cancer in humans and has been dated 
back to approximately the seventeenth century BC [8]. The terms cancer and carcinoma were 
coined by Hippocrates (460-375 BC), who believed that cancer was initiated by natural causes 
due to disturbances in the proportion of the bodily fluids (humors) [9]. In 1829, even before 
the work of Gregor Mendel was published, which is considered to be the start of modern 
genetics [10], the possible role of heritability in cancer development was suspected [11]. In 
the late nineteenth/early twentieth century, the genetic basis of cancer became evident when 
David von Hansemann and Theodor Boveri found that the amount of genetic material (i.e., 
chromosomes) differed in cancer cells compared to normal cells and, therefore, could possibly 
explain tumorigenesis [12-14]. The rapidly evolving field of human genetics in the late 1900s 
finally provided the tools to identify genetic factors underlying cancer predisposition. In 1987 
the predisposing role of the tumor suppressor gene RB1 to retinoblastoma was revealed [14, 
15], and in 1991 the first CRC predisposing gene was identified, APC [16-18]. In its mainstream, 
eventually 13 cancer predisposing genes that are strongly associated with a moderate- to high-
penetrant predisposition to CRC were identified [7].
Colorectal cancer predisposing syndromes
 CRC predisposing genes can be divided in two different subgroups, based on the 
presence or absence of polyposis in the patient (Table 1). Polyposis is defined by the constitutive 
development of multiple polyps in the colon and rectum. Polyps are benign outgrowths of tissue 
into the lumen of the colorectum, but they have the potential to evolve into an in-situ carcinoma 
by the accumulation of additional somatic mutations [3] (Figure 1). This phenomenon is known 
as the adenoma-to-carcinoma sequence and it is generally accepted now that the vast majority 
of colorectal carcinomas evolve from these adenomatous polyps [19]. In polyposis patients, 
the development of small and large polyps occurs frequently, eventually resulting in tens to 
thousands of polyps in the colon and rectum. However, only a subset of these polyps will develop 
into carcinomas. In contrast, the development of polyps in patients with a non-polyposis CRC 
predisposing syndrome is rare, but these polyps evolve rapidly into carcinomas since the polyp-
to-carcinoma sequence appears to be accelerated in these patients [20]. Below, the currently 
known non-polyposis and polyposis CRC predisposing syndromes will be discussed in more 
detail.
Non-polyposis CRC predisposing syndromes
Lynch syndrome (also known as hereditary non-polyposis colon cancer; HNPCC) is 
an autosomal dominant syndrome caused by heterozygous germline mutations in MLH1 [21], 
MSH2 [22], MSH6 [23] or PMS2 [24], or by epigenetic silencing of MSH2 due to a germline 
deletion affecting the 3’ exon of EPCAM [25]. Lynch syndrome patients are at a high risk to 
develop early-onset CRC, but the development of multiple polyps is uncommon. In addition, 
patients with Lynch syndrome are at an increased risk to develop other types of cancer, for 
example endometrial-, ovarian- and gastric cancer [26]. All currently known genes predisposing 
to Lynch syndrome (MLH1, MSH2, MSH6 and PMS2) are involved in DNA mismatch repair and, 
therefore, genome stability. The DNA mismatch repair pathway prevents the accumulation of 
single base pair mismatches and small nucleotide insertions and deletions, which are formed 
during replication of small tandem repeat sequences [27, 28]. After a somatic functional loss of 
the wild type allele, consistent with Knudson’s two-hit hypothesis [29], cells have lost the ability 
to recognize and correct these small nucleotide insertions and deletions and rapidly accumulate 
such anomalies in e.g. tandem repeat sequences like microsatellites. The accumulation of single 
base pair mismatches and small insertions/deletions in mononucleotide repeats of cancer driving 
genes, for example in APC and TGFBR2, result in an accelerated progression from hyperplastic 
epithelium to carcinoma [20, 30, 31]. As a consequence, tumors derived from Lynch syndrome 
patients harbor high numbers of single base pair mutations and are highly enriched for 
alterations in the length of tandem repeats within microsatellite repeat regions and, therefore, 
are considered hypermutated and microsatellite instable [20]. 
Polyposis and CRC predisposing syndromes
The first familial cases of polyposis were already identified in the late 1800s when 
large families with highly increased incidences of polyposis and CRC were reported [32]. During 
the third decade of the 20th century, the hypothesis was put forward that heritable factors may 
underlie the development of multiple adenomas [33]. As of yet, thirteen different polyposis and 
CRC predisposing genes have been identified (Table 1), which can be classified based on the 
histology of the polyps that predominantly develop. These syndromes are mostly associated 
with the development of hamartomatous polyps or adenomatous polyps.
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Hamartomatous polyposis predisposing syndromes
 The incidence of hamartomatous polyposis predisposing syndromes is relatively low 
and accounts for a limited percentage of all CRC cases [34, 35]. Hamartomatous polyposis 
predisposing syndromes, including PTEN hamartoma tumor syndrome, juvenile polyposis 
syndrome and Peutz-Jeghers syndrome, all exhibit an autosomal dominant inheritance pattern 
[34]. PTEN hamartoma tumor syndrome, caused by germline mutations in PTEN [36], is 
associated with the development of breast, endometrium and thyroid cancers [37], whereas 
the risk of colon cancer is not well established yet [34]. Germline aberrations in SMAD4 and 
BMPR1A, both involved in the transforming growth factor-beta (TGF-β) signaling pathway, 
predispose to the development of juvenile polyposis syndrome [38, 39]. Patients with juvenile 
polyposis syndrome are at a highly increased risk to develop CRC [40]. Patients diagnosed with 
Peutz-Jeghers syndrome carrying germline mutations in STK11 [41] are at a high risk to develop 
gastrointestinal cancers, including pancreas and colon cancer [42]. 
Autosomal dominant adenomatous polyposis syndromes
 Familial adenomatous polyposis (FAP) is the most common high-penetrant Mendelian 
syndrome which predisposes to adenomatous polyposis with an estimated incidence ranging 
from 1:8,000 to 1:37,600 [43-46]. FAP is caused by monoallelic germline mutations in the APC 
gene, and shows an autosomal dominant inheritance pattern [16-18]. An inactivating somatic 
mutation in the remaining wild type allele results in functional loss of APC activity, which is one 
of the initiating events of the adenoma-to-carcinoma sequence. The high proliferation rate in the 
colorectum leads to a substantial number of cells that accrue inactivation of the second allele, 
which explains why FAP patients usually develop hundreds to thousands of adenomatous polyps 
and, if left untreated, inevitably develop CRC [47]. In the majority of FAP patients (~95%), a 
truncating nonsense or frameshift germline mutation in the APC gene is observed [46]. In a subset 
of the FAP patients (10-25%), the germline mutation in APC appears to be de novo [48, 49]. 
The clinical manifestation of FAP is related to the genomic position of the APC 
mutation. The most severe phenotype, also known as the profuse phenotype (thousands of 
colorectal polyps), is encountered when the germline mutation in APC is located between 
codons 1250 and 1464. In contrast, the much milder attenuated FAP (AFAP) phenotype is 
caused by mutations at the 5’ and 3’ regions of the gene, and presents with <100 colorectal 
polyps and a later age-of-onset of CRC (extensively reviewed in [50]).
 Recently, a novel adenomatous polyposis predisposing syndrome has been identified, 
for which the name polymerase proofreading-associated polyposis (PPAP) has been proposed 
[51, 52]. PPAP is an autosomal dominant cancer syndrome caused by monoallelic germline 
mutations in the exonuclease (proofreading) domains of POLE and POLD1 [51]. The exact 
incidence of PPAP in the population has not been established yet, but one of the common 
germline variants in POLE, the pathogenic p.L424V variant, has been encountered with variable 
frequencies (1:67 to 1:858) in different cohorts of unexplained polyposis and/or early-onset and 
familial CRC cases [51, 53-56]. POLE and POLD1 encode the polymerases ε and δ, respectively, 
and accurate proofreading via their exonuclease domains is required to correct mispaired 
bases inserted during DNA replication. All mutation carriers identified thus far have properly 
functioning polymerase domains, but impaired proofreading activity. As a consequence, these 
patients accumulate base substitutions during life, which eventually results in the development 
of hypermutated tumors [51, 52]. Next to several large PPAP families that have been reported, 
also de novo mutations have been identified [53, 56], but the prevalence of these mutations 
remains to be determined. The exact clinical phenotype of PPAP has not been established yet, 
but available data strongly indicate that PPAP results in a high-penetrant predisposition to 
develop polyposis (on average <100 polyps) and early-onset CRC [51, 53-56].
Autosomal recessive adenomatous polyposis syndromes
 MUTYH-associated polyposis (MAP) is considered to be the second most common 
high-penetrant Mendelian cancer syndrome associated with adenomatous polyposis, with 
an estimated incidence of 1:5,000 to 1:40,000 in Europe [57]. In unselected APC mutation-
negative European adenomatous polyposis cases the incidence appears to be approximately 
15-20%. In contrast to FAP and PPAP, MAP is inherited in an autosomal recessive manner due to 
biallelic germline mutations in the MUTYH gene [58]. MAP patients lack expression of functional 
MUTYH, the base excision repair protein required for recognition and correction of mismatches 
between an oxidation-damaged guanine base and an adenine base [59]. Consequently, this 
will lead to an increased incidence of G:C to T:A transversions and an enrichment for this 
specific base substitution is, indeed, observed in tumors derived from MAP patients [58]. Both 
truncating as well as missense germline variants are frequently encountered in MAP patients 
[57], but the observed mutations strongly differ between different ethnicities [60]. For example, 
the prevalence of two pathogenic missense mutations, p.Tyr179Cys and p.Gly396Asp, ranges 
between 50% and 82% in MAP patients from European descent due to a founder effect [61], 
but has so far not been identified in Asian populations [60, 61]. Compared to FAP, MAP patients 
develop a milder phenotype and the majority of MAP patients are diagnosed with less than 100 
polyps [62]. MAP patients have an approximately 28-fold increased life-time risk to develop CRC 
compared to the general population [63], and the reported penetrance at the age of 60 ranges 
from 43 to 100% [63-65].
Missing heritability in polyposis and CRC
Despite the identification of 13 polyposis and colorectal cancer predisposing genes 
(Table 1), as yet a substantial fraction of the polyposis and familial CRC cases remains 
unexplained [55, 66]. The identification of novel polyposis and CRC predisposing genes is 
considered crucial for a proper clinical management and for reducing the mortality rates of CRC 
patients [67, 68]. It has been estimated that approximately 12-35% of the CRC cases may be 
explained by heritable genetic factors [69, 70], whereas only 2-5% of the CRC cases is explained 
by germline mutations associated with known high-penetrant CRC predisposing syndromes 
[71, 72]. Recently, it has been reported that in a cohort of 626 early-onset familial CRC cases, 
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only 14.2% could be explained by mutations in known high-penetrant CRC predisposing 
genes, suggesting that the underlying genetic defects remain to be identified in the majority 
of the cases [55]. The development of polyposis is strongly associated with high-penetrant 
heritable germline defects and, although estimates depend on the number of polyps and the 
age of diagnosis, approximately 20-30% of the polyposis cases remains unexplained [66, 73]. To 
identify novel germline aberrations that predispose to the development of polyposis and CRC, 
three previous successfully applied genetic approaches may be considered.
Genetic approaches to identify polyposis and CRC predisposing genes
Three genetic approaches have significantly contributed to the identification of cancer 
predisposing genes: linkage analysis, candidate gene analysis and genome-wide mutation 
analysis [7]. In the past, the identification of cancer predisposing genes was mainly achieved using 
linkage analyses and candidate gene analyses. Copy number variation (CNV) analysis, based on 
the identification of (small) insertions and deletions within the genome, can be considered 
as the first genome-wide analysis. The recent introduction of whole-exome sequencing (WES) 
and whole-genome sequencing (WGS), resulting in the possibility to perform genome-wide 
mutation analyses at base-pair resolution, has revolutionized this approach. Together, these 
three approaches have resulted in the identification of more than 100 moderate- to high-
penetrant cancer predisposing genes (reviewed in [7]). All three approaches have been proven 
to be successful in the elucidation of novel polyposis and CRC predisposing genes, as illustrated 
by the adenomatous polyposis predisposing genes APC, MUTYH and POLE/POLD1.
Linkage analysis
Linkage analysis represents a valuable approach to narrow down the genomic region 
that contains the aberration underlying a clinical phenotype. Linkage analysis is based on 
the assumption that not only the causative germline aberration, but also the genomic region 
surrounding this aberration, is inherited. Using polymorphic DNA markers, the genomic regions 
shared between different affected family members, but not present in unaffected family 
members, can be determined. Through statistical tests, for example the calculation of LOD 
scores [74], it can be established whether the observed results are likely to be caused by chance 
or, instead, indicate linkage of the DNA markers with the (as yet unknown) causative germline 
aberration. Large families with multiple affected and unaffected members are required to 
reduce the number of shared genomic variants and regions, and to obtain sufficient statistical 
power for linkage. 
As an example, the identification of APC as an adenomatous polyposis predisposing 
gene was based on linkage analyses in multiple families with this syndrome. Following up on a 
reported interstitial deletion of chromosome 5 in a mentally disabled patient with polyposis and 
a large desmoids tumor [75], the gene underlying FAP was assigned to chromosome 5, probably 
in the region 5q21-5q22, using several DNA markers for this chromosome in conjunction with 
multiple FAP families [76, 77]. After the identification of small deletions in this region, only 
three candidate genes remained [78], and, subsequently, pathogenic germline variants in APC 
(previously known as DP2.5) were identified in unrelated patients with FAP [16]. Simultaneously, 
others had identified six genes in the previously assigned genomic region on chromosome 5 
[17] and, subsequently, also identified germline mutations in APC in FAP patients [18]. So, using 
linkage analysis, the genomic region of the gene underlying FAP was determined after which 
the role of APC as an adenomatous polyposis predisposing gene could be established.
Candidate gene analysis
The candidate gene approach exploits functional information to select for genes that 
are expected to be associated with tumor development. By using pre-determined selection 
criteria, a limited number of candidate genes is selected and screened for an enrichment of 
germline aberrations in patient cohorts compared to matched control cohorts. These selection 
criteria can be based on the observed phenotype in the patient (e.g. chromosomal gains 
and losses in patients with mosaic variegated aneuploidy, BUB1B [79]) or the function of 
previously identified genes predisposing to similar phenotypes (e.g. the mismatch repair genes 
in Lynch syndrome, PMS2 and MSH6 [23, 24]). So far, however, no associations with cancer 
predisposition have been observed for a large number of candidate cancer predisposing genes 
[7] and, as a consequence, candidate gene approaches have been criticized, especially due to 
the lack of reproducibility of initial associations between (candidate) genetic variants and cancer 
risk [80-82]. Nevertheless, the candidate gene approach has revealed over 40 different cancer 
predisposing genes during the last decades [7].
The candidate gene approach was successfully applied to establish the adenomatous 
polyposis and CRC predisposing role of MUTYH. Al-Tassan et al. noticed that tumors derived 
from members from an adenomatous polyposis family without a germline mutation in APC were 
enriched for somatic C:G to A:T transversions [58]. It was known from previous studies that 
8-oxo-dGTP, a product of oxidative DNA damage, is highly mutagenic due to its ability to mispair 
with adenine residues, thus resulting in C:G to A:T transversions [83]. In addition, it had been 
reported that at least three genes in E. coli, mutM, mutT and mutY, could protect against these 
DNA errors [84] and the human homologs of mutM (OGG1), mutT (MTH1) and mutY (MUTYH) 
were identified [85-87]. Genetic analysis of the OGG1, MTH1 and MUTYH genes in the germline 
of members of the adenomatous polyposis family revealed that all affected members carried 
compound heterozygous pathogenic mutations in MUTYH, whereas no mutations in OGG1 or 
MTH were encountered [58]. Consequently, MUTYH -associated polyposis was identified using 
this approach.
Genome-wide analysis
 In contrast to candidate gene approaches, the entire (protein-coding region of the) 
genome can be screened for germline aberrations using genome-wide mutation analyses, 
which enables an unbiased screening for causative germline defects. High-resolution genome-
wide copy number profiling techniques (e.g. array comparative genome hybridization) have 
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enabled the detection of (small) copy number variations within the genome. This approach 
was successfully applied to the identification of causative genes for various human syndromes 
(e.g. CHARGE syndrome [88]), and similar approaches have been recommended to identify 
novel cancer predisposing genes [89]. Indeed, by using such approaches, several polyposis and 
CRC predisposing candidate genes have been identified [90, 91], including GREM1 in which 
duplications in or around the gene predispose to mixed polyposis [92]. However, a base-pair 
resolution has not been reached using these techniques and, therefore, the variant detection is 
limited to relatively small genomic insertions and deletions.
Base-pair resolution was obtained with the introduction of whole-exome sequencing 
(WES), a next generation sequencing (NGS) technique that has revolutionized the elucidation 
of causative genes underlying Mendelian diseases [93]. Using WES, the protein-coding regions 
of the genome are sequenced at base-pair resolution. Only structural genomic variations (e.g. 
complex genomic rearrangements and small copy number variants) and aberrations in non-
coding regions cannot be detected efficiently by WES [94, 95]. These disadvantages can, 
however, be overcome using whole-genome sequencing (WGS), but this approach is relatively 
expensive [93]. Nevertheless, the use of WGS is becoming increasingly common in clinical 
and research settings due to an ongoing reduction in costs [96] and WGS has already been 
successfully used for the identification of novel Mendelian disease genes (e.g. Charcot-Marie-
Tooth neuropathy and metachondromatosis [97, 98]). Due to the reduced costs and advantages 
over WES, including improved coverage of coding regions [99], WGS has emerged as a powerful 
technique to identify novel cancer predisposing genes.
 A genome-wide mutation approach was applied to identify germline mutations in the 
proofreading domains of POLE or POLD1 causing polymerase proofreading associated polyposis 
[51]. WGS has been performed on DNA derived from three family members who developed 
multiple adenomas and, subsequently, the data were filtered for non-silent variants in the 
coding sequences within shared regions of the genome. These shared regions were determined 
using pre-existing linkage data, which underlines that such data may be extremely valuable to 
identify causative germline variants in WES/WGS data. Indeed, linkage analysis has successfully 
been employed in other WGS studies as well [98]. The elucidation of polymerase proofreading-
associated polyposis indicates that WES and WGS can be applied as valuable tools to identify 
novel polyposis or CRC predisposing genes, but additional filtering strategies, for example 
based on linkage data and candidate gene selection, may be required to identify the causative 
germline variant among the vast number of variant calls in these datasets.
Recent attempts to identify novel polyposis and CRC predisposing genes 
Despite the identification of 13 polyposis and CRC predisposing genes (Table 1), a 
substantial fraction of the polyposis and familial CRC cases remains to be elucidated [55, 66]. 
During the last years, several genome-wide approaches have been applied to identify novel 
polyposis and colorectal cancer predisposing genes, but the identification of rare, high-penetrant 
germline variants appears challenging. To exclude benign germline polymorphisms from these 
analyses, variants in novel candidate predisposing genes should co-segregate with the disease 
phenotype within families, and pathogenic variants in these genes should be encountered in 
multiple unrelated affected individuals but not in healthy matched controls. Therefore, the main 
bottlenecks are incomplete co-segregation and absence of recurrency in (extended) patient 
cohorts. For example, multiple novel candidate genes have been proposed in different studies 
based on whole-exome sequencing of germline DNA derived from CRC patients [100-103] and 
genome-wide analyses of germline copy number variants in adenomatous polyposis patients 
[90], but the causality of these candidate genes remains inconclusive until replicated in other 
polyposis and/or CRC patients.
An example of a candidate gene awaiting confirmation in larger cohorts is RPS20. 
A truncating germline mutation in this gene has been associated with the development of 
hereditary non-polyposis colorectal carcinoma. This association was based on whole-exome 
sequencing of multiple affected individuals from a single family and, subsequently, in vitro 
functional assays [104]. Mutations in this gene have, however, only been encountered in a single 
family, which may be considered to be insufficient to prove causality or may be private family-
restricted [105]. Similar to the other identified novel candidate genes, further validations are 
required to reveal whether pathogenic germline aberrations in RPS20 underlie the development 
of non-polyposis colorectal carcinoma in other families as well.
Recently, two novel CRC predisposing genes have been identified using whole-exome 
sequencing and, in contrast to the previous studies, extensive co-segregation analyses in 
multiple affected families were performed. The first study reported the predisposing effects of 
heterozygous missense variants in the SEMA domain of the SEMA4A gene to the development 
of familial CRC type X [106]. In line with the recent identification of POLE and POLD1 as novel 
colorectal adenoma and carcinoma predisposing genes [51], variants in the SEMA domain of the 
SEMA4A gene were encountered in the germline of affected individuals from multiple unrelated 
families, but were rare in healthy controls, thus confirming causality [106]. Future research 
may strengthen the predisposing role of germline variants in SEMA4A, as has recently been 
shown for POLE and POLD1 [53, 56]. The second study showed that nonsense and missense 
variants in the DNA repair gene FAN1 may predispose to the occurrence of CRC [107]. In 
this study, co-segregation of germline variants in FAN1 with CRC was demonstrated in five 
independent families [107]. However, these recent discoveries only explain a limited number of 
the unexplained patients with polyposis and additional novel polyposis and CRC predisposing 
genes still await discovery.
Establishing the predisposing effect of novel candidate polyposis and CRC predisposing 
genes
 Through genome-wide analyses (e.g. CNV and WES), a large number of (benign) 
germline aberrations are usually detected. To identify causative germline aberrations, data 
filtering must be applied to reduce the amount of potential candidate genes. To this end, it 
should be determined whether an encountered aberration is rare in the general population and 
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whether this aberration has a potential deleterious effect on the encoded protein. Subsequently, 
different studies should be performed to establish if the remaining germline aberrations, 
possibly in novel candidate genes, indeed predispose to the development of polyposis and/or 
CRC. Both genetic and functional studies can be considered to achieve this goal. Using genetic 
and statistical approaches, is should be established whether the genetic aberration is strongly 
related to the development of the clinical phenotype in families and patient cohorts. Next, a 
direct molecular relation between the germline defect and the development of polyps and 
carcinomas should be established.
Genetic approaches to establish the predisposing effect of novel candidate polyposis 
and CRC predisposing genes
 Genome-wide variation data (including copy number and sequence data) usually 
contain a large number of benign germline variants. Many of these variants are common in the 
population, and a high-penetrant predisposing effect of such variants to the development of 
polyposis and CRC is considered unlikely. The overall frequency of copy number variants, small 
insertions and deletions and base substitutions, can be determined using publically available 
databases (e.g. the Database of Genomic Variants [108] and the Exome Aggregation Consortium 
(ExAC) database [109]). If a potential candidate variant is frequently encountered in one of 
these databases or other large control cohorts (MAF >5%), these variants can be considered 
to be benign without testing large cohorts of patients [110]. In addition, if the frequency of a 
germline variant exceeds the incidence of the disease, a high-penetrant predisposing effect can 
be excluded [110]. By using this filtering step, a large number of called germline variants can be 
considered to be benign and, therefore, excluded from further analysis. 
Next, the deleterious effect of the candidate germline aberrations on the function of the 
protein should be estimated. For CNVs, the function of the genes located within insertions 
or deletions is probably affected, but also genes located in close proximity of the bracketing 
breakpoints could be affected (e.g. loss of regulatory elements, promoter regions, etc.). Small 
insertions or deletions and base substitutions are considered loss-of-function events if they 
result in a nonsense mutation, affect a canonical splice site, or introduce a frameshift in the 
open reading frame of the gene. Loss-of-function mutations are considered to be damaging 
for the function of the protein. However, caution is required for loss-of-function tolerant genes 
[111], loss-of-function variants that are located at the 3’ end of the gene, canonical splice site 
variants that induce exon skipping, but do not affect the rest of the protein, and for genes that 
express multiple transcripts [110]. Various in-silico prediction tools are available to estimate the 
pathogenicity of missense variants, for example PolyPhen [112], SIFT [113] and CADD [114]. 
Although these in-silico prediction tools are helpful in interpreting the potential deleterious 
effect of missense variants, it should be noted that the accuracy of most in-silico prediction tools 
is limited to 65-80% [115]. Therefore, an estimation of the effect of the encountered variant 
on the encoded protein can be valuable to reduce the number of candidate genes, but these 
filtering steps should be used carefully.
 Co-segregation analysis is a convenient and straightforward approach to establish 
whether the remaining germline aberrations may be associated with the high-penetrant 
predisposition to develop polyposis and CRC. These studies are highly informative when 
multiple affected and unaffected family members are available. If the variant is not observed in 
all affected family members, another germline variant that predisposes to the same phenotype 
may be involved [116]. However, this scenario is rare and mostly indicates that the tested 
germline variant is not causative for the disease. Sometimes the candidate germline variant is 
present in all affected family members, but also in (a subset of) the unaffected family members. 
This may indicate that (i) the variant does not predispose to the development of the clinical 
phenotype, (ii) the unaffected subject did not develop the clinical phenotype yet or (iii) the 
germline aberration is not fully penetrant, which is the case for most CRC syndromes [71]. Co-
segregation analysis may be hampered by a limited availability of family members for genetic 
testing. Only when multiple (affected) family members are available, co-segregation analysis 
can be used to establish whether a germline aberration is likely to underlie the high-penetrant 
predisposition to disease development [117].
  Next to co-segregation analysis, it is expected that a certain variant predisposes to 
the development of polyposis and CRC when this variant is recurrently encountered in large 
cohorts of polyposis or CRC patients, but is rare in matched control cohorts. For example, the 
p.L424V variant in POLE was recurrently encountered (n = 12) in a large cohort of 3,805 patients 
with CRC, but was absent in 6,721 controls and, therefore, highly significantly enriched in 
the CRC cohort (P = 2.46 * 10−6, Fisher Exact test, one tailed) [51]. The increasing availability 
of genetic information in publicly available population databases, including the frequencies 
of numerous germline variants in populations from different ethnicities, is extremely useful 
for similar approaches. Only if a germline aberration is recurrently encountered in unrelated 
polyposis and CRC patients, but is rare or absent in controls, this variant can be considered to 
exhibit a potential high-penetrant polyposis or CRC predisposing effect.
Functional approaches to establish the predisposing effect of novel candidate polyposis 
and CRC predisposing genes
 Finally, functional studies can provide additional evidence for a germline aberration to 
predispose to the development of polyposis or CRC. Two possible approaches can be discerned. 
First, experiments can be based on commonly used models, which may vary from conventional 
in vitro cell models to in vivo animal models. Second, material derived from patients and control 
subjects can be used to determine the effect of a germline defect.
 After the establishment of the first human cancer cell line in 1951, i.e., HeLa [118], 
cell culturing has become routine in (cancer) research. A large spectrum of in vitro assays has 
been developed to measure the potential effect of genes and genomic aberrations on tumor-
associated cellular processes. Most assays rely on general characteristics of tumorigenic cells 
(e.g. decreased apoptosis, increased proliferation, etc.) and, therefore, are useful to determine 
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the general tumorigenic potential of specific genes. A PubMed search for HeLa yields almost 
85,000 hits, which illustrates the common and widespread use of this cell line. However, it 
should be noted that an abundance of genetic anomalies may be present in commonly used 
cell lines, as has been observed for HeLa cells [119, 120], which may hamper the interpretation 
of the data obtained. In addition, cell culturing does not reflect the cellular (micro)environment 
present within tissues and organs, and may thus result in biased and simplified conditions [121] 
and, therefore, potential data bias.
The cellular environment is more likely to be preserved in in vivo studies using animal 
models. Mouse models have proven to be valuable in cancer research, primarily due to a high 
similarity in physiological and pathological processes between humans and mice. For example, 
after generation of the APCmin mouse, a model in which a truncating mutation at codon 851 of 
Apc causes autosomal dominantly inherited predisposition to intestinal neoplasia development 
[122], more than 40 different APC mouse models have been reported [123]. Despite the 
fact that this model has been valuable in cancer research, discrepancies between mice and 
men regarding germline defects and concomitant phenotypes have been reported as well. 
For example, humans who carry biallelic pathogenic mutations in MUTYH are predisposed to 
develop multiple polyps and carcinomas [58]. A similar tumor predisposition was not observed in 
biallelic Myh (the MUTYH homolog) knockout mice, but only in mice deficient for both Myh and 
Ogg1 [124]. Although a second study has reported a significant increase in tumor incidence in a 
larger cohort of MUTYH-null mice [125], the polyposis and CRC phenotype was found to be less 
pronounced. We conclude that animal studies can provide valuable information regarding the 
cancer predisposing effect of particular genes, but these models are expensive and laborious, 
and the effects may differ from those observed in humans.
The majority of the disadvantages of in vitro cell models and in vivo animal models do 
not apply to ex vivo studies that use biological materials directly derived from patients. There are 
several ways to extract and in vitro establish cell and tissue cultures from patients, but here we 
will only focus on organoids and primary tumors. Using organoids and primary tumors derived 
from patients, a possible causative effect of a candidate germline aberration may be established.
The availability of colon tissue derived from patients is limited and, in the past, these tissues 
could not be grown or modified in vitro. The recent establishment of organoids has provided a 
potentially limitless source of colon tissue and, additionally, these 3D structures can be grown 
and modified in vitro. Colonic organoids are crypt-villus structures that contain all major intestinal 
cell types, are genetically stable [126], and can be maintained in long-term culture [127]. By 
using these organoids, cells that are involved in the development of polyps and carcinomas 
can be studied in a situation which is strongly reminiscent of the cellular environment in vivo. 
Recently, CRC development was modeled by introducing mutations in known CRC driver genes 
in such organoids [128, 129] using the genome engineering technique CRISPR/CAS9 [130]. By 
doing so, it was found that these organoids can be used to (i) obtain additional insight into 
the function of a gene in cells that are involved in the development of polyps and carcinomas 
and (ii) to establish the tumorigenic role of novel candidate polyposis or CRC predisposing 
genes. Next to organoids, primary patient-derived tumors may be highly informative for the 
identification of causative germline aberrations. The expression pattern and mutation status 
of the tumor can be informative for recognizing heritable polyposis and CRC predisposing 
syndromes. For example, sequencing of tumor DNA revealed that tumors derived from MAP, 
PPAP and Lynch syndrome patients are enriched for C:G to A:T transversions [58], hypermutated 
[52] or microsatellite instable [131], respectively. In addition, immunohistochemical analyses 
showed that the expression of at least one of the mismatch repair genes is lost in the majority 
of the tumors derived from Lynch syndrome patients [132, 133]. Immunohistochemical studies 
also revealed that tumors derived from FAP patients show an accumulation of β-catenin in the 
nucleus, indicative for a constitutive activation of the WNT signaling pathway. In addition, it 
was found that APC expression, consistent with Knudson’s two-hit model, was lost in more 
than 80% of the tumors [131]. In line with its initiating role in the adenoma-to-carcinoma 
sequence (Figure 1), somatic mutations in APC and accumulation of β-catenin in the nucleus 
are also frequently observed in sporadic CRCs [134, 135]. Thus, mutation spectra in polyps and 
carcinomas can be informative in cases where germline aberrations in DNA repair genes are 
involved, whereas second-hit mutation analyses can be informative when the role of a classical 
tumor suppressor is expected.
 In conclusion, there is ample evidence indicating that hereditary germline aberrations 
can predispose to the development of polyposis and CRC. However, the currently known 
predisposing genes only explain a subset of these cases and, thus, additional polyposis and CRC 
predisposing genes still await discovery. The identification of these genes is crucial for a proper 
clinical management and for reducing the mortality rate of CRC patients. In the search for 
these novel predisposing genes, several genetic approaches that were proven to be successful 
in the past, can be applied. The introduction of WES has revolutionized the field of genetics 
and enables large and unbiased genome-wide mutation screens aimed at uncovering novel 
polyposis and CRC predisposing genes. However, a vast number of possible causative variant 
calls is encountered in these studies, and elucidation of the causative germline variant appears 
challenging. Therefore, additional genetic and functional data are required to firmly establish 
whether novel germline aberrations truly predispose to the development of polyposis and 
CRC. We anticipate that the identification of novel polyposis and CRC predisposing genes is 
challenging, but can be achieved using CNV, WES and WGS analyses.
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Aim and outline of the thesis
 Despite the successful identification of polyposis and CRC predisposing germline 
aberrations, a significant subset of patients, highly suspected of a hereditary cause, still 
remains unexplained. Identification of these germline aberrations may provide novel insights 
into the pathogenesis of heritable polyposis and CRC and, in addition, enable proper clinical 
management. We anticipated that the recent introduction of novel genome-wide (sequencing) 
techniques might provide the opportunity to reveal the predisposing germline aberrations that 
still awaited discovery. Our main aim was to identify germline aberrations that contribute to the 
development of polyposis and CRC.
First, we followed up on our high-resolution genomic profiling study and revealed that 
germline aberrations in FOCAD, expressed in the epithelial cells of the colon, are significantly 
enriched in polyposis and CRC patients compared to controls (chapter 2). Next, we used 
genome-wide and targeted copy number and mutation analyses on a cohort of patients with 
non-polyposis early onset CRC, and showed the potential CRC predisposing role of heterozygous 
germline aberrations in the spindle assembly checkpoint genes BUB1 and BUB3, which was 
supported by our observation that haploinsufficiency of BUB1 results in an increased incidence 
of aneuploidies in vitro (chapter 3). Using WES, we discovered that a homozygous germline 
mutation in the BER gene NTHL1 predisposes to the development of adenomatous polyposis 
and CRC. The corresponding novel high-penetrant autosomal recessive adenomatous polyposis 
predisposing syndrome, NTHL1-associated polyposis (NAP), explained three independent 
polyposis families and enabled the identification of individuals at a highly increased risk of 
CRC (chapter 4). Subsequently, we extensively analyzed the WES dataset to establish the 
role of other known and/or novel candidate cancer predisposing genes in the development of 
adenomatous polyposis (chapter 5). After the identification of NAP, we employed a targeted 
sequencing approach to screen over 700 polyposis patients for germline aberrations in DNA 
glycosylase genes, including NTHL1, to establish the incidence of NAP and to reveal whether 
other DNA glycosylase genes may act as (high-penetrant) polyposis predisposing genes as well 
(chapter 6). We also present a large family with an autosomal dominant inheritance pattern of 
serrated polyposis and applied WES to several of its affected family members to obtain novel 
insights into the germline aberrations underlying this clinical phenotype (chapter 7). Finally, the 
impact of our results is discussed in chapter 8, as well as elaborations on future directions to 
recognize novel familial polyposis and CRC cases and novel approaches to identify additional 
candidate polyposis and CRC predisposing genes in the near future.
Figure 1. Adenoma-to-carcinoma sequence. Genetic model of colonic tumorigenesis based on an 
accumulation of mutations (depicted by lightning bolts) in tumor suppressor genes and oncogenes, as 
proposed by Fearon and Vogelstein (note: only a selection of common genetic aberrations is depicted) [3]. 
In this model, loss of APC function is considered to be the initiating event, resulting in aberrant proliferation 
of epithelial cells and the development of an adenoma (polyp). Subsequently, activating mutations in e.g. 
KRAS will accelerate the growth of the adenoma. Additional mutations in for example SMAD4, TP53 and 
PIK3CA will finally result in the formation of a full-blown carcinoma. It should be noted that the type and 
sequential occurrence of the somatic mutations varies between different tumors.
Table 1. High-penetrant polyposis or colorectal cancer predisposing syndromes and genes
Gene Cancer syndrome Mode of inheritance1 Year of discovery Polyposis
APC Familial adenomatous polyposis AD 1991 Yes
AXIN2 Oligodentia-colorectal cancer syndrome AD 2004 Yes
MUTYH MUTYH-associated polyposis AR 2002 Yes
POLD1 Polymerase proofreading associated polyposis AD 2013 Yes
POLE Polymerase proofreading associated polyposis AD 2013 Yes
BMPR1A Juvenile polyposis syndrome AD 2001 Yes
PTEN PTEN hamartoma tumor syndrome AD 1997 Yes
SMAD4 Juvenile polyposis syndrome AD 1998 Yes
STK11 Peutz-Jeghers syndrome AD 1998 Yes
MLH1 Lynch syndrome AD 1994 No
MSH2 Lynch syndrome AD 1993 No
MSH6 Lynch syndrome AD 1997 No
PMS2 Lynch syndrome AD 1994 No
1 AD: Autosomal Dominant; AR: Autosomal Recessive.
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Abstract
Heritable genetic variants can significantly affect the life-time risk to develop cancer, 
including polyposis and colorectal cancer (CRC). Variants in genes currently known to be 
associated with a high risk for polyposis or CRC, however, explain only a limited number of 
hereditary cases. The identification of additional genetic causes is, therefore, crucial to improve 
CRC prevention, detection and treatment. We have performed genome-wide and targeted DNA 
copy number profiling and resequencing in early-onset and familial polyposis/CRC patients, and 
show that deletions affecting the open reading frame of the tumor suppressor gene FOCAD 
are recurrent and significantly enriched in CRC patients compared to unaffected controls. All 
patients carrying FOCAD deletions exhibited a personal or family history of polyposis. RNA 
in-situ hybridization revealed FOCAD expression in epithelial cells in the colonic crypt, the 
site of tumor initiation, as well as in colonic tumors and organoids. Our data suggest that 
monoallelic germline deletions in the tumor suppressor gene FOCAD underlie moderate genetic 
predisposition to the development of polyposis and CRC.
Introduction
Adenomatous polyposis, the development of numerous polyps in the colon and 
rectum, is strongly associated with the prevalence of heritable genomic variants. These polyps 
have been shown to act as precursors of in-situ carcinomas. Therefore, individuals who develop 
adenomatous polyposis are considered to be at an increased risk to develop colorectal cancer 
(CRC) [1], the second most frequent cause of cancer-related death in the Western world. In 
the past, several genes have been associated with a high risk for polyposis, including APC, 
MUTYH, AXIN2, SMAD4, BMPR1A, STK11, POLD1 and POLE[2]. Although germline mutations 
in these genes underlie the majority of polyposis cases, approximately 20% of the cases remain 
unexplained[3,4]. The identification of additional heritable genomic variants will be instrumental 
for increasing our understanding of the molecular mechanisms underlying polyposis and CRC 
initiation. This, in turn, will lead to an improved clinical management of individuals and families 
at risk, including surgical removal of polyps at regular intervals during surveillances[5].
It is generally accepted that aberrant proliferation of epithelial cells in colonic crypts 
represents an initiating step in the development of polyposis and CRC, and it has convincingly been 
shown that so-called crypt base columnar (CBC) and +4 cells, both considered to be crypt stem 
cells, possess cancer initiating potential[6-8]. Due to this potential, normal intestinal proliferation 
of these epithelial cells requires strict regulation. Loss of this strict regulation may underlie the 
development of multiple polyps in the colon, as illustrated by Familial Adenomatous Polyposis 
(FAP), Juvenile Polyposis Syndrome (JPS) and Hereditary Mixed Polyposis Syndrome (HMPS)[9]. 
FAP is caused by loss of functional expression of APC, a negative regulator of ß-catenin, which 
results in increased activation of the WNT signaling pathway and transcriptional activation of 
proliferation-enhancing genes, including MYC and CCND1[10,11,12]. JPS and HMPS are both caused 
by decreased activation of the TGF-ß signaling pathway, due to loss of functional expression of 
the cytoplasmic mediator gene SMAD4 and the serine-threonine kinase type I receptor gene 
BMPR1A [13,14]. Deregulation of both the WNT and the TGF-ß signaling pathways is known to 
be associated with aberrant proliferation of epithelial cells in the colonic crypt. The proliferation 
of these cells is regulated by genes expressed in stem cell progenitor cells[15]. These latter genes 
may, therefore, act as potential polyposis or CRC susceptibility genes.
In the search for novel CRC susceptibility genes in unexplained CRC families, we 
previously screened a cohort of 41 early-onset CRC subjects with a clear positive family history 
of CRC for the presence of rare DNA copy number variants (CNVs). This screening effort revealed 
several germline CNVs in genes that are considered to be candidates for CRC susceptibility, 
such as PTPRJ and GREM1[16,17]. PTPRJ was previously identified as a CRC susceptibility gene in 
mice[18] and loss of heterozygosity (LOH) of PTPRJ has frequently been observed in early stages 
of colorectal cancer development[19]. Genome-wide association studies (GWAS) have revealed 
that GREM1-related germline variants are associated with CRC susceptibility[20,21]. In addition, it 
has been found that a 40-kb germline duplication upstream of the GREM1 locus is associated 
with an increased expression of GREM1. This duplication was found to be recurrent in hereditary 
mixed polyposis patients of Ashkenazi descent[22]. These examples clearly illustrate the power 
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of CNV screening in the identification of novel heritable genomic variants affecting the risk to 
develop polyposis/CRC.
Here, we show that the tumor suppressor gene FOCAD[23] (encoding Focadhesin; 
previously known as KIAA1797), located on 9p21.3, is recurrently affected by CNVs in early-
onset/familial CRC index patients with a personal or family history of polyposis. Previous studies 
have suggested a relatively low overall expression of FOCAD in the colon compared to other 
tissues[23]. We show that FOCAD is abundantly expressed in epithelial cells within the colonic 
crypt and that, as such, this gene may play a role in the development of polyposis and/or CRC. 
The variable numbers of FOCAD expressing cells in colonic organoids and tumors from different 
patients suggest a role of this gene in at least a subset of colonic tumors. Our findings indicate 
that intragenic deletions in FOCAD are a novel risk factor for polyposis and CRC development.
Materials and Methods
Patient and control cohorts. Our initial discovery cohort, encompassing 41 patients with 
microsatellite stable (MSS) early-onset or familial CRC, has been described previously[16]. For a 
subsequent targeted screening of the FOCAD locus, we used an independent validation cohort 
of 1,232 patients diagnosed with early-onset and/or familial CRC from the Radboud university 
medical center, Nijmegen, the Netherlands (n=89), from the Universitätsklinikum Carl Gustav 
Carus, Dresden, Germany (n=159), and from the Wellcome Trust Centre for Human Genetics, 
University of Oxford, United Kingdom (n=984). An additional unrelated validation cohort of 
38 polyposis patients from the Netherlands, who were diagnosed with at least 10 polyps and 
(i) developed serrated adenomas or (ii) developed CRC or (iii) had a positive familial history of 
polyposis, was also included. In order to exclude common copy number polymorphisms, we 
compared the patient-derived data with CNVs reported in the Database of Genomic Variants 
(http://projects.tcag.ca/variation)[24], our in-house database of copy number variants obtained 
from healthy individuals in the Netherlands (n=1,604), another control cohort encompassing 
1,880 individuals from the Nijmegen Biomedical Study[25] and our in-house database of 
genomic variants, Genome Diagnostics, department of Human Genetics, Nijmegen (n=9,000). 
To determine the frequency of (highly conserved) single nucleotide variants (SNVs) in FOCAD 
in subjects without a known history of polyposis/CRC, exome data from the Exome Variant 
Server (EVS)(n=6,500)[26] and our in-house exome sequencing database (MDI) (n=2,096) were 
retrieved. An overview of all cohorts, including the selection criteria and genomic screening 
techniques used, is provided in supplementary Table S1. All patient and control samples were 
obtained after informed consent.
Multiplex ligation-dependent probe amplification (MLPA) and genomic qPCR. MLPA 
probes were designed for the FOCAD/miR-491 locus according to guidelines provided by MRC-
Holland (Amsterdam, The Netherlands) and, subsequently, MLPA assays were performed and 
analyzed as described previously[16]. Genomic qPCR was performed on a 7500 Fast Real-Time 
PCR system (Applied Biosystems, Foster City, CA, USA) as described previously[16] using SYBR 
Green-based quantification according to the manufacturer’s protocol (Bio-Rad, Veenendaal, the 
Netherlands). Both MLPA and genomic qPCR primers are available upon request.
Real-time quantitative RT-PCR. Real-time quantitative reverse-transcriptase PCR (RT-PCR) was 
performed as described previously[27]. Briefly, cDNA was prepared from 1-2 μg of RNA through 
RT-PCR with Oligo (dT) and random primers using a RNA LA PCR kit (AMV; Takara Bio Inc, 
Shiga, Japan). Real-time quantification was performed on a 7500 Fast Real-Time PCR system 
(Applied Biosystems, Foster City, CA, USA) using SYBR Green-based quantification (Applied 
Biosystems). All experiments were performed at least in duplicate and data were normalized 
using the housekeeping gene HPRT (primer sequences available upon request).
Targeted resequencing. Amplification of the 43 coding exons of FOCAD of a selected 
number of samples of our extended cohort from the Netherlands and Germany (n=117 of 
248 samples) as well as polyposis patients from the Netherlands (n=33 of 38 samples) (see 
above) was performed using an Access Array IFC system (Fluidigm, primer sequences available 
upon request) and, subsequently, the amplified fragments were used for library preparation 
and massive parallel sequencing. Sequencing of the 117 selected cohort samples and the 33 
polyposis patient samples was performed using a 454 GS FLX sequencer (Roche) with Titanium 
series reagents and an IonTorrent semiconductor sequencer (Life Technologies), respectively. 
Data analyses were performed using the Seqnext (JSI medical systems GmbH) and NextGENe 
software packages (Softgenetics), respectively. The average depths of coverage per amplicon 
are provided in the supplementary data (Figures S1 and S2). In-silico pathogenicity predictions 
were performed using an in-house data analysis pipeline[28], PolyPhen 2.0 (http://genetics.bwh.
harvard.edu/pph2/), SIFT, Align GVGD and phyloP (Alamut version 2.1; Interactive Biosoftware, 
Rouen, France). Non-synonymous SNVs present in dbSNP, in our in-house exome database and/
or in EVS were considered non-damaging polymorphisms and, therefore, excluded from our 
analyses. Sanger sequencing was performed to confirm novel variants which fulfilled our a priori 
quality settings (Table S2).
Colonic organoids. Human colonic organoids and tumoroids were obtained and cultured as 
described previously[29]. Briefly, colonic samples were collected during endoscopies and, after 
crypt/adenoma isolation, cultured using previously described conditions[30]. 
RNA in-situ hybridization. RNA in-situ hybridization analyses were performed as described 
previously[31]. Briefly, digoxigenin-labeled RNA probes were generated using IMAGE clone 
1204456 as template (Source BioScience). Both healthy and neoplastic colonic tissues were fixed, 
embedded in paraffin and pretreated prior to hybridization. After hybridization, the detection of 
signals was performed using an alkaline phosphatase coupled anti-digoxigenin antibody.
236 CHAPTER 2 37GERMLINE DELETIONS IN FOCAD ARE ASSOCIATED WITH POLYPOSIS AND CRC
Statistics. A one-sided χ2 test with Yates’ correction was applied to determine the statistical 
significance of enrichment of FOCAD deletions in CRC patients compared to the control groups. 
Statistical significance of the RT-PCR results was determined using a two-tailed t-test assuming 
equal variances. For both tests, the predetermined level of significance was p=0.05.
Results
FOCAD deletions are recurrent in familial and early-onset CRC patients
In a previous microarray-based CNV screen of familial and early-onset microsatellite 
stable (MSS) colorectal cancer (CRC) patients (n=41), we identified an intragenic deletion 
affecting the FOCAD gene locus, which encodes the potential tumor suppressor Focadhesin 
and miRNA miR-491, in one of the index patients (patient A)[16]. In order to assess whether an 
association of FOCAD deletions with CRC development could be confirmed, we screened an 
additional cohort of familial and early-onset CRC patients (n=1,232) as well as healthy controls 
(n=1,880), using targeted MLPA analysis. This screen revealed two additional FOCAD deletions 
in the CRC patient cohort (patients B and C), but none in the healthy control cohort (Fig. 1). 
In addition, no FOCAD deletions were found to be reported in our in-house database of copy 
number variants obtained from healthy individuals in the Netherlands (n=1,604), whereas only 
a single intragenic FOCAD deletion was identified in the samples run by our array diagnostics 
pipeline at the department of Human Genetics, Nijmegen (n=9,000). Therefore, the enrichment 
of FOCAD deletions in CRC patients (2/1,232) compared to the control group (1/12,400) is 
significant (P=0.0067). Together, these results indicate that deletions in FOCAD are rare but 
recurrent in familial and early-onset CRC patients.
The open reading frame is affected in all patients with FOCAD deletions
To determine the genetic boundaries of the FOCAD deletions, we mapped the deletion 
breakpoints in each of the three patients, using a combined MLPA and genomic qPCR-based 
approach. All three deletions were found to be different in size and location, encompassing 
exons 4 to 23 in patient A, exons 2 to 14 in patient B and exons 7 to 20 in patient C (Fig. 2). 
Therefore, the miR-491 locus, located within intron 4 of the FOCAD gene, was only affected 
in patients A and B. All three deletions do affect the FOCAD gene: two deletions include exon 
4, containing the ATG start site (patients A and B), whereas the deletion in patient C results 
in a frameshift in the coding sequence and, consequently, a premature translational stop. As 
a consequence, all identified deletions encompass several exons and disturb the open reading 
frame (ORF) of FOCAD, strongly suggesting a loss-of-function scenario.
Truncating second-hit mutations are not detected in polyps and tumors of FOCAD 
deletion carriers 
Based on Knudson’s two-hit paradigm, we questioned whether loss of the remaining 
wild-type allele might be a common event in the development of polyps and tumors in FOCAD 
deletion carriers. Therefore, Sanger sequencing was performed to reveal the presence of 
truncating somatic second-hit mutations in available tumor tissues of two index patients with 
FOCAD deletions. In none out of three independent adenomas derived from patient C, nor in 
a tumor sample derived from patient B, truncating somatic mutations were identified. These 
findings suggest haplo-insufficiency, rather than a classical two-hit tumor suppressor gene 
scenario, to be the most likely mechanism underlying CRC susceptibility in these patients. 
Pathogenic FOCAD single nucleotide variants are not enriched in polyposis/CRC 
patients
Since all identified deletions result in a loss-of-function of FOCAD, we reasoned that 
pathogenic single nucleotide variants (SNVs) affecting the function of its encoded protein 
(Focadhesin) might also be enriched in early-onset or familial CRC patients as compared to 
healthy controls. No nonsense, frameshift or splice site mutations were identified in a selected 
cohort of 117 early-onset/familial CRC patients and 33 polyposis patients. We did, however, 
identify three previously unreported missense variants: p.Y759F, p.T1313A and p.S1660F (for 
all variants, see Table S3), one of which (p.S1660F) was predicted to be deleterious (Table S4). 
However, in order to draw firm conclusions about its pathogenicity additional (functional) 
evidence has to be obtained. Moreover, missense variants with similar in-silico characteristics 
have also been reported in healthy controls (Table S5).
Germline deletions of FOCAD are associated with polyposis
To reveal whether FOCAD deletion-positive patients share any phenotypic characteristics, 
the clinical data of our patients and their family members were collected and compared (Table 
1). Patient A developed over 20 polyps and a rectal microsatellite stable carcinoma at the age 
of 33. He had four relatives (second and third degree) with CRC, but both parents did not 
develop CRC (Figure S3). Co-segregation analysis revealed that the same deletion was present 
in the germline of his mother, who was not affected by polyposis or CRC at time of last contact 
(age 66). Patient B was diagnosed with CRC at 62 years of age, in addition, was found to have 
four relatives (first, second and third degree) diagnosed with CRC. Patient B developed one 
traditional adenoma, her sister developed three adenomas and two hyperplastic polyps and her 
son was diagnosed with two hyperplastic polyps (Figure S3). Also patient C had a family history 
positive of CRC, i.e., three relatives (first and second degree) were affected (Figure S3). He was 
diagnosed with adenomatous polyps at 64 years of age and had a well-documented history of 
constitutive polyp development for at least seven years. Therefore, in addition to familial CRC, 
these FOCAD deletion carriers appear to share a personal or family history of polyposis.
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FOCAD is expressed in epithelial cells of the colonic crypt
 Based on information available in public databases and published data[23], FOCAD 
appears to be ubiquitously expressed in almost all tissues, with highest levels in brain and 
relatively low levels in colonic tissues and localization of the encoded protein Focadhesin in 
the focal adhesion complex has been shown [23]. To address the question whether FOCAD may 
execute a biologically relevant role within the colon, we determined its expression level and 
pattern in normal colonic tissue. Using real-time quantitative RT-PCR, we indeed confirmed that 
the overall expression level of FOCAD in colonic tissue is relatively low (Fig. 3a). Since normal 
colonic tissue contains several cell types not directly associated with colonic tumorigenesis (e.g. 
myofibroblasts, endothelial cells and nonpericryptal fibroblasts), we set out to determine the 
expression of FOCAD in human colonic organoids. Human colonic organoids originate from 
crypt base columnar (CBC) stem cells and form in vitro crypt-villus-like structures without a 
mesenchymal niche and, therefore, only contain epithelial cells known to be involved in CRC 
development. We found that the expression level of FOCAD is higher in organoids compared 
to normal colonic samples (~12 fold on average, normalized on HPRT) (Fig. 3b), which indicates 
that FOCAD is primarily expressed in epithelial cells within the colon. By subsequently employing 
RNA in-situ hybridization (ISH), we again found that FOCAD is expressed in the epithelial cells 
within the colon (Fig. 3c). Our findings show that FOCAD is expressed in colonic epithelial 
cells which may be involved in tumor formation and, therefore, FOCAD may act as a tumor 
suppressor in polyposis and CRC.
Variable expression of FOCAD in tumors and tumoroids
To explore the expression pattern of FOCAD in CRC samples, we initially compared 
the expression levels of this gene in 12 matched normal and primary tumor tissues using 
quantitative RT-PCR. This analysis revealed variable, but overall increased levels of FOCAD 
expression in the tumors (Fig. 4a). However, when expression levels were compared between 
organoids and patient-matched tumoroids, which are the tumorigenic equivalents of human 
colonic organoids originating from adenocarcinoma stem cells[30], no differences were observed. 
In fact, some tumoroids even showed a significantly reduced expression of FOCAD compared 
to their matched organoids (Fig. 4b). Next, we applied RNA in-situ hybridization to multiple 
primary colonic tumor tissues and revealed that the number of FOCAD expressing cells differs 
between different tumors (Fig. 4c). This difference in FOCAD expressing cells may explain the 
observed differences in FOCAD expression levels in tumor samples, and suggests an enrichment 
of a specific epithelial cell sub-type in some tumors. The exact nature of these cells, however, 
still needs to be defined. Taken together, our results show that cells expressing FOCAD are 
present in most tumors and that, in accordance with the absence of second-hit mutations, 
complete loss of expression of FOCAD in colonic tumors is not likely to be a common event in 
CRC development.
Discussion
Our data show that rare intragenic deletions in the FOCAD gene recurrently occur in 
familial and early-onset colorectal cancer (CRC) patients and that these deletions are significantly 
enriched in patient cohorts compared to unaffected control cohorts (P=0.0067). Furthermore, 
we noticed that germline FOCAD deletions may be associated with a polyposis phenotype, 
since multiple polyps were observed in all affected individuals or their family members. This 
observation is in agreement with a recent report in which three individuals with attenuated 
polyposis were described carrying a deletion or truncating mutation in FOCAD[32] (Figure 2). In 
addition, a constitutional monoallelic deletion in the FOCAD gene has recently been reported in 
an early-onset breast cancer patient[33], and recurrent deletions and somatic point mutations in 
FOCAD have been observed in sporadic cases of other cancer types[34,35,36,37] (Figures 2 and S4). 
These somatic and constitutional deletions in FOCAD substantiate its putative role as a novel 
cancer (susceptibility) gene.
Polyposis/CRC susceptibility factors can be divided into very rare variants with a high 
penetrance[38], intermediate to rare variants with a moderate penetrance[16] and common 
variants with a low penetrance[39]. Extensive co-segregation analyses within the families reported 
here could, unfortunately, not be performed due to a lack of material from the affected, 
often deceased, family members. However, since this germline deletion was also found to be 
present in a non-affected control and in the non-affected mother of patient A, we conclude 
that germline FOCAD deletions are not fully penetrant and that additional germline variants 
may act as modifiers, as has, for example, been reported previously for APC and MLH1[40,41]. 
Indeed, our patient with the earliest age of onset (Patient A, 33 years) was found to harbor 
a de novo pathogenic germline mutation in the exonuclease domain of POLE, p.Leu424Val, 
which may explain the early age of onset compared to the other polyposis/CRC patients with a 
germline deletion in FOCAD. Rare variants such as FOCAD deletions with moderate penetrances 
may, however, still account for a significant number of the unexplained hereditary polyposis/
CRC cases, which can now easily be identified through the availability of efficient and robust 
detection methods[28,42,43].
To further assess whether FOCAD may play a role in polyposis and CRC development, 
we determined the expression pattern of this gene in healthy colonic tissues, including in vitro 
cultured organoids. Based on information available in public databases and published data[23], 
FOCAD appears to be ubiquitously expressed in almost all tissues, with highest levels in brain. 
Here, we show that FOCAD is expressed in epithelial cells within the colon. Since normal colonic 
tissue contains several non-epithelial cell types, the overall expression of FOCAD is relatively low. 
This observation is in line with the observed relatively high expression of FOCAD in organoids, 
which consist of only colonic epithelial cells. The high expression levels of FOCAD in epithelial 
cells within the colon is also in line with its potential role as novel polyposis/CRC susceptibility 
gene, since aberrant proliferation of epithelial cells in colonic crypts is considered to be an 
initiating step in the development of polyposis/CRC.
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All encountered deletions affect the open reading frame (ORF) of FOCAD and 
previously published data have shown that Focadhesin, the FOCAD-encoded protein, acts as 
a tumor suppressor [23]. The observed germline deletions strongly suggest a loss-of-function 
scenario, but somatic second-hit mutations could not be identified in the tumor and adenoma 
samples tested (from patients B and C, respectively) and RNA-ISH on sporadic colonic tumors 
revealed that loss of FOCAD expression is not a common event in colonic tumorigenesis. These 
findings may point towards a haplo-insufficiency scenario. On the other hand, complete loss 
of FOCAD expression due to homozygous FOCAD deletions has been reported in glioblastomas 
[23] and breast cancers[36]. In addition, somatic second hit mutations in FOCAD were reported 
in an individual with attenuated polyposis[32]. Together, these data suggest that FOCAD is a 
tumor suppressor gene that can be subject to either a classical two-hit or a haplo-insufficiency 
scenario. In the epithelial cells of the colon loss of one allele of this gene may already underlie 
the development of polyposis and CRC.
The lack of enrichment of deleterious germline single nucleotide variants (SNV) in the 
FOCAD gene in our CRC cohorts is remarkable, since overall such variants are more frequent in 
CRC predisposing genes as compared to deletions[42,44]. Protein truncating FOCAD variants are 
very rare in the normal population, i.e., only two identical nonsense variants were identified in 
our in-house exome database (n=2,096) and truncating variants were only observed in a small 
percentage of subjects (<0,07%) listed in the ExAC database [45] (Figure S4). In contrast to our 
results, it has been reported that targeted sequencing of 192 polyposis/CRC patients revealed 
potentially truncating germline SNVs in two attenuated polyposis patients[32]. We assume 
that our strictly selected cohort was too small and/or heterogeneous to reveal a significant 
enrichment of truncating variants in the FOCAD gene.
Previously published data have shown that Focadhesin serves as a novel component 
of the focal adhesion complex[23]. Although the exact function of Focadhesin remains to be 
established, components of the focal adhesion complex, such as the focal adhesion kinase 
(FAK), have already been linked to intestinal tumorigenesis[46]. Similar to the role of FAK in 
intestinal tumor development, Focadhesin does not only act as a novel interaction partner for 
the focal adhesion complex, but also exerts crucial functions in cell survival and proliferation, as 
illustrated by its negative effect on tumor growth[23]. Thus, like other components of the focal 
adhesion complex, a role of Focadhesin in the regulation of cell proliferation and, therefore, 
tumorigenesis is assumed.
In conclusion, we show that FOCAD germline deletions are recurrent and significantly 
enriched in patients with a positive (familial) history of polyposis/CRC. All identified deletions 
affect the ORF, suggesting a loss-of-function scenario. The enhanced expression of FOCAD in 
epithelial cells within colonic crypts suggests a regulatory role of this gene in the proliferation 
of potentially tumor-initiating colonic stem cells. We conclude that FOCAD may serve as a novel 
polyposis/CRC susceptibility gene.
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Table 1. Overview of clinical phenotypes of carriers of mono-allelic FOCAD deletions. 
Patient A B C
Gender Male Female Male
Age of Onset 33y 62y 64y
CRC Yes Yes No
Polyposis >20 polyps Son and sister with polyps Constitutive polyp development
#Relatives with CRC 4 4 3
FOCAD exons deleted 4 to 23 2 to 14 7 to 20
Figure 1. Confirmation and identification of genomic deletions in the FOCAD gene. Confirmation of 
the genomic deletion by MLPA in germline DNA of patient A (index patient) and identification of genomic 
FOCAD deletions by MLPA in the germline of patient B and C (extended cohort). Three controls were 
included in the MLPA assay. ex: exon.
Figure 2. Diagram of germline FOCAD deletions all affecting the ORF. The upper line schematically 
represents the FOCAD gene, its exons (1-46) and the location of the miR-491 locus therein (intron 4). Bars 
represent the deletions identified in each patient (A-C). Deletions (bars) and truncating mutations (arrow 
heads) depicted in grey have been encountered in an early-onset breast cancer (BC) and three attenuated 
polyposis patients, respectively (see references 32 and 33).
Figure 3. Expression of FOCAD in normal colonic tissue. A) Relative average expression of FOCAD 
in normal colonic tissue normalized to household gene HPRT (n=12). B) Expression levels of FOCAD in 
normal and organoid samples (average expression of 12 and 5 tissue samples, respectively). C) RNA in-situ 
hybridization reveals expression of FOCAD (red arrowheads) in epithelial cells within the colon. Left-Right: 
10x and 20x magnification, respectively.
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Figure 4. Expression of FOCAD in colonic cancerous tissue. A) Expression levels of FOCAD in normal 
and matched tumor samples (n=12), normalized to housekeeping gene HPRT. B) Expression levels of 
FOCAD in organoid and patient-matched tumoroid (n=5). C) RNA in-situ hybridization for FOCAD in colonic 
tumor samples. Upper panels: large numbers of FOCAD expressing epithelial cells are observed in tumor 
sections (4x and 10x magnification). Lower Panels: Microarray tumor sections show that the amounts of 
FOCAD expressing cells (red arrowheads) vary between colon tumors of different patients (4 samples, 10x 
magnification). Tumors derived from germline FOCAD deletion carriers could not be included in this analysis. 
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Table S2) Quality settings applied for variant calling using the SeqNext and NextGENe software 
package. 
Software Package SeqNext NextGENe
#samples/barcode 1 3/4
Min. % var. reads >25% >7%
Min. coverage (reads) ≥5 ≥5
Max. recurrent genomic position1 <9 -
Max. recurrent mutation call1 - <4
 
1) To exclude sequencing artifacts from further analysis, variants recurrently called in multiple samples were 
discarded. Based on software package, filtering was performed for recurrent genomic positions or mutation 
calls, respectively.
 
Table S3) Variants identified by targeted amplicon resequencing of FOCAD in early-onset CRC 
and polyposis. 
Cohort Chr. position mRNA Change1 AA Change %Var.reads2 #Var.reads Validation3
Early-onset CRC chr9:20,778,727 c.954A>G p.L318L 42 26 Synonymous
Early-onset CRC chr9:20,865,973 c.2104A>G p.K702E 30 11 EVS
Early-onset CRC chr9:20,874,765 c.2276A>T p.Y759F 39 14 Validated
Early-onset CRC chr9:20,881,957 c.2405C>T p.A802V 73 132 EVS
Early-onset CRC chr9:20,885,204 c.2600A>G p.Q867R 60 128 EVS
Early-onset CRC chr9:20,929,531 c.3253G>A p.V1085M 66 33 EVS
Early-onset CRC chr9:20,933,030 c.3335A>C p.E1112A 47 30 EVS
Early-onset CRC chr9:20,933,030 c.3335A>C p.E1112A 26 23 EVS
Early-onset CRC chr9:20,944,629 c.3411G>A p.T1137T 76 35 Synonymous
Early-onset CRC chr9:20,949,663 c.3937A>G p.T1313A 57 26 Validated
Early-onset CRC chr9:20,981,542 c.4495C>T p.P1499S 48 11 EVS
Early-onset CRC chr9:20,988,403 c.4979C>T p.S1660F 60 15 Validated
Early-onset CRC chr9:20,988,423 c.4999G>A p.D1667N 88 22 EVS
Early-onset CRC chr9:20,988,423 c.4999G>A p.D1667N 39 7 EVS
Early-onset CRC chr9:20,988,423 c.4999G>A p.D1667N 40 8 EVS
Early-onset CRC chr9:20,990,164 c.5047G>A p.A1683T 55 44 EVS
Early-onset CRC chr9:20,995,584 c.5362G>C p.E1788Q 54 38 MDI
Polyposis chr9:20,764,889 c.516A>G p.Q172Q 18 19 Synonymous
Polyposis chr9:20,881,957 c.2405C>T p.A802V 19 26 EVS
Polyposis chr9:20,988,423 c.4999G>A p.D1667N 23 54 EVS
Polyposis chr9:20,990,164 c.5047G>A p.A1683T 17 25 EVS
1) NM_017794.3 
2) #samples/barcode varies between early-onset CRC- and polyposis cohort; see supplementary table S2.
3) Synonymous variants and variants present in exome data from the Exome Variant Server (EVS) were not 
validated by Sanger Sequencing. 
Table S4) In silico prediction of three previously unreported missense variants in the FOCAD 
gene.
mRNA 
change1
Protein 
change
PhyloP 
score
Align GVGD 
score
SIFT 
score
PolyPhen 
score
c.2276A>T p.Y759F 3.112 C0 (GV: 43.96 - GD: 0.00) 0.2 (Tolerated) 0.018 (Benign)
c.3937A>G p.T1313A 0.453 C0 (GV: 215.31 - GD: 0.00) 0.7 (Tolerated) 0.000 (Benign)
c.4979C>T p.S1660F 2.872 C15 (GV: 94.81 - GD: 93.27) 0.01 (Deleterious) 0.963 (Probably Damaging)
1) NM_017794.3
2) Moderately conserved nucleotide 
3) Weakly conserved nucleotide
Table S5) In silico prediction scores of potential pathogenic missense variants called in the EVS 
database. 
N mRNA change1
Protein 
variant
PhyloP 
score
Align GVGD 
score
SIFT 
score
PolyPhen 
score
1 c.1874C>A p.P625Q 4.732 C25 (GV: 26.87 - GD: 74.28) 0.01 4 0.999 5
2 c.2276A>G p.Y759C 3.113 C35 (GV: 43.96 - GD: 191.71) 0.00 4 0.998 5
1 c.2434G>C p.G812R 5.772 C15 (GV: 206.04 - GD: 124.98) 0.00 4 1.0 5
1 c.2441C>T p.P814L 5.772 C65 (GV: 0.00 - GD: 97.78) 0.00 4 1.0 5
1 c.2653C>T p.R885C 3.843 C65 (GV: 0.00 - GD: 179.53) 0.00 4 1.0 5
1 c.2719G>A p.G907R 3.923 C25 (GV: 60.00 - GD: 97.30) 0.01 4 1.0 5
2 c.3118C>T p.R1040C 4.243 C55 (GV: 26.00 - GD: 177.62) 0.00 4 1.0 5
1 c.3260T>G p.I1087S 4.972 C55 (GV: 21.28 - GD: 141.80) 0.00 4 0.966 5
1 c.4394A>G p.Y1465C 2.633 C25 (GV: 83.33 - GD: 155.12) 0.01 4 0.999 5
1 c.5074C>T p.L1692F 5.452 C15 (GV: 0.00 - GD: 21.82) 0.00 4 1.0 5
1 c.5150G>T p.G1717V 3.683 C65 (GV: 0.00 - GD: 109.55) 0.00 4 1.0 5
N) Specific variant counts in the EVS database.
1) NM_017794.3
2) Highly conserved nucleotide 
3) Moderately conserved nucleotide
4) Deleterious
5) probably damaging
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Figure S1. Average depth of coverage per FOCAD amplicon obtained with 454 targeted amplicon 
resequencing of 117 patients with early-onset CRC. CDS: coding sequence of the FOCAD gene.
Figure S2. Average depth of coverage per FOCAD amplicon per barcode obtained with IonTorrent 
targeted amplicon resequencing of 33 polyposis patients. 14 barcodes were used and, therefore, 
2 or 3 patient samples were pooled per barcode. As a consequence, depicted average coverage is the 
accumulative coverage of 2 or 3 patient samples. CDS: coding sequence of the FOCAD gene.
Figure S3. Pedigrees of FOCAD deletion patients. a) pedigree of patient a, b) pedigree of patient 
b and C) pedigree of patient C. arrows indicate index patients. dots, half filled symbols and filled 
symbols represent individuals who developed polyps, CrC and both polyps and CrC, respectively. 
numbers represent age of onset.
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Figure S4. Germline and somatic variants in the FOCAD gene. A) Depicted are all truncating variants 
encountered in the ExAC database[45] (germline) and COSMIC database[37] (somatic) in the FOCAD gene. 
B) All germline truncating variants depicted in (A) are only observed at low minor allele frequencies. The 
most frequently encountered truncating variant, affecting a canonical donor splice site (c.2625+2T>C), was 
observed 7 times in the ExAC database (MAF 0.000057).
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The spindle assembly checkpoint (SAC) controls proper chromosome segregation during 
mitosis and prevents aneuploidy, a hallmark of cancer. We performed genome-wide 
and targeted copy number and mutation analyses in germline DNA of 208 patients with 
familial or early-onset (≤40) colorectal cancer (CRC), and identified haploinsufficiency 
or heterozygous mutations in the SAC genes BUB1 and BUB3 in 2.9% of them. Next to 
CRC, these patients exhibited variegated aneuploidies in multiple tissues and variable 
dysmorphic features. Our results indicate that mutations in BUB1 and BUB3 cause 
mosaic variegated aneuploidy and increase the risk of CRC at young age.
Chromosomal aneuploidies are common in cancer and may exert oncogenic effects.1,2 
The spindle assembly checkpoint (SAC) controls correct chromosome segregation by delaying 
anaphase onset until all chromosomes are properly attached to mitotic spindles. Studies in 
mice have shown that proper SAC functioning is highly dependent on the strictly orchestrated 
expression of its components and that an imbalance of one of these components can lead to 
aneuploidies and tumor formation.3,4,5,6 In humans, biallelic mutations in the SAC component 
BUB1B cause Mosaic Variegated Aneuploidy (MVA) syndrome (OMIM: 257300), which is marked 
by developmental abnormalities, MVA, and a predisposition to develop childhood cancer.7,8 
Recently, it was found that milder BUB1B mutations may lead to an increased risk of developing 
gastrointestinal tumors.9
We performed high-resolution genome-wide copy number profiling in patients 
diagnosed with non-polyposis, mismatch-repair (MMR) proficient CRC before or at the age 
of 40 (n=39) and identified a heterozygous germline microdeletion in chromosome 2q13 in 
a patient who developed CRC at the age of 37 (patient 1, Table 1).10 This ~1.75 Mb deletion 
encompasses 10 genes, including BUB1 (Figures 1A and S1A). BUB1 is an integral component 
of the SAC, and disruption of this complex may result in chromosomal missegregation.11,12 
Cytogenetic analyses of lymphocytes and primary skin fibroblasts revealed variegated 
aneuploidies and structural abnormalities in 38% and 35% of the metaphases, respectively 
(Figure S2A). Real-time quantitative PCR and Western blot analyses showed that BUB1 mRNA 
and protein levels were reduced by ~50% in lymphoblastoid cells and fibroblasts compared to 
age-matched controls, suggesting haploinsufficiency. Immunofluorescence analyses confirmed 
normal BUB1 localization at the kinetochores (Figure S3). In addition, we identified 10 similar 
2q13 microdeletions in 10,139 patients with congenital abnormalities, as previously described 
by Yu et al.13 Cytogenetic analyses of four of these cases revealed low levels of MVA in one case 
and premature sister chromatid separation in another case (Figure S4).
To reveal whether haploinsufficiency of BUB1 is responsible for the chromosome 
segregation defects observed, we generated an isogenic HCT116 cell line with a monoallelic 
disruption of BUB1 (Figures S1B-C). Cytogenetic analysis of HCT116-BUB1+/- revealed a gain 
of one or more chromosomes in 11% (range: 47-53) and a loss of one or more chromosomes 
in 38% (range: 43-45) of the metaphases, which is significantly increased compared to the 
parental HCT116-BUB1+/+ cells (losses in 26.3% of the metaphases; Figure 1B). These results 
support a causal relationship between BUB1 haploinsufficiency and the occurrence of variegated 
aneuploidy.
Subsequent whole-exome sequencing of 10 Dutch and 23 Chinese patients with early-
onset CRC revealed three additional mutations: a nonsense substitution in BUB1 (patient 2, 
age 34, p.Gln16*), a 1-bp deletion in BUB1 (patient 3, age 31, p.Gln949fs), both predicted to 
result in nonsense-mediated decay, and a highly conserved non-synonymous missense mutation 
in another SAC gene, BUB3 (patient 4, age 29, p.Phe264Leu; Figures 1C-D). Subsequently, we 
performed targeted copy number and mutation screening of a replication cohort of 146 familial 
or early-onset CRC patients, and 28 unsequenced samples from the initial cohort (n=39), and 
identified two missense variants in BUB3 that were absent in 1,154 controls, and were predicted 
to be pathogenic. One of these variants (patient 5, age 32, p.Lys21Asn) was found to be 
located in the core of the protein, whereas the second variant (patient 6, age 38, p.Arg149Gln) 
was predicted to destabilize one of the protein-interacting domains (Figures 1C-F). Next, we 
performed cytogenetic analyses of lymphocytes and primary skin fibroblasts of patients 4 and 5 
(Figure S2A). Patient 4 revealed variegated aneuploidies and structural abnormalities in 27% of 
the lymphocytes and a mosaic (50%) trisomy 8 in fibroblasts, which was absent in lymphocytes, 
normal colon, and tumor tissue (data not shown). In patient 5 variegated aneuploidies and 
structural abnormalities were observed in 23% and 6.6% of lymphocytes and fibroblasts, 
respectively. In contrast, on average only 5% of the lymphocytes from 10 healthy controls 
revealed aneuploidy, without chromosome gains or structural rearrangements (Figure S2B). 
Furthermore, two mutation carriers (patients 1 and 2) presented with anomalies reminiscent of 
MVA syndrome (Table 1). Familial histories for cancer revealed that 8 out of 12 parents of the 
patients were diagnosed with cancer (full description in the supplementary files and Figure S5A).
Our data suggest that mutations or haploinsufficiency of the SAC genes BUB1 and BUB3 
increase the risk to develop MVA in multiple tissues and CRC at a young age. The association 
between haploinsufficiency of SAC genes, MVA and cancer predisposition is supported by studies 
in mouse and human.3,9,12 The high mitotic rate of cells in the gastrointestinal tract may give rise 
to an increased cancer risk, but SAC gene defects may also increase the risk to develop other 
cancer types, such as lung cancer (patients 2 and 4). One of the BUB1 mutation carriers (patient 
2) also carries a pathogenic germline MLH1 mutation, which is associated with Lynch syndrome, 
and all four of his tumors showed loss of both MLH1 and PMS2 expression. Segregation analysis 
in three siblings of patient 2 (Figure S5B), led to the identification of an MLH1 mutation-positive, 
BUB1 wild-type, sister who did not develop cancer at the age of 58. We, therefore, hypothesize 
that BUB1 haploinsufficiency may have contributed to the development of multiple tumors in 
patient 2 by increasing the risk of losing of the wild-type MLH1 allele, as has been shown in 
mouse models5. Thus BUB1 may have acted as a modifier gene in CRC development in this 
patient. Unfortunately, most parents of the BUB1 or BUB3 mutation carriers were deceased 
and two families were no longer available for performing segregation analysis. Therefore, the 
identification of new families with BUB1 or BUB3 germline mutations in larger cohorts of CRC 
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patients will be necessary to accurately estimate the lifetime cancer risk of these carriers.
In summary, we report a novel class of mutations that is associated with an increased 
risk to develop CRC. Next to the previously reported SAC component BUB1B, we show that 
heterozygous germline mutations in BUB1 or BUB3 recurrently occur in early-onset CRC cases. 
These cases present with a heterogeneous clinical phenotype reminiscent of MVA syndrome.7,8 
Further delineation of these features will provide a basis for improved recognition of individuals 
with SAC component anomalies and targeted prevention of primary and secondary cancers in 
carriers of such mutations.
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Figure 1. Identification of constitutional variants in BUB1 and BUB3. (A) A ~1.75 Mb deletion affecting 
BUB1 in patient 1. (B) Monoallelic disruption of  BUB1 in HCT116 cells causes chromosomal segregation 
defects. The percentages of cells with a chromosome loss, gain, or normal chromosome number in parental 
HCT116-BUB1+/+ (n=129) and haploinsufficient HCT116-BUB1+/- (n=134) cells are shown. Haploinsufficient 
HCT116-BUB1+/- cells exhibit a significantly higher percentage of aneuploidies than parental HCT116-
BUB1+/+ cells. Error bars represent SD values; *P-value<0.05; **P-value<0.01. (C) Localization of the variants 
(in red) identified in BUB3. (D) Close-up of residue 264: the replacement of a phenylalanine (green) by 
a leucine (red) may cause steric hindrance, thereby disturbing hydrophobic interactions. (E) Close-up of 
residue 21: a lysine (green) is replaced by an asparagine (red) and predicted to cause loss of interaction of 
residues (blue) in adjacent WD40 domains. (F) Close-up of residue 149: an arginine (green) is replaced by 
a glutamine (red). The predicted local conformational changes may affect interactions with other proteins.
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Materials and MetHods 
Study cohorts - In the discovery phase of this study, we used a cohort of 62 colorectal cancer 
(CRC) cases, without obvious polyposis, diagnosed at age 40 years or younger referred to 
the department of Human Genetics of the Radboud University Medical Centre, Nijmegen, 
the Netherlands (n=39, all patients were mismatch-repair proficient), and the department 
of Gastroenterology of the General Hospital of Beijing Military Region, Beijing, China (n=23, 
patients were not tested for mismatch-repair deficiency). For validation, a cohort of 146, 
non-polyposis and mismatch-repair proficient, CRC cases from both Nijmegen and Dresden, 
Germany was used. This validation cohort included patients with early-onset and/or familial 
CRC that were diagnosed ≤40 years of age (n=92), diagnosed before 50 years of age with at 
least two first-degree relatives or with a clear recessive inheritance pattern (n=54). The entire 
cohort was screened for mutations in MUTYH using a targeted next generation sequencing 
approach (M. Hahn, manuscript in preparation), which revealed that all patients with a 
pathogenic BUB1 or BUB3 mutation were MUTYH mutation-negative. All patients provided 
written informed consent. The study was approved by the CMO (study number 2009/256), 
Arnhem and Nijmegen, the Netherlands. 
Copy number profiling - Genomic DNA was extracted from peripheral blood cells of the 
39 CRC cases from Nijmegen, the Netherlands and hybridized to Affymetrix 6.0 SNP arrays 
(Affymetrix, Santa Clara, CA, USA) according to the protocol provided by the manufacturer 
(Genome-Wide Human SNP Nsp/Sty 6.0 User Guide). Genotypes were generated using the 
Birdseed analysis software package in the Affymetrix Genotyping Console v2.1 (Affymetrix, 
CA, USA). To exclude regions that represent normal copy number variation, we compared all 
detected copy number variants (CNVs) to those present in the Database of Genomic Variants 
and in our in-house database of CNVs in healthy controls (n=1,604), as described previously.14 
To assess whether rare CNVs had previously been linked to particular phenotypes, we compared 
all rare CNVs that we encountered to those in the clinical databases DECIPHER (www.
decipher.sanger.ac.uk) and the European Cytogeneticists Association Register of Unbalanced 
Chromosome Aberrations (ECARUCA; www.ECARUCA.net). In addition, we compared these 
CNVs to those encountered through routine diagnostic copy number profiling of patients with 
intellectual disability, developmental delay, and/or congenital anomalies (n = 10,139) referred 
between 2006 and 2011 to the department of Human Genetics, Radboud University Medical 
Centre, Nijmegen, the Netherlands, the department of Genetics, University Medical Centre 
Groningen, the Netherlands, and the department of Medical Genetics, Haukeland University 
Hospital Bergen, Norway, using the 250K (Affymetrix, Santa Clara, CA, USA), Agilent 105K 
(Oxford design, AMADID 019015) and 180K (Amadid 27730, Agilent Technologies, Santa 
Clara, CA, United States), and the Affymetrix 6.0 and 2.7M SNP array platforms, respectively.
Whole exome sequencing - Massive parallel whole exome sequencing of genomic DNA 
extracted from peripheral blood cells of 10/39 MSS CRC cases from Nijmegen, previously 
analyzed on the Affymetrix 6.0 array, was performed using an ABI SOLiD 4 platform (Life 
Technologies). Gene coding sequences were enriched using the human SureSelect 50Mb set 
(version 2), targeting ~21,000 human genes (Agilent Technologies, Santa Clara, CA, United 
States). Reads were mapped to the hg19 reference genome using SOLiD LifeScope software. 
For 23 CRC cases from Beijing, whole exomes were enriched using the SureSelect human exome 
kit (version 2, Agilent Technologies) and sequenced at BGI, Shenzhen, China using an Illumina 
HiSeq 2000 platform (Illumina, Inc., San Diego, CA). Single-nucleotide variants were called by 
the DiBayes algorithm, and small insertions and deletions were detected using BWA software.
Variant prioritization - All variants were annotated using an in-house annotation pipeline, 
as described previously.15 High-confidence (≥5 variant reads and/or ≥20% variant reads) non-
synonymous variants that were not present in dbSNPv132, our in-house variant database (1,154 
in-house analyzed exomes mostly from European ancestry)15 or The National Heart, Lung, and 
Blood Institute (NHLBI) Exome Sequencing Project (ESP; 6,503 exomes)16 were prioritized for 
variants that result in protein-truncation, splice site defects, or missense mutations at highly 
conserved (PhyloP ≥2.0) nucleotide positions. The frequency of variants that comply with the 
above selection in the Chinese exomes were also assessed in 700 control exome data sets with 
Han Chinese ancestry (Juan Tian and Zhimin Feng, BGI, personal communication). Identified 
variants were analyzed using Alamut 2.0 software (Interactive Biosoftware) and integrated 
mutation prediction software (align GVDV, SIFT and Polyphen-2) packages.17-19 Predictions of 
splicing effects were performed using NNSplice and ESEfinder software packages.20,21 Coding 
variants were analyzed using the online tool ‘project HOPE’ (http://www.cmbi.ru.nl/hope/) that 
provides insight into the structural consequences of a mutation.22
Targeted disruption of BUB1 - Monoallelic disruption of exon 1 of BUB1 in the microsatellite 
instable (MSI), but chromosome stable, CRC cell line HCT116 was achieved through homologous 
recombination as reported by Iiizumi et al.23 Genomic regions encompassing 2.4 kb upstream 
(5’ arm) and 3.8 kb downstream (3’ arm) of exon 1 of BUB1 were amplified using HCT116 
genomic DNA as template. Through the MultiSite Gateway system a floxed hygromycin resistance 
cassette was inserted between the 5’ and 3’ arms in a plasmid carrying a diphtheria toxin A (DT-A) 
gene, which allows selection against random integration (vectors kindly provided by N. Adachi). 
Subsequently, HCT116 cells were transfected with the targeting vector using electroporation 
(Amaxa Nucleofector System). Clones with stable integration of the linearized construct were 
recovered using hygromycin selection. Screening for clones with a correct integration at the BUB1 
locus was performed using a PCR-based approach.23 Subsequently, the loxP flanked hygromycin 
resistance cassette was removed from the positive HCT116 clone using Cre-recombinase. The 
correct excision and concomitant introduction of a monoallelic deletion of exon 1, as revealed by 
PCR-based screening, was confirmed by multiplex ligation-dependent probe amplification (MLPA).
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Cytogenetic analysis - Fresh peripheral blood samples, skin biopsies and cell lines were used for 
routine cytogenetic analyses. Blood cells were cultured in RPMI 1640 medium (Invitrogen, Paisley, 
UK), supplemented with 10% fetal calf serum (FCS) and phytohemagglutinin (PHA). Cultures 
were incubated for 72-96 hours. Skin fibroblasts were cultured in F10 medium (Invitrogen) 
supplemented with 10% FCS. HCT116 cells were cultured in McCoy’ s medium (Invitrogen) 
supplemented with 10% FCS. All cells were cultured at 37°C in a humidified atmosphere with 
5% CO2. After treatment with colcemid, cells were harvested, incubated in hypotonic solution, 
fixed in methanol-acetic acid and transferred to microscope slides using standard cytogenetic 
procedures. Metaphase spreads were scored for aneuploidies and structural rearrangements 
after GTG-banding, and premature sister chromatid separation (PSCS) defects after Giemsa 
staining, respectively.
Multiplex ligation-dependent probe amplification - To validate the candidate CNV region 
on 2q13, and to screen the additional cohort of CRC cases for this CNV in a targeted fashion, 
we performed MLPA, essentially as described before.14 Novel MLPA probes were designed for 
BUB1, BCL2L11 and ANAPC1, all located within the 2q13 candidate region, according to the 
guidelines of MRC-Holland (Amsterdam, Netherlands; probe sequences available upon request). 
In total 10 probes were employed in conjunction with 12 control probes outside the 2q13 
region in a single MLPA assay. For confirmation of the targeted disruption of exon 1 of BUB1 in 
HCT116 cells, an adjusted MLPA assay was used including a probe located within exon 1. The 
data were normalized by dividing the peak areas of each probe by the average peak areas of 
the control probes. These normalized peak values were divided by the average peak values of 
all samples in the same experiment.
Antibodies - Primary and secondary antibodies used for immunofluorescence and Western 
blotting assays were as follows: rabbit anti-BUB1 (Abcam, Cambridge, UK), mouse anti-BUB1 
(Sigma, MO, USA), mouse anti-RAN (BD Biosciences, CA, USA), mouse anti-α-tubulin (Santa 
Cruz, CA, USA), goat-anti-rabbit Alexa fluor 568 (Molecular probes, Invitrogen), and chicken-
anti-mouse Alexa fluor 488 (Molecular probes).
Immunofluorescence assays - For the subcellular localization of proteins, primary fibroblasts 
were grown on microscopic slides, fixed in 3.7% paraformaldehyde/PBS for 20 minutes at RT 
and permeabilized in PBS/0.1%Triton. Subsequently, the slides were incubated with primary 
antibodies in PBS/BSA for 1 hour, followed by incubation with a fluorescently conjugated 
secondary antibody. Finally, the slides were embedded in Vectashield with DAPI (Vector Labs, 
Burlingame, CA, USA) and analyzed using a Zeiss Axio Imager Z1 equipped with DAPI, GFP and 
Alexa 568 filter sets.
Real-time quantitative RT-PCR - Total mRNA was extracted from lymphocytes and fibroblasts 
of patients and age-matched healthy controls using an RNeasy mini kit (Qiagen, CA, USA). cDNA 
was prepared from 2 µg of RNA through a reverse-transcriptase polymerase chain reaction (RT-
PCR) with Oligo (dT) primers using a RNA LA PCR kit (AMV; Takara Bio Inc, Shiga, Japan). Real-
time quantification was performed on a 7500 Fast Real-Time PCR system (Applied Biosystems, 
CA, USA) using SYBR Green-based quantification (Applied Biosystems). All experiments were 
performed in triplicate and data were normalized using the housekeeping genes GAPDH and 
HPRT (primer sequences available upon request).
Western blot analysis - For Western blot analysis, proteins were extracted using a lysis buffer 
(10mM Tris-HCL, 150mM NaCl, 0.1%SDS, 1% Triton, 0.5%DOC, 5% glycerol). Samples 
were loaded onto a 4-12% Bis-Tris gel (Invitrogen). Next, the proteins were transferred to 
a nitrocellulose membrane. The resulting blots were blocked with 5% nonfat dry milk and 
incubated overnight at 4°C with primary antibodies and, subsequently, with a fluorescently 
conjugated secondary antibody. Signals were visualized using an Odyssey infrared system (Li-
cor Biosciences, NE, USA) and 6.5-180-kDa pre-stained Molecular Weight Marker (Bio-rad) was 
used for size comparison. The amount of BUB1 protein was normalized by dividing the BUB1 
signal of each sample by the signal derived from RAN, which was used as a loading control, 
using Odessey v3.0 software.
Sanger sequencing - Genomic sequencing of the coding regions and intron/exon boundaries 
of the BUB1 and BUB3 genes was performed with the Big Dye Terminator version 1.1 and a 
3730 DNA Analyzer (Applied Biosystems, CA, USA), using standard protocols (primer sequences 
available upon request). Mutation analyses were performed using the Vector NTI software 
package (Invitrogen, Paisley, UK) and Sequence Pilot v3.4.0 (JSI medical, Kippenheim, Germany).
CLINICAL DESCRIPTION CRC PATIENTS WITH A BUB1 OR BUB3 MUTATION
Patient 1 (female, European ancestry, age 37, 2q13 microdeletion) was diagnosed with an 
adenocarcinoma of the descending colon (T3N0M0)10. She underwent left-sided hemicolectomy 
and was disease-free 5 years after diagnosis. The normal colon tissue showed a distortion of 
colonic crypts and the tumor tissue showed many tumor infiltrating lymphocytes (Appendix Fig 
A1A-C). She exhibited a normal intelligence and an occipitofrontal head circumference of 52.5 
cm (20.7 in., -1.7SD), which is below the 10th percentile after correction for height (158 cm 
[62.2 in.])24. She presented with several mild dysmorphic features, including an asymmetrical 
face and hairline and a prominent forehead. Her medical history included 2 pregnancies: a 
spontaneous miscarriage (within 8 weeks after conception) and the birth of one healthy son. 
There was no familial history for cancer. Patient 2 (male, Han Chinese ancestry, age 34, BUB1 
p.Gln16*) carried an additional pathogenic splice site mutation in MLH1 (c.453+1G>T), which 
is associated with Lynch syndrome. He was diagnosed with an adenocarcinoma of the jejunum 
(T4N0M0), two colonic adenocarcinomas (T3N0M0) at the hepatic flexure and the ileocecal 
junction, respectively (at age 40), a renal pelvis transitional epithelial cell carcinoma (at age 44) 
and two squamous cell carcinomas of the right lung (T1N0M0; at age 45). In all tumors there 
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was a loss of both MLH1 and PMS2 expression by immunohistochemistry. Treatment involved 
surgery and chemo/radiotherapy. He had a smoking history (>20 cigarettes per day for more 
than 20 years), normal intelligence, normal height (170 cm), and he conceived one healthy son. 
He died at age 47. Family history for cancer showed a father with esophageal cancer at age 70 
(died at age 75), a mother with rectum carcinoma at age 42 (died at age 45), and a sister with 
colonic polyps at age 49. Three siblings of the patient were available to perform segregation 
analysis. Patient 3 (male, Han Chinese ancestry, age 31, BUB1 p.Gln949fs) was diagnosed 
with an adenocarcinoma of the rectum (T3N1M0) and was treated with chemotherapy, local 
radiotherapy, and total mesorectal excision. At age 35 a tumor was detected in the ischiadic 
artery. He died at age 36. He had a normal intelligence and he conceived one healthy son. 
Family history for cancer showed a father with esophageal cancer at age 60 (deceased), a 
mother with gastric cancer at age 46 (deceased), and a brother with colonic polyps. The family 
was unavailable to perform segregation analysis. Patient 4 (female, European ancestry, age 29, 
BUB3 p.Phe264Leu) was diagnosed during pregnancy with a poorly differentiated squamous 
cell carcinoma of the cecum (T3N0M0). She underwent an ileocoecal resection. Tissue sections 
of normal colon and tumor tissue revealed atherosclerosis in arterioles (Appendix Fig A1D). She 
exhibited a normal intelligence and an occipitofrontal head circumference of 53,5 cm (21.1 
in., -1SD), which is below the 25th centile after correction for height (160 cm [63 in.]). She 
presented with several mild dysmorphic features, including an asymmetrical face, a crooked 
nose and a short philtrum. She had 16 pregnancies, including 13 spontaneous miscarriages 
(within 8 weeks after conception), and gave birth to three healthy sons. Her further medical 
history included an anal benign giant condyloma acuminatum (at age 31), bilateral cataract (at 
age 43) and a lung carcinoma with multiple brain metastases (at age 44). She had a smoking 
history (>20 cigarettes per day for more than 20 years). Family history for cancer showed a 
mother with ovarian cancer at age 61 (deceased). Patient 5 (male, European ancestry, age 32, 
BUB3 p.Lys21Asn) was diagnosed with an adenocarcinoma of the rectum (pT2-T3N0M0), and 
treated with chemotherapy and local radiotherapy, followed by a total mesorectal excision. 
Clinical examination of the patient revealed a normal intelligence, normal height (179 cm), 
and a normal occipitofrontal head circumference (59.5cm). He conceived one healthy son. 
Family history for cancer showed a father with Hodgkin lymphoma at age 32 and basal cell 
carcinoma at age 61, and a sister with a tubular colon adenoma at age 36. The family was 
unavailable to perform segregation analysis. Patient 6 (male, European ancestry, age 38, BUB3 
p.Arg149Gln) was diagnosed with an adenocarcinoma in the sigmoid colon. He was treated 
with left hemicolectomy followed by chemotherapy. Colonoscopies were performed at a regular 
basis and 4 tubular adenomas with low grade dysplasia were removed from the sigmoid (two 
times), the ascending colon, and the rectum between ages 59 and 61. Family history for cancer 
showed a father with lung cancer at age 78 (deceased) and a mother with breast cancer at age 
68 (deceased). He died at age 71.
Supplementary Figure 1. (A) Validation of the 2q13 microdeletion by MLPA in germline (red line) and 
tumor (blue line) DNA from patient 1. Black and grey lines indicate healthy unrelated controls. (B) Validation 
of the targeted monoallelic deletion of exon 1 of BUB1 in HCT116 cells by MLPA, confirming that exon 1 is 
deleted (red line) compared to six independent control DNAs that were used for normalization (grey lines). 
(C) RT-PCR levels of BUB1 demonstrating reduced BUB1 expression in the HCT116-BUB1+/- (dark purple) 
cells compared to the parental HCT116 cell line (BUB1+/+; light purple). Data are normalized against GAPDH 
and HPRT expression. Error bars represent SD values. (D) Validation of the BUB3 variant identified by whole-
exome sequencing of patient 4 in DNA from both peripheral blood cells and tumor tissue.
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Supplementary Figure 2. Cytogenetic analysis of CRC patients with a monoallelic deletion of 2q13 
or germline mutations in BUB3, or controls. (A) Cytogenetic analysis of lymphocyte and primary fibroblast 
metaphases of CRC patients. A mosaic trisomy 8, identified in the fibroblasts of patient 4, was confirmed by 
FISH analyses on interphase spreads to be present in 50% of the fibroblasts, but absent in lymphocytes. (B) 
Percentage of cells that show aneuploidy and structural abnormalities in lymphocytes from CRC patients and 
controls. The random loss, and occasionally, gain of chromosomes is usually observed at a low percentage in 
standard cytogenetic analysis, mostly because of technical artifacts during metaphase spreading. We analyzed 
30 metaphase spreads of 10 healthy controls (white bars) and compared these to the analyzed metaphase 
spreads from the 2q13 microdeletion (patient 1), p.Phe264Leu (patient 4) and BUB3 p.Lys21Asn (patient 5) 
mutation carriers (black bars). Bars represent the average percentage of cells with the specified chromosomal 
aberration. Error bars represent the standard deviation. *P-value <0.01; ** P-value <0.001.
 
Supplementary Figure 3. Expression and subcellular localization of BUB1. (A) RT-PCR levels of 
BUB1, BCL2L11 and ANAPC1 measured in lymphoblastoid cells and primary fibroblasts from the 2q13 
microdeletion carrier and four healthy controls. Measurements were performed in triplicate and error bars 
represent the SD values. (B) Expression of wild-type BUB1 (122-kDa) in lymphoblastoid cells from three 
healthy controls (lanes 1-3, BUB1+/+) and the 2q13 deletion carrier (lane 4, BUB1+/-). Immunostaining of RAN 
(25-kDa) was used to correct for loading. (C) Localization of BUB1 in primary fibroblasts from the 2q13 
deletion carrier and a healthy control. In blue, DAPI staining, in red BUB1 and in green α-tubulin. 
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Supplementary Figure 4. Recurrent 2q13 microdeletions. (A) Schematic representation of the genomic 
region on 2q13 containing microdeletions (black bars) identified in 11 children and one adult (Nij7) with 
variable congenital abnormalities from clinical centers in the Netherlands (Nijmegen and Groningen) and 
Norway (Bergen) by microarray platforms. The microdeletion in 10 cases (~1,8 Mb) tightly cluster and are 
flanked by two copies of RGDP (marked in green), a low-copy repeat gene, which suggests homologous 
recombination as the underlying mechanism for this deletion. All breakpoints most likely cluster within 
the RGPD5/6 genes and differences in breakpoint locations may occur as a result of the different array 
platforms used, since MLPA analysis for Gro2, Nij6, Nij7, and Nij8 revealed a complete monoallelic loss 
of BUB1 in all cases. In red are the genes located in the 2q13 microdeletion. (B) Cytogenetic analysis of 
lymphocytes obtained from patients with 2q13 microdeletions, not ascertained for colorectal cancer. The 
random loss, and occasionally, gain of chromosomes is usually observed at a low percentage in standard 
cytogenetic analysis, mostly because of technical artifacts during metaphase spreading. PSCS: Premature 
sister chromatid separation. *Gains of chromosomes are rarely observed in standard cytogenetic analysis of 
healthy controls (see supplementary figure 2B).
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Supplementary Figure 5. (A) Pedigrees of families of six patients with a BUB1 or BUB3 mutation. Index 
patients are indicated by an arrow. Families 1, 4, 5, and 6 are from European ancestry, Families 2 and 3 
are from Han Chinese ancestry. Tumors diagnosed in each family member at indicated ages. PC: prostate 
cancer; SC: skin cancer; BC: breast cancer; CRC: colorectal cancer; EC: esophageal cancer; RCC; renal cell 
carcinoma; LC: Lung cancer; GC: gastric cancer; OC: ovarian cancer; HCC; hepatocellular carcinoma; HD: 
hodgkin’s lymphoma; BCC: basal cell carcinoma. (B) Segregation analysis in siblings of patient 2 (family 2) 
for the BUB1 nonsense mutation (c.46C>T, p.Gln16*) and MLH1 splice site mutation (c.453+1G>T). His 
brother (II-1) carried neither the BUB1 nor the MLH1 mutation. A sister (II-2), who was diagnosed with 
polyps at age 49, but not with CRC, is a carrier of the MLH1 mutation, but not the BUB1 mutation. A second 
sister (II-4)  carried the BUB1 mutation, but not the MLH1 mutation. The son of the index patient does not 
carry the BUB1 mutation, but is a carrier of the MLH1 mutation. He is currently 30 years of age and healthy. 
+: mutation is present; -: mutation is absent; NA: not assessed.
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sequencing variants with a minor allele frequency (MAF) ≥0.1% (het erozygous variants) or ≥1% 
(homozygous variants) were excluded. First, we screened for the presence of deleterious variants 
in known can cer-predisposing genes7 and detected variants in POLD1 (c.961G>A; p.G321S; 
NM_002691) and POLE (c.850A>G; p.K284E; NM_006231) affecting the exonuclease domain 
in individuals P17 and P35, respectively (Supplementary Table 3).
To identify loss-of-function mutations in new candidate genes, we subsequently focused on 
all truncating variants. We found 14 genes that were recurrently affected by heterozygous 
mutations in unrelated indi viduals (Supplementary Table 4a). Furthermore, we identified 
puta tive homozygous truncating variants in 18 different genes, 5 of which were recurrently 
altered (Supplementary Table 4b). One of the vari ants constituted a nonsense mutation 
encoding p.Q90* in the BER pathway gene NTHL1 (c.268C>T; NM_002528), which results in 
nonsense-mediated decay and was found to be homozygous in four indi viduals from three 
independent families (Table 2 and Supplementary Figs. 1 and 2), suggesting a BER defect 
similar to that observed in patients with MAP. We did not detect additional biallelic variants 
in BER pathway genes but did observe heterozygous nonsense vari ants in OGG1 (c.391C>T; 
p.R131*; NM_002542), MPG (c.352C>T; p.R118*; NM_002434) and SMUG1 (c.370C>T; 
p.R124*; NM_014311) in three additional unrelated individuals (Table 2).
The pedigrees of the three families with the homozygous NTHL1 mutation encoding p.Q90* are 
shown in Figure 1. Sanger sequenc ing showed that three additional clinically affected individuals 
in families B and C were also homozygous for this mutation (Table 2 and Supplementary Fig. 
3), whereas a heterozygous carrier in fam ily B was not clinically affected. Additional evaluation 
of the family histories identified consanguinity in family B. All the pedigrees were in agreement 
with a recessively inherited trait; that is, adenomatous polyposis or early-onset CRC was 
encountered in only one genera tion in all three families. All individuals who tested positive 
for the homozygous germline mutation encoding p.Q90* developed mul tiple adenomatous 
polyps (range of 8–50). None of the subjects had hyperplastic or serrated polyps, and four were 
diagnosed with CRC, with each of them having multiple colorectal carcinomas. We noticed that 
all three affected women developed cancerous or precancerous lesions (complex hyperplasia) 
in the endometrium (Fig. 1). In addition, two individuals from family A (P01) and family B (P07) 
developed multiple duodenal adenomas at age 62 years and duodenal cancer at age 52 years.
The mutation in NTHL1 encoding p.Q90* has been reported incidentally in targeted BER gene 
sequencing studies on polyposis or CRC cohorts but always in a heterozygous state and with 
fre quencies similar to those in controls8,9. We screened an additional cohort of 149 subjects 
with polyposis for compound heterozygous or homozygous pathogenic germline mutations 
in NTHL1, but no pathogenic mutations were detected. To determine the frequency of the 
mutation encoding p.Q90* in the human population, we next analyzed available exome 
data with high local coverage from an in-house database (n = 2,329 exomes) and the Exome 
Aggregation Consortium (ExAC) browser (n = 61,486 exomes), containing individuals who, to 
our knowledge, have not been diagnosed with polyposis or CRC (Materials and Methods). We 
found the muta tion in NTHL1 encoding p.Q90* in 17 (in-house database; MAF = 0.0036) and 
The genetic cause underlying the development of multiple colonic adenomas, the 
premalignant precursors of colorectal cancer (CRC), frequently remains unresolved 
in patients with adenomatous polyposis. Here we applied whole-exome sequencing 
to 51 individuals with multiple colonic adenomas from 48 families. In seven affected 
individuals from three unrelated families, we identified a homozygous germline 
nonsense mutation in the base-excision repair (BER) gene NTHL1. This mutation 
was exclusively found in a heterozygous state in controls (minor allele frequency of 
0.0036; n = 2,329). All three families showed recessive inheritance of the adenomatous 
polyposis phenotype and progression to CRC in at least one member. All three affected 
women developed an endometrial malignancy or premalignancy. Genetic analysis of 
three carcinomas and five adenomas from different affected individuals showed a 
non-hypermutated profile enriched for cytosine-to-thymine transitions. We conclude 
that a homozygous loss-of-function germline mutation in the NTHL1 gene predisposes 
to a new subtype of BER-associated adenomatous polyposis and CRC.
DNA repair mechanisms are fundamental for maintaining the genomic integrity of the cell, and 
their malfunctioning is strongly associated with cancer predisposition and progression owing 
to higher mutation rates, particularly in epithelial tissues recurrently exposed to exogenous 
mutagens and having high turnover rates1. Several inherited CRC syndromes have been 
associated with genetic defects in DNA repair pathways. Germline aberrations in the mismatch-
repair genes MLH1, MSH2, MSH6 and PMS2, for example, cause Lynch syndrome, which is 
associated with increased risk of developing mismatch repair–deficient tumors in the colon and 
several other tissues. Additionally, biallelic mutations in the BER pathway gene MUTYH cause 
MUTYH-associated polyposis (MAP)2, and monoallelic germline mutations in POLE and POLD1 
affecting the encoded exonuclease domains have been found to predispose to polymerase 
proofreading-associated polyposis (PPAP)3. Both MAP and PPAP are characterized by the 
presence of adenomatous polyps and defined mutation spectra in the tumors4,5. Nevertheless, 
a sub stantial fraction of colorectal adenomatous polyposis and (familial) CRC cases still remain 
unexplained6.
To identify new genes associated with predisposition to adenomatous polyposis and CRC, we 
selected 51 individuals who were highly sus pected of having a hereditary cause for disease 
(Table 1). All these individuals had been diagnosed with multiple adenomas but tested negative 
for APC and MUTYH alterations. Most of them were also diagnosed with CRC (n = 21) or had a 
first-degree relative with polyposis or CRC (n = 27). For two families, we included two and three 
affected individuals (Supplementary Table 1). We performed whole-exome sequencing on 
peripheral blood–derived DNA using 5500xl (Life Technologies) or HiSeq (Illumina) sequencers. 
Performance was dependent on the platform used, with an average coverage of 84.7-fold on 
target (range of 63.1- to 99.3-fold) (Supplementary Table 2). Mapping of sequencing reads, 
variant calling, and variant quality filtering and prioritization were performed using standard 
procedures (Materials and Methods). Variants present in our in-house database of exome 
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mutation encoding p.Q90* (P49 and P71) identified six additional somatic nonsense mutations, 
all involving C:G>T:A transitions (Fig. 2c and Supplementary Table 8). In comparison to the 
mutation spectrum of APC in 189 sporadic, non-hypermutated CRCs14, this bias toward C:G>T:A 
transitions was significant (P = 9.0 × 10−3). To confirm that this mutation spectrum was different 
from those observed in MAP-associated tumors, we determined the mutation spectrum for the 
409 cancer-related genes in 2 CRCs from individuals with biallelic MUTYH mutations. These 
tumors had five and three somatic mutations, respectively, of which the majority involved 
C:G>A:T transversions (Fig. 2d and Supplementary Table 9).
On the basis of previous studies8,10,15, it has been suggested that the role of BER pathway genes 
other than MUTYH in polyposis and CRC predisposition may be limited. Here we show for the 
first time, to our knowledge, that NTHL1 is a susceptibility gene for reces sive adenomatous 
polyposis and CRC. In addition, individuals with a homozygous loss-of-function mutation 
in NTHL1 may be at increased risk of developing other types of carcinomas. Establishing an 
accurate risk estimate and a definite specific tumor spectrum in affected individuals will be 
instrumental for the (early) recognition of these carcinomas in individuals with similar germline 
defects in BER pathway genes.
189 (ExAC browser; MAF = 0.0015) individuals, but it was always in a heterozygous state. On 
the basis of the frequency of this mutation in our in-house database, homozy gosity would be 
expected to occur once in every 75,076 individuals, which is sig nificantly lower than what we 
found in the 197 polyposis cases tested (P = 7.1 × 10-8).
Control exome sequencing data showed that deleterious NTHL1 variants were rare in different 
ancestry subgroups, with the p.Q90* variant being most frequent (Supplementary Fig. 4). The 
highest prevalence of the p.Q90* variant was encountered in subjects of European descent, 
including Dutch individuals (Supplementary Table 5). Furthermore, the mutation carriers P07 
and P23 both exhib ited large homozygous stretches around the NTHL1 locus and else where 
within the genome as compared to controls, suggesting that, as with family B, family C may 
also be consanguineous (Supplementary Fig. 5 and Supplementary Table 6). Despite the 
variability in the NTHL1 haplotypes observed in our cohort (Supplementary Fig. 6), the higher 
local prevalence of this variant and consanguinity may explain why we, in contrast to others8–10, 
were able to identify families with polyposis harboring homozygous NTHL1 mutations encoding 
p.Q90*. Taking our observations together, we conclude that the mutation encoding p.Q90* is 
rare but recurrent in the normal popu lation but is encountered in a homozygous state only in 
individuals who develop colorectal adenomas and carcinomas.
Pathogenic germline aberrations in DNA repair genes can affect somatic mutation spectra 
in tumors. In patients with MAP, biallelic loss of MUTYH prevents the removal of incorrectly 
incorporated adenine residues opposite 8-oxoguanine, which results in C:G>A:T transversions. 
Indeed, high transversion rates have been reported in carcinomas from patients with MAP, 
particularly in APC and KRAS2,5,11. In comparison to MUTYH, NTHL1 targets a broader range of 
DNA lesions12, but, on the basis of the mutation spec tra observed in double-knockout mice13, 
an increase in C:G>T:A transitions rather than C:G>A:T transversions is expected in carcinomas 
derived from individuals with a biallelic NTHL1 mutation. To assess the somatic mutation spectra 
in carcinomas from individ uals with a homozygous mutation encoding p.Q90*, we sequenced 
409 cancer-related genes (AmpliSeq Comprehensive Cancer Panel, Life Technologies) in the 
CRCs of 3 different affected members from family B (P07) and family C (P23 and P69), using the 
Ion Torrent PGM sequencing platform. In total, we observed 13, 15 and 17 somatic mutations, 
respectively (Supplementary Table 7). On the basis of data extracted from a previous report14, 
these numbers are below those observed in hypermutated CRCs (Fig. 2a). In line with this 
observation, all three carcinomas carried mutations in APC, TP53, KRAS and PIK3CA, which 
are among the most frequently mutated drivers in non-hypermutated cancers14 (Fig. 2b). 
Fifteen of the 16 mutations in these 4 driver genes involved C:G>T:A tran sitions (Fig. 2c), which 
constitutes a significantly higher fraction than that for the mutations previously described in 189 
sporadic non-hypermutated CRCs (P = 0.0139)14. When we included all the mutations identified 
in the 409 cancer-related genes in this analysis, this bias toward C:G>T:A transitions remained 
significant for all carcinomas together (P = 5.1 × 10−4), as well as for 2 of the 3 carcinomas 
separately (P07, P = 1.3 × 10−2; P23, P = 6.9 × 10−4) (Fig. 2d). Targeted deep sequencing 
of the APC gene in eight polyps from two different individuals homozygous for the NTHL1 
482 CHAPTER 4 83A HOMOZYGOUS LOF MUTATION IN NTHL1 CAUSES POLYPOSIS AND CRC
Table 1. Clinical characteristics of the 51 individuals included for whole-exome sequencing 
Clinical selection Number of individuals
number of polyps
Between 5 and 10 polyps 3
Between 10 and 20 polyps 20
Between 20 and 50 polyps 22
More than 50 polyps 6
type of polyps
Adenomatous polyps 22
Adenomatous + hyperplastic polyps 22
Adenomatous + serrated polyps 1
Adenomatous + hyperplastic + serrated polyps 6
also diagnosed with colorectal cancer 
Yes 21
No 30
Family history Fdr (first degree relative)
Polyposis 3
CRC 12
Polyposis + CRC 12
Negative/unknown 24
 
Table 2. Nonsense germline mutations in base excision repair pathway genes
Family Subject Gene Variant1 Protein 
alteration
Allelic state Clinical features
of the patient2
A P01 NTHL1 c.268C>T p.Q90* homozygous C40, C49, 15A
A P49 NTHL1 c.268C>T p.Q90* homozygous 40A
B P07 NTHL1 c.268C>T p.Q90* homozygous C47, 50A
B P71 NTHL1 c.268C>T p.Q90* homozygous 50A
B P72 NTHL1 c.268C>T p.Q90* homozygous 10A
C P23 NTHL1 c.268C>T p.Q90* homozygous C64(2x), 20A
C P69 NTHL1 c.268C>T p.Q90* homozygous C63(2x), 8A
D P54 OGG1 c.391C>T p.R131* heterozygous 13A + 8H
E P57 MPG c.352C>T p.R118* heterozygous 15A
F P09 SMUG1 c.370C>T p.R124* heterozygous C49, 20A
 
1All variants were validated by Sanger sequencing 2 C: colorectal cancer, A: adenomatous polyps, H: 
hyperplastic polyps. Numbers represent age of onset of colorectal cancer (C) or the number of adenomatous 
(A) or hyperplastic (H) polyps present at time of diagnosis.
Acknowledgments
We thank N. Arts, A. van Raaij, S. van Vliet, M. van de Vorst and M. Kwint for technical assistance, 
and R. Derks and M. Nelen for targeted tumor sequencing and data analysis. We thank H. 
Brunner for critical reading of the manuscript. The authors would like to thank the Exome 
Aggregation Consortium and the groups that provided exome variant data for comparison. A 
full list of contributing groups can be found at http://exac.broadinstitute.org/about. This work 
was supported by research grants from the Dutch Cancer Society (KWF; grant 2009-4335) and 
the Netherlands Organization for Scientific Research (NWO; grant 917-10-358).
Author contribution
R.D.A.W., R.P.K. and N.H. designed the study. R.D.A.W. analyzed and interpreted whole-
exome sequencing data. R.D.A.W., R.M.d.V. and E.J.K. performed laboratory experiments and/
or analyzed data. E.T.P.V. and J.Y.H.-K. performed haploblock analysis. R.D.A.W. and B.B.J.T. 
performed somatic mutation analyses. C.G. supervised bioinformatics data assembly and 
performed statistical analysis. J.S., E.A.B. and A.H. designed molecular inversion probes. I.D.N. 
and J.H.J.M.v.K. collected tumor samples and interpreted histology. C.M.K., L.S., W.A.G.v.Z.-S., 
M.C.J., F.M.N. and N.H. were responsible for patient counseling and clinical data acquisition. 
M.J.L.L., A.G.v.K., R.P.K. and N.H. supervised the work. R.D.A.W., R.P.K. and N.H. wrote the 
manuscript, with assistance and final approval from all co-authors. 
Competing financial interests
The authors declare no competing financial interests.
484 CHAPTER 4 85A HOMOZYGOUS LOF MUTATION IN NTHL1 CAUSES POLYPOSIS AND CRC
 
 
Figure 2. Mutation spectra of adenomas and carcinomas derived from individuals homozygous for NTHL1 
p.Q90*. Three carcinomas, derived from P07 (family B), P23 and P69 (family C) exhibit (a) comparable 
numbers of somatic base substitutions and (b) all carry non-synonymous mutations in the CRC driver 
genes APC, TP53, KRAS and PIK3CA. (c) The mutations in APC, TP53, KRAS and PIK3CA almost exclusively 
represent C:G>T:A transitions. Diamonds underneath the APC gene represent six somatic nonsense 
mutations identified in five polyps (P49 and P71), all representing C:G>T:A transitions. (d) Based on all 
somatic mutations observed, two of the carcinomas (P07 and P23) show a strong bias toward C:G>T:A 
transitions (C>T), which is in sharp contrast to two MAP-associated carcinomas (MAP1: homozygous for 
p.P407L and MAP2: p.P407L and p.D161H) that are enriched for C:G>A:T transversions (C>A). 
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Illumina HiSeq 2500). Local coverage of the locus for p.Q90* was, according to cover age data 
for 95.5% of these exomes, high in all samples (median = 134, standard deviation = 32.2, range 
= 38–283). The ExAC database (n = 61,486) contains all germline variants identified in exomes 
derived from unrelated individuals of African, Asian, European or Latino descent without severe 
pediatric diseases. In this database, local coverage of the locus for p.Q90* was high in these 
samples (median ≥ 100 (capped), average = 91.7).
RNA expression analysis. Epstein-Barr virus (EBV)-transformed B lym phocytes, which were 
established in house using standard technical procedures, were cultured in 20 ml of RPMI-1640 
(Sigma) supplemented with 10% FBS (PAA Laboratories), penicillin-streptomycin (Sigma) and 
l-alanyl-l-glutamine (Sigma). Cell splitting was performed twice a week (1:3 ratio). Cells were 
cultured at 37 °C in a humidified atmosphere with 7.5% CO
2
. For cyclohexamide treatment, 
5 × 106 cells were seeded (overnight), and cyclohex amide was added (Sigma; 1:1,000 dilution) 
for 4 h at 37 °C. To collect cells for RNA isolation, cells were spun down at 1,000g, and cell 
pellets were stored at −80 °C after the removal of medium. Total RNA was isolated from EBV-
transformed B lymphocytes using the RNeasy mini kit (Qiagen). Equal amounts of RNA (2 μg) 
were used to synthesize cDNA with oligo(dT) and random primers using the RNA LA PCR kit 
(Takara Bio). The cDNA obtained was diluted tenfold in MQ, and 5 μl of diluted cDNA was 
mixed, according to the manufacturer’s protocol, with GoTaq qPCR Master Mix (Promega) 
supplied with forward and reverse primers (primer sequences available upon request). Real-time 
quantitative RT-PCR was performed on a 7500 Fast Real-Time PCR system (Applied Biosystems).
Statistical analysis. The expected frequency of homozygous carriers of the variant in NTHL1 
encoding p.Q90* in the local control population was determined using Hardy-Weinberg 
equilibrium. On the basis of the number of heterozygous carriers of the mutation encoding 
p.Q90* in our in-house database, the frequency of the wild-type allele (p) and the frequency of 
the allele for p.Q90* (q) were determined to be 0.9964 and 0.0036, respec tively. According to 
Hardy-Weinberg equilibrium, the expected frequency of homozygous carriers of the allele for 
p.Q90* (q2) was determined to be 1.33198 × 10−5 (1/75,076).
The Fisher exact test was applied to determine the significant enrichment of homozygous 
mutation carriers in our polyposis cohort (3/197) in compari son to the expected frequency of 
homozygous carriers in controls (1/75,076). The same test was applied to determine whether 
the observed mutation spectra in carcinomas and polyps derived from individuals homozygous 
for NTHL1 mutation encoding p.Q90* were significantly different from those observed in 
sporadic CRCs.
Homozygosity mapping. All samples were examined for loss of heterozy gosity (LOH), as 
were 200 control samples (from healthy parents of patients with intellectual disability) that 
had also been sequenced with the same pro tocol using an Illumina HiSeq instrument. Variants 
were identified as being homozygous or heterozygous on the basis of the percentage of non-
Materials and MetHods
Subject and clinical samples. Index subjects in this study have been diagnosed with multiple 
adenomatous polyps and were referred to the Radboudumc Nijmegen for genetic diagnosis. 
All patients tested negative for the presence of pathogenic germline mutations in the APC and 
MUTYH genes before exome sequencing. DNA was isolated from peripheral blood leukocytes 
for all patients in our cohort. For cosegregation analyses, DNA was isolated from peripheral 
blood leukocytes (P71) or formalin-fixed, paraffin-embedded material of non-affected colonic 
tissue (P69). Informed consent for whole-exome sequencing was obtained from all participating 
subjects. All participants provided written informed consent or samples were irreversibly 
anonymized. This study was approved by the medical ethics committee/institutional board 
(CMO, study 2014/032) of the Radboudumc.
Whole-exome sequencing. DNA from 51 subjects with polyposis was purified (Qiagen), and 
exome capture was subsequently performed using the Agilent SureSelect Human All Exon v4 
enrichment kit (Agilent Technologies). Whole-exome sequencing was performed on the 5500xl 
platform (Life Technologies) for nine samples (Radboudumc Genomics Technology Platform) 
and on the Illumina HiSeq platform (2 × 100 bp, paired end) for 42 samples (BGI, Copenhagen, 
Denmark; Supplementary Table 2). Reads were mapped to the reference genome (hg19) 
using SOLiD Lifescope software and annotated as described previously16. To discard low-
quality variant calls, we excluded all variant calls with <10 total reads or <20% variant reads. 
Variants present with a MAF ≥0.1% (heterozygous variants) or ≥1% (homozygous variants) 
in our in-house database of exome sequencing variants (containing all the germline variants 
identified in 2,037 individuals without suspected cancer predisposi tion who were sequenced 
under similar conditions) were considered benign polymorphisms and excluded from further 
analyses. Missense variant calls were selected when they were at highly conserved nucleotide 
positions (phyloP > 3). In silico prediction analyses were performed using Alamut Visual software 
(Interactive Biosoftware).
Sanger sequencing of additional patients with polyposis. To determine the frequency of 
(homozygous) carriers of the variant in NTHL1 encoding p.Q90* in patients with polyposis, we 
collected germline DNA samples from 149 additional patients with polyposis who lacked known 
pathogenic germline mutations in APC and MUTYH. We applied Sanger sequencing for the 
entire NTHL1 gene (NM_002528; five amplicons, primer sequences available upon request). PCR 
and Sanger sequencing were performed according to standard procedures.
Control cohorts. To determine the frequency of the nonsense variant in NTHL1 encoding 
p.Q90* in the local population, we searched for this specific variant in an additional cohort 
of individuals without a suspected hereditary form of cancer (n = 2,329), for whom paired-
end exome sequencing data were available with >75-fold median coverage (Agilent V4 kit; 
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and MAP2). To confirm the somatic origin of mutations, we also obtained DNA from formalin-
fixed, paraffin-embedded samples derived from non-affected colonic tissue from these patients. 
Library enrichment using the Ion AmpliSeq Comprehensive Cancer Panel (Life Technologies) was 
performed for these DNA samples (except for DNA derived from non-affected colonic tissue 
from P69) accord ing to the manufacturer’s protocols. Briefly, after PCR-based target amplifi-
cation and digestion of primer sequences, Ion P1 adaptors and Ion Xpress barcodes were ligated 
to the amplified products. The barcoded libraries were purified using the Agencourt AMPure 
XP kit (Beckman Coulter Genomics) and washed with 70% ethanol before PCR-based library 
amplification. Purification of the amplified libraries was performed using the AMPure XP kit, 
and the purified libraries were quantified using the Qubit 2.0 Fluorometer (Life Technologies).
An amplification run was performed on diluted aliquots of the bar coded libraries (3 ng/μl) 
using the OneTouch emulsion PCR system (Life Technologies) before targeted sequencing of 
the libraries using one Ion 318 chip per library. The data obtained were mapped and variants 
were called using SeqNext (JSI Medical Systems; version 4.2.0). The following variant calls were 
excluded: (i) variant calls located in regions covered by less than 40-fold and those with <10% 
variant reads or with less than 8% variant reads in any direction (forward or reverse reads), (ii) all 
variants that were called in control samples with >5-fold coverage per direction and >2% variant 
reads in both directions, (iii) variants with a MAF of >0.01 in dbSNP (Build 138), (iv) variants in 
non-exonic regions and all insertions and deletions, and (v) variants identified in both tumor 
samples and matched normal samples. For the one cancer sample (P69) that had no matched 
control sample available, we used the control sample of her brother (P23) and validated all 
remaining variants using Sanger sequencing. All variants in the other cancer samples with less 
than 15% variant reads were confirmed using Sanger sequencing. Deamination artifacts were 
not observed in the stringently selected variants: 26 mutations with variant calls above 15% 
(including all driver genes) were selected for Sanger sequencing, yielding 25 informative reads, 
which all con firmed the somatic presence of the corresponding mutation.
Analysis of somatic mutations in 189 sporadic CRCs. We extracted exome data from a 
previous study14 to obtain a total of 17,865 somatic mutations in coding regions in 189 CRCs and 
filtered for base substitutions. Variants in noncoding regions, germline variants and duplicates 
were discarded (16,800 mutations remaining). We next selected all the variants in the 409 genes 
included in the Life Technologies comprehensive cancer panel (1,216 mutations remaining), 
which were used for further analysis as indicated. The average coverage of the coding regions 
of these 409 genes was high (78.8%), on the basis of minimum base coverage required for 
variant detection (read depth ≥14 and ≥8 for tumor and normal samples, respectively)19. On 
average, suf ficient read depth for variant detection (>40-fold read depth) was obtained for 
89.0% of the coding regions of these 409 genes using our targeted screening (range of 87.7–
89.8%). This increased sensitivity of targeted sequencing in comparison to the exome data for 
variant calling (78.8% versus 89.0%) may have slightly increased the total number of somatic 
mutations observed but not the frequency of and bias toward C:G>T:A transitions. Furthermore, 
reference reads supporting a variant call. The thresholds for calling a variant as heterozygous or 
homozygous were determined by the following steps. The binomial distribution was clustered 
around two peaks, and the standard devia tion and skewness were calculated. Samples 
sequenced using the Illumina HiSeq platform had a mean of 48%, a standard deviation of 8.4% 
and a skewness of −0.14 for heterozygous variants; for homozygous, non-reference variants, 
the standard deviation was 1.4%. Samples sequenced using the Solid 5500xl platform had 
a mean of 42%, a standard deviation of 13.4% and a skewness of 0.18 for heterozygous 
variants; for homozygous, non-reference variants, the standard deviation was 3.5%. On the 
basis of these values, a variant was deemed heterozygous if the fraction of variant calls was 
between 14 and 89% for the Illumina samples and between 35 and 76% for the Solid 5500xl 
samples. Segments of LOH were then identified containing 28 or more variants and larger than 
2 Mb in size that were determined to be homozygous. Each segment was allowed 2% tolerance 
(1 in 50 variant calls) for a potential heterozygous variant. The total level of homozygosity in 
each sample was compared to that for the control samples using a one-sided z test.
Haplotype analysis. We analyzed all SNPs in the 1-Mb region surrounding the NTHL1 locus 
that were covered in all four exomes (P01, P07, P23 and P49). For visualization of different 
haploblocks, we included all informative SNPs that were (i) discordant between sample P07 and 
P23 or (ii) heterozygous in P01 and P49. Furthermore, we filtered out sequencing and mapping 
artifacts by excluding heterozygous calls in the homozygous stretches of P07 and P23 and variants 
that were not shared by P01 and P49. Recombination rates used to identify recombination 
hotspots on chromosome 16 were generated using LDhat as described previously17.
Autozygosity mapping. Genome-wide autozygosity mapping of the exome sequence 
data derived from P01, P07, P23 and P49 was based on non-reference variant calls and was 
performed as described previously18. Images were gener ated using the AgileVariantMapper18 
with a minimum read depth of 10 and heterozygous cutoff settings of 10%.
Read depth–based copy number variation analysis. The median coverage of 6,953 target 
regions of chromosome 16 was determined for 8 exomes (including P07) sequenced on the 
5500xl platform and 41 exomes (including P23) sequenced on the Illumina HiSeq platform (2 
× 100 bp, paired end). Regions with <10-fold median coverage on average were discarded. 
For each sample, the median coverage per target region was corrected for the total median 
coverage of chromosome 16. The corrected median coverage per target region of P07 and P23 
was then compared to the average median coverage observed in seven exomes sequenced on 
the 5500xl platform and 40 exomes sequenced on the Illumina HiSeq platform, respectively.
Targeted sequencing of cancer-related genes in tumor samples. DNA from cancer material 
was obtained from formalin-fixed, paraffin-embedded colon cancer tissues for three different 
NTHL1 mutation carriers (P07, P23 and P69) and two different MUTYH mutation carriers (MAP1 
490 CHAPTER 4 91A HOMOZYGOUS LOF MUTATION IN NTHL1 CAUSES POLYPOSIS AND CRC
Supplementary Table 1. Clinical characteristics of individuals included for exome sequencing. 
Subject Polyp type Polyp number Colorectal cancer FDR with CRC
or Polyposis
NS BER gene
P07 A 50 Y Y NTHL1 (p.Q90*)
P30 A 30 Y Y
P09 A 20 Y Y SMUG1 (p.R124*)
P23 A 20 Y Y NTHL1 (p.Q90*)
P01a A 15 Y Y NTHL1 (p.Q90*)
P22 A 15 Y Y
P15 A 10 Y Y
P08 A 250 Y N
P36 A 40 Y N
P03 A 25 Y N
P02 A 20 Y N
P52 A 15 Y N
P12 A 10 Y N
P42 A 50 N Y
P49a A 40 N Y NTHL1 (p.Q90*)
P25 A 20 N Y
P16 A 10 N Y
P31 A 30 N N
P34 A 30 N N
P58 A 16 N N
P19 A 15 N N
P57 A 15 N N MPG (p.R118*)
P04 A H 25 Y Y
P20 A H 15 Y Y
P51 A H 10 Y Y
P05 A H 30 Y N
P28 A H 25 Y N
P26 A H 24 Y N
P24 A H 20 Y N
P38 A H 60 N Y
P44 A H 50 N Y
P37 A H 45 N Y
P32 A H 30 N Y
P27 A H 25 N Y
P46b A H 17 N Y
P18 A H 15 N Y
P17 A H 14 N Y
P11 A H 10 N Y
P47b A H 10 N Y
P45b A H 5-10 N Y
P54 A H 21 N N OGG1 (p.R131*)
P53 A H 15 N N
P56 A H 15 N N
P41 A H 5-10 N N
P06 A H S 30 Y N
P43 A H S 50 N Y
P62 A H S 9 N Y
P35 A H S 30 N N
P29 A H S 25 N N
P55 A H S 12 N N
P14 A S 10 N N
 
List is ranked based on (i) polyp type, (ii) positive history of CRC development in the index patient, (iii) 
positive history of CRC or polyposis development in a first degree relative (FDR) of the index patients and 
(iv) the number of polyps present at time of diagnosis. Polyp type: A: Adenomatous polyps, H:Hyperplastic 
polyps, S:Serrated polyps. Polyp number: amount of polyps present at time of diagnosis. Colorectal cancer: 
positive (Y) if index patient developed CRC. FDR with CRC or polyposis: first degree relatives diagnosed with 
CRC and/or polyps; negative (N) if available clinical data of relatives did not mention a positive history of 
CRC or polyposis. NS BER gene: germline nonsense variant present in one of the base excision repair genes. 
For two families two (a) and three (b) family members were included.
the four driver genes APC, KRAS, PIK3CA and TP53 were equally covered in the whole-exome 
sequencing data (97.2%, 99.2%, 83.0% and 93.4%, respectively) and the targeted sequencing 
data (97%, 94%, 85% and 97%, respectively).
Targeted resequencing of APC by single-molecule molecular inversion probes. DNA 
was obtained from formalin-fixed, paraffin-embedded colonic polyps from two different NTHL1 
mutation carriers (P49 and P71). A total of 202 single-molecule molecular inversion probes 
(smMIPs) were designed as previously published20,21 with minor modifications, covering all 
coding regions and intron-exon boundaries of APC with double tiling, i.e., with minimal over-
lapping coverage of all plus- and minus-strand bases (sequences available upon request). We 
used an smMIP capture protocol as previously published20,22 with minor modifications. In brief, 
a total of 100 ng of genomic DNA was used as input material for MIP capture, and barcoded 
Illumina primers were incorporated in a PCR reaction after MIP capture and exonuclease 
treatment. Barcoded MIP libraries of all eight samples were sequenced using the Illumina 
NextSeq500 system, with 2 × 150-bp paired-end reads. The bcl files obtained were converted 
into fastq files that were split by barcode. The data obtained were annotated for the APC gene 
(NM_001127510), and nonsynonymous vari ants were called using SeqNext (version 4.2.0). 
To exclude false positive calls due to technical or deamination artifacts, we excluded regions 
covered by less than 40-fold, variants with <10% variant reads in the forward or reverse reads, 
and variants not present in the smMIP covering the opposite strand. Insertions and deletions 
were discarded and excluded from further analysis. Variants present in all polyps derived from 
one individual were considered to be germline variants and were therefore not reported here.
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Supplementary Table 2. Overview of exome sequencing statistics 
Subject NGS Platform Total bases 
sequenced 
(Gb)
Total bases on / 
near target (Gb)
% bases on 
target
Average 
Coverage 
of targets
Median 
Coverage
% regions 
≥ 10x 
coverage
% regions 
≥ 20x 
coverage
P01 SOLID 5500 5.48 4.36 73.72% 73.53 57 93.01% 84.97%
P02 SOLID 5500 6.14 4.91 74.11% 82.56 63.5 93.24% 86.06%
P03 SOLID 5500 6.31 4.98 73.01% 81.93 63 93.35% 86.09%
P04 SOLID 5500 6.78 5.44 74.35% 89.96 68 93.82% 87.19%
P05 SOLID 5500 6.75 5.43 74.60% 89.92 69 93.97% 87.75%
P06 SOLID 5500 6.53 5.09 72.07% 85.16 66 93.65% 87.05%
P07 SOLID 5500 6.91 5.53 74.15% 92.49 71 94.32% 88.22%
P08 SOLID 5500 4.77 3.81 73.99% 63.05 48 91.47% 81.37%
P09 SOLID 5500 6.56 5.23 73.77% 87.14 67 93.56% 86.72%
P11 Illumina Hi Seq 5.95 4.91 64.61% 77.39 75 98.72% 96.44%
P12 Illumina Hi Seq 6.68 5.56 64.71% 88.64 85 98.91% 97.03%
P14 Illumina Hi Seq 6.39 5.27 63.90% 83.95 80 98.89% 96.67%
P15 Illumina Hi Seq 6.82 5.59 63.33% 88.06 84 99.04% 97.10%
P16 Illumina Hi Seq 6.17 5.13 64.99% 78.60 75 98.90% 96.64%
P17 Illumina Hi Seq 6.50 5.32 63.18% 83.07 79.5 98.79% 96.53%
P18 Illumina Hi Seq 6.67 5.54 64.91% 91.96 87 98.98% 97.02%
P19 Illumina Hi Seq 7.33 6.16 66.18% 99.25 95 99.15% 97.55%
P20 Illumina Hi Seq 6.30 5.26 65.48% 80.08 76 98.85% 96.55%
P22 Illumina Hi Seq 7.15 5.96 65.32% 94.83 90.5 99.08% 97.42%
P23 Illumina Hi Seq 6.60 5.56 66.01% 88.32 85 98.84% 96.96%
P24 Illumina Hi Seq 7.30 6.13 66.46% 98.74 94 99.16% 97.56%
P25 Illumina Hi Seq 7.13 5.88 64.80% 93.43 89 99.08% 97.28%
P26 Illumina Hi Seq 5.25 4.35 64.89% 67.49 64 98.44% 95.26%
P27 Illumina Hi Seq 6.70 5.61 66.00% 89.73 86 98.91% 97.03%
P28 Illumina Hi Seq 6.89 5.75 65.95% 95.20 91 98.91% 97.04%
P29 Illumina Hi Seq 5.30 4.43 66.11% 69.76 66 98.52% 95.55%
P30 Illumina Hi Seq 5.93 4.96 65.68% 82.75 79 98.70% 96.42%
P31 Illumina Hi Seq 5.95 4.93 66.27% 82.55 79 98.82% 96.63%
P32 Illumina Hi Seq 6.72 5.57 65.84% 92.52 88 99.01% 97.13%
P34 Illumina Hi Seq 6.69 5.54 65.72% 89.33 85 98.96% 97.03%
P35 Illumina Hi Seq 6.49 5.44 66.12% 89.88 86 98.90% 96.96%
P36 Illumina Hi Seq 6.59 5.51 66.04% 89.65 85 98.95% 96.85%
P37 Illumina Hi Seq 5.90 4.88 65.84% 79.13 75 98.81% 96.33%
P38 Illumina Hi Seq 6.25 5.21 64.97% 85.67 81 98.79% 96.67%
P41 Illumina Hi Seq 6.16 5.15 66.73% 86.48 82.5 98.90% 97.01%
P42 Illumina Hi Seq 5.79 4.83 65.59% 75.93 72 98.81% 96.15%
P43 Illumina Hi Seq 6.37 5.36 67.08% 91.62 87 99.09% 97.26%
P44 Illumina Hi Seq 7.24 6.03 65.50% 98.67 94 98.96% 97.24%
P45 Illumina Hi Seq 5.37 4.44 65.16% 69.94 65 98.56% 94.92%
P46 Illumina Hi Seq 5.41 4.53 66.81% 83.99 79.5 98.93% 96.92%
P47 Illumina Hi Seq 6.65 5.63 67.64% 92.70 88.5 98.95% 97.25%
P49 Illumina Hi Seq 6.42 5.35 66.26% 84.96 76 98.96% 96.54%
P51 Illumina Hi Seq 6.76 5.65 65.61% 91.20 87 99.04% 97.15%
P52 Illumina Hi Seq 6.66 5.54 66.14% 90.33 86 99.08% 97.25%
P53 Illumina Hi Seq 6.76 5.62 65.81% 94.31 90 99.11% 97.33%
P54 Illumina Hi Seq 4.98 4.14 66.10% 64.22 61 98.39% 94.95%
P55 Illumina Hi Seq 5.61 4.69 65.29% 78.16 74 98.72% 96.39%
P56 Illumina Hi Seq 5.92 4.94 65.74% 79.13 75 98.74% 96.45%
P57 Illumina Hi Seq 5.92 4.93 65.71% 81.12 77 98.90% 96.59%
P58 Illumina Hi Seq 6.47 5.37 65.05% 87.48 83 98.93% 96.86%
P62 Illumina Hi Seq 4.87 4.06 66.26% 64.92 62 98.44% 94.89%
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Supplementary Table 7. Somatic base substitutions in comprehensive cancer panel genes in 
CRCs of individuals with biallelic NTHL1 mutations
Sample Gene mRNA accession number mRNA change AA Change Base Subst.
P07 APC NM_001127510 c.2269C>T p.Q757* C:G>T:A
P07 APC NM_001127510 c.4285C>T p.Q1429* C:G>T:A
P07 ERBB3 NM_001982 c.695C>T p.A232V C:G>T:A
P07 ERBB4 NM_005235 c.1183G>T p.V395F C:G>A:T
P07 FANCG NM_004629 c.1402G>A p.A468T C:G>T:A
P07 KRAS NM_033360 c.35G>A p.G12D C:G>T:A
P07 PIK3CA NM_006218 c.2176G>A p.E726K C:G>T:A
P07 PIK3CA NM_006218 c.353G>A p.G118D C:G>T:A
P07 RNF213 NM_001256071 c.10853G>A p.G3618D C:G>T:A
P07 SEPT9 NM_001113491 c.1321C>T p.P441S C:G>T:A
P07 SYNE1 NM_033071 c.16285A>G p.K5429E T:A>C:G
P07 TP53 NM_000546 c.853G>A p.E285K C:G>T:A
P07 ZNF521 NM_015461 c.1490G>A p.R497Q C:G>T:A
P07 NF1 NM_001042492 c.6678G>A p.L2226L C:G>T:A
P07 RNF213 NM_001256071 c.13704G>A p.V4568V C:G>T:A
P07 SMARCA4 NM_001128845 c.4038C>T p.Y1346Y C:G>T:A
P07 SOX11 NM_003108 c.693C>T p.D231D C:G>T:A
P23 APC NM_001127510 c.1909G>A p.G637R C:G>T:A
P23 APC NM_001127510 c.4405C>T p.Q1469* C:G>T:A
P23 APC NM_001127510 c.3268C>T p.Q1090* C:G>T:A
P23 ARID1A NM_006015 c.6208C>T p.Q2070* C:G>T:A
P23 BRAF NM_004333 c.1780G>A p.D594N C:G>T:A
P23 KRAS NM_033360 c.38G>A p.G13D C:G>T:A
P23 PIK3CA NM_006218 c.1624G>A p.E542K C:G>T:A
P23 PTCH1 NM_001083602 c.3219G>A p.M1073I C:G>T:A
P23 SMAD4 NM_005359 c.1255G>A p.G419R C:G>T:A
P23 TP53 NM_000546 c.722C>T p.S241F C:G>T:A
P23 ATR NM_001184 c.2850G>A p.P950P C:G>T:A
P23 PTPRT NM_133170 c.3486G>A p.A1162A C:G>T:A
P23 RALGDS NM_006266 c.225C>T p.V75V C:G>T:A
P23 TCF3 NM_003200 c.1743C>T p.N581N C:G>T:A
P23 TRIM33 NM_015906 c.1914C>T p.T638T C:G>T:A
P69 APC NM_001127510 c.4285C>T p.Q1429* C:G>T:A
P69 KRAS NM_033360 c.35G>T p.G12V C:G>A:T
P69 LPHN3 NM_015236 c.252T>G p.Y84* T:A>G:C
P69 PIK3CA NM_006218 c.1624G>A p.E542K C:G>T:A
P69 PIK3CG NM_001282427 c.1703C>A p.T568K C:G>A:T
P69 ROS1 NM_002944 c.5104G>T p.V1702F C:G>A:T
P69 SETD2 NM_014159 c.535G>A p.E179K C:G>T:A
P69 TCF3 NM_003200 c.1670G>A p.R557Q C:G>T:A
P69 TP53 NM_000546 c.743G>A p.R248Q C:G>T:A
P69 BCL9 NM_004326 c.660+1G>A p.? C:G>T:A
P69 CSMD3 NM_198123 c.8778T>A p.P2926P T:A>A:T
P69 ITGA9 NM_002207 c.1299C>T p.G433G C:G>T:A
P69 PRKDC NM_006904 c.5532G>A p.V1844V C:G>T:A
Supplementary Table 5. Frequency of the p.Q90* variant in NTHL1 in different ethnic groups. 
Population # Allele p.Q90* # Alleletotal # Homozygotes Allele Frequency
European (Dutch) 17 4,658 0 0.003649635
European (Finnish) 25 6,748 0 0.003705
European (Non-Finnish) 154 66,850 0 0.002304
Other 1 916 0 0.001092
Latino 5 11,598 0 0.0004311
African 2 10,514 0 0.0001902
South Asian 2 16,626 0 0.0001203
East Asian 0 8,740 0 0
Total 206 126,650 0 0.001627
Supplementary Table 6. Homozygous stretches observed in the exome data of polyposis 
patients.
Subject Family Total length of homozygous segments (Mb) P-Value1 NTHL1 homozygous segment2
P01 A 7,3 0,35 N
P07 * B 20,2 0,027 Y
P23 C 25,1 0,006 Y
P49 A 9,0 0,28 N
 
1) Compared to 200 controls to determine possible significant enrichment of homozygous segments in the 
corresponding exomes; one-sided, right-tailed z-test. (average length of homozygous segments in controls: 
4,2Mb; StDev: 8,3). 
2) Homozygous region encompassing the genomic locus of the NTHL1 gene.
* consanguinity confirmed based on family history. For further details: see online methods.
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Supplementary Figure 1. Loss of NTHL1 RNA expression in homozygous p.Q90* carriers due to 
nonsense-mediated decay. EBV-transformed B-lymphocytes derived from two homozygous p.Q90* 
carriers (P01 and P49, family A) show approximately ten-fold reduced NTHL1 RNA expression compared 
to EBV-transformed B-lymphocytes derived from controls. Partial rescue of NTHL1 expression is obtained 
after treatment with cyclohexamide (CHX) which indicates that expression is reduced due to nonsense-
mediated decay. Data were normalized using the expression of the housekeeping gene HPRT. Experiments 
were performed in duplo and depicted results reflect the data obtained from two independent experiments; 
error bars represent the standard deviation based on the relative expression levels of NTHL1 in all included 
samples. 
Supplementary Table 8. Somatic mutations in APC in colorectal adenomas of individuals with 
biallelic NTHL1 mutations
Sample mRNA 
change*
AA Change # reads Fw # reads Rv %Var. Reads Fw %Var. Reads Rv Base Subst.
P49 (2) c.1417C>T p.Q473* 7,463 9,506 13.1 13.6 C:G>T:A
P49 (1) c.2097G>A p.W699* 6,011 1,791 24.6 34.2 C:G>T:A
P49 (3) c.3688C>T p.Q1230* 6,609 6,544 42.2 42.0 C:G>T:A
P49 (3) c.3880C>T p.Q1294* 2,306 2,218 32.8 54.7 C:G>T:A
P71 (2) c.739C>T p.Q247* 4,087 4,101 18.7 18.6 C:G>T:A
P71 (1) c.2995C>T p.Q999* 1,748 4,768 16.1 10.1 C:G>T:A
*NM_001127510. Numbers between brackets represent corresponding polyp sample.
Supplementary Table 9. Somatic base substitutions in comprehensive cancer panel genes in 
CRCs of individuals with biallelic MUTYH mutations
Sample Gene mRNA accession number mRNA change AA Change Base Subst.
MAP1 ADAMTS20 NM_025003 c.1723G>A p.G575R C:G>T:A
MAP1 PIK3CG NM_001282427 c.1912G>T p.E638* C:G>A:T
MAP1 SMAD4 NM_005359 c.1572G>T p.W524C C:G>A:T
MAP1 SMARCA4 NM_001128845 c.4296G>T p.M1432I C:G>A:T
MAP2 APC NM_001127510 c.4120G>T p.E1374* C:G>A:T
MAP2 KRAS NM_033360 c.436G>A p.A146T C:G>T:A
MAP2 NLRP1 NM_033004 c.2415G>T p.K805N C:G>A:T
MUTYH germline mutations. MAP1: p.P405L (homozygous) and MAP2: p.P405L (heterozygous) and 
p.D161H (heterozygous).
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Supplementary Figure 3. Validation and co-segregation analysis by Sanger sequencing. The 
c.268C>T (p.Q90*) variant in NTHL1 was present in all clinically affected members of families A (P01 and 
P49), B (P07, P71 and P72), and C (p23 and P69). WT: wild type control negative for the c.268C>T variant 
in the NTHL1 gene. Arrow: the change of guanine to adenine results in the introduction of a stop codon.
 
Supplementary Figure 2. Read depth analysis of exome data. Read depth of P07 (Top panel, red 
dots, SOLiD exome sequencing data) and P23 (Bottom panel, orange dots, Illumina exome sequencing 
data) compared to 7 and 40 NTHL1 wild type samples, respectively (grey dots). Both P07 and P23 are 
homozygous around the NTHL1 locus (blue bars; Supplementary Fig. 6), but median read-depth analysis 
of chromosome 16 shows that large genomic deletions encompassing this locus are not present. 
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Supplementary Figure 5. Continued on next page.
Supplementary Figure 4. Recurrent truncating and missense variants in the NTHL1 gene and ethnic 
distributions. Upper part: eight truncating variants are recurrently (≥2 calls) encountered in our in-house 
database, or the database from the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org/). 
All variants were encountered in a heterozygous state. The p.Q90* variant (red underlined) is present in 
subjects from different descent, but significantly enriched in European cohorts. Lower panel: seventeen 
missense variants were recurrently (≥10 calls) encountered in our in-house- or ExAC databases. Frequencies 
of these variants are depicted for the different populations and, based on in-silico predictions, most of these 
missense variants are predicted to be benign polymorphisms.
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Supplementary Figure 6. Haplotype analysis around the NTHL1 locus. (a) B-allele frequency plots extracted 
from the exome sequencing data of P01 and P49 (family A), P07 (family B), and P23 (family C). Both 
individuals from family A encompass heterozygosity around the NTHL1 locus, whereas homozygous stretches 
encompassing the NTHL1 locus were present in P07 and P23. Boundaries of the homozygous regions in P07 
(~7 Mb) and P23 (~10 Mb) are indicated by asterisks connected by dashed lines. (b) Haplotype analysis of 
a 1-Mb genomic locus encompassing the NTHL1 gene (red line). At least three different haplotypes were 
observed in four carriers of the p.Q90* variant in the NTHL1 gene. The presence of a recombination hotspot 
(recombination rate: 18.9 cM/Mb 17) upstream of the NTHL1 p.Q90* locus (chr16:2,096,239) may explain 
the observed variability in haplotypes. Blocks represent informative SNPs in close proximity (1 Mb region) of 
the NTHL1 p.Q90* locus; (A) and (B) represent major and minor alleles, respectively.
 
 
Supplementary Figure 5. Genome-wide autozygosity mapping. Homozygosity/autozygosity mapping 
based on exome data from four patients (P01, P07, P23 and P49) from three families confirms homozygous 
stretches (black regions) encompassing the NTHL1 locus in P07 and P23 (red arrow). Overall, homozygous 
stretches were more abundant in P07 and P23 compared to P01 and P49 due to consanguinity (family B) or 
predicted consanguinity (family C) in these families (see supplementary table 6), but overlap of homozygous 
regions between P07 and P23 was only observed at the NTHL1 locus. Yellow regions represent heterozygous 
regions, numbers correspond to chromosomal numbering and y-axis defines the genomic position on the 
corresponding chromosome. For details, see online methods.
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Abstract
Adenomatous polyposis, the constitutive development of premalignant adenomas in the 
colorectum, is strongly associated with heritable germline aberrations. In spite of the fact 
that several genes underlying the development of adenomatous polyposis have already 
been identified, a significant subset of the cases still remain unexplained. The identification 
of causative germline aberrations is crucial for the clinical management of individual patients 
and for the identification of other (related) individuals at risk. In addition, it is imperative for 
improving our understanding of colonic polyp formation and colorectal cancer development. 
Previously, we performed whole-exome sequencing (WES) on germline DNA derived from a 
stringently selected cohort of 51 adenomatous polyposis patients from 48 families that were 
tested negative for mutations in the APC and MUTYH genes. Three of these families were 
found to carry biallelic mutations in the base excision repair gene NTHL1, thereby explaining 
the development of adenomatous polyposis in seven family members and colorectal cancer in 
four of them (chapter 4). Here, we performed additional systematic analyses on this dataset to 
identify germline aberrations that may explain the development of adenomatous polyposis in 
the remaining 45 families. We searched for i) germline variants in known cancer predisposing 
genes and candidate colorectal cancer genes, ii) homozygous and compound heterozygous 
variant calls, and iii) recurrent heterozygous variant calls and rare loss-of-function heterozygous 
variant calls. Using these strategies, we encountered several candidates, including potentially 
pathogenic variants in POLE and POLD1, homozygous conserved missense variants in AHCTF1 
and NUP133 and heterozygous loss-of-function variants in ATM, CIAO1, GEN1 and PTPN13. 
A final pathway analysis on protein truncating germline variants in the 48 adenomatous 
polyposis families compared to 2,329 non-affected controls revealed that the base excision 
repair pathway was the only pathway for which rare variants were enriched in the patient 
cohort. In conclusion, WES of our cohort of unexplained adenomatous polyposis index-patients 
and families has revealed the genetic cause in 3 families (NTHL1, 6.3%), the probable cause in 
two patients (POLE and POLD1, 4%) and interesting variants in 10 patients (21%). Screening 
for recurrencies in large adenomatous polyposis cohorts and co-segregation analyses in affected 
families is required to establish the putative predisposing role of these latter variants.
Introduction
Adenomas are initially benign outgrowths of the epithelial tissue in the lumen of the 
colorectum, but have the potential to evolve into carcinomas through the accumulation of 
somatic mutations [1]. The lifetime risk to develop colorectal cancer (CRC) is associated with the 
number of adenomas present in the colorectum [2], and it has been established that patients 
diagnosed with 10s to 100s of adenomas are at an increased risk. The early recognition of 
adenomatous polyposis significantly improves cancer prevention through tailor-made clinical 
management (i.e., removal of polyps or colectomy), especially since the cancer incidence (CRC 
or others) has been found to be associated with the age of the patients [3]. Here, we set out to 
detect additional germline adenomatous polyposis predisposing aberrations in order to identify 
individuals at risk and to uncover novel leads to colorectal polyp and cancer development.
To date, four high-penetrant hereditary adenomatous polyposis predisposing syndromes 
have been reported: familial adenomatous polyposis (FAP), polymerase proofreading-associated 
polyposis (PPAP), MUTYH-associated polyposis (MAP) and NTHL1-associated polyposis (NAP) 
[4-8]. FAP shows an autosomal dominant inheritance pattern and is caused by mutations in the 
APC gene, As yet, FAP is the most common high-penetrant hereditary adenomatous polyposis 
predisposing syndrome known [9]. Recently, it has been found that missense mutations in the 
proofreading domains of the POLE and POLD1 genes predispose to the development of PPAP, 
which is also inherited in an autosomal dominant manner [7]. The two remaining syndromes show 
a recessive inheritance pattern and are caused by germline mutations in the base excision repair 
genes MUTYH and NTHL1. Biallelic germline mutations in MUTYH underlie the development of 
MAP, which explains approximately 20% of the APC germline mutation-negative adenomatous 
polyposis cases [10]. We recently found that a homozygous nonsense mutation in NTHL1 also 
causes adenomatous polyposis and an increased risk for cancer development, including CRC [8] 
(chapter 4). The prevalence of this syndrome still remains to be determined. As yet, however, 
approximately 20% of the adenomatous polyposis cases cannot be explained by germline 
aberrations in these known predisposing genes [9]. Therefore, we hypothesize that additional 
high-penetrant adenomatous polyposis and CRC predisposing genes still await discovery.
Whole-exome and whole-genome sequencing (WES and WGS) have proven to be 
efficient strategies to identify novel adenomatous polyposis and CRC predisposing genes, as 
was recently demonstrated by the discovery of causative mutations in POLE and POLD1 in PPAP 
and in NTHL1 in NAP [7, 8]. A strong association between POLE and POLD1 mutations and 
the occurrence of adenomatous polyposis has been further substantiated in several targeted 
sequencing studies through which additional affected families were identified [11-13]. In 
addition, several other candidate CRC predisposing genes have been identified through WES, 
including the spindle assembly checkpoint genes BUB1 and BUB3 and the nuclease gene FAN1, 
which both link CRC predisposition to chromosomal instability [14, 15]. Several other studies 
have also indicated that adenomatous polyposis may be genetically heterogeneous and that 
many candidate predisposing genes still await validation in large patient-control cohorts [16-
19].
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In this chapter, we provide a comprehensive analysis of WES data obtained from 51 
unexplained adenomatous polyposis patients from 48 families (chapter 4). First, we screened 
for pathogenic germline mutations in known cancer predisposing genes and describe two 
putative PPAP patients in our cohort. We also screened for pathogenic germline mutations in the 
candidate CRC predisposing genes FOCAD (chapter 2), BUB1, BUB1B, BUB3 (chapter 3) and 
FAN1 [15], but no deleterious mutations were found. To identify novel recessive predisposing 
genes (like MUTYH and NTHL1), we searched for homozygous and compound heterozygous 
variants calls. Furthermore, compliant with a possible dominant inheritance pattern, we 
screened for recurrent heterozygous variant calls and rare heterozygous loss-of-function variant 
calls. Finally, we performed pathway analyses to search for a putative enrichment. Through 
these patient/family analyses, we were able to reveal the cause in 3 families (NAP, 6.3%), the 
putative cause in two patients (PPAP, 4%) and candidate variants in 10 patients (21%).
Materials and Methods
Clinical characteristics of patients included for WES
We selected 51 individuals from 48 families who developed adenomatous polyposis and were 
suspected of a hereditary cause (supplementary Table 1 in chapter 4,). All 51 individuals 
developed adenomatous polyps and 48 of them were diagnosed with at least 10 polyps 
(median: 20, range 5-250 polyps). In addition to adenomatous polyps, 28 and 7 individuals 
were diagnosed with hyperplastic and serrated polyps, respectively. In line with the malignant 
potential of adenomatous polyps, the incidence of CRC in these 51 adenomatous polyposis 
patients was high (n=21). 27 individuals had a positive family history of polyposis and/or CRC 
and from two families, two and three affected siblings were included. All patients included were 
tested negative for germline aberrations in APC and MUTYH prior to whole-exome sequencing 
(WES) of blood derived DNA. All participants provided written informed consent or samples were 
irreversibly anonymized. This study was approved by the medical ethics committee (CMO, study 
number 2014/032)/institutional board of the Radboudumc. For more details and information 
regarding the patient cohort, control cohort and whole-exome sequencing, see the material and 
method section of chapter 4.
Whole-exome sequencing statistics
 WES was performed on peripheral blood-derived DNA using 5500xl (Life technology) 
or HiSeq (Illumina) sequencers. On average, 6.30 Gb were sequenced (median 6,47 Gb, range 
4.77-7.33 Gb), of which 67.1% were aligned to the human reference genome (hg19) (median 
66.0, range 63.2-74.6%). The average median on-target coverage was 77.9-fold (range 48-
95 fold) and 97.9% of target regions was covered at least 10-fold (range 91.5-99.2%). A 
comprehensive overview of WES statistics per sample is provided in (supplementary Table 2) 
in chapter 4. 
 Using standard procedures (see chapter 4), a median of 43,144 variants was called per 
sample (range 42,363- 52,293). Variant calls frequently encountered in our in-house database 
of WES variants (minor allele frequency >1%) were considered benign polymorphisms and 
excluded from further analyses, reducing the average number of variants per sample to 1,451 
(median 1234, range 1049-4015). On average, 299 missense variants, 22 in-frame insertions/
deletions, 3 variants affecting a canonical splice site (CSS), 13 frameshift variants (insertion/
deletion) and 5 nonsense variants were encountered per sample (supplementary Figure 1). 
 
Variant selection
 We filtered for loss-of-function variants (variants affecting a canonical splice site, 
insertions/deletions introducing a frameshift, and nonsense mutations) and missense mutations 
affecting conserved regions (PhyloP ≥3) which are rare in our in-house database of exome 
sequencing variants and the dbSNP142 database [20] (MAF ≤1). Variants that were called in ≥10 
of the 51 polyposis exomes were excluded from further analysis.
To select for homozygous variants, we filtered for variant calls with ≥20 fold coverage 
and ≥95% variant reads. Variants located on the X or Y chromosome were excluded. In 
addition, insertions and deletions in homopolymeric stretches of >10 consecutive nucleotides 
were excluded from further analysis. In total 12 potential homozygous calls were identified.
Genes with multiple variants in one sample were considered candidate compound 
heterozygous. A total of 49 compound heterozygous variant calls in 28 polyposis samples 
affecting 35 different genes was initially identified, but 13 compound heterozygous variant calls 
were excluded because these variants were located on the same read in the whole-exome data. 
Therefore, in total, 36 potential compound heterozygous calls were identified.
For heterozygous variant calls, assuming autosomal dominant inheritance, only variant 
calls that are (nearly) absent in control datasets were included for analysis (MAF<0.001 in both 
our in-house database of exome sequencing variants and the dbSNP142 database [20]). In 
addition, we filtered for variant calls with ≥20 fold coverage and ≥20% variant reads. To prevent 
recurrency due to the inclusion of family members (see chapter 4 and chapter 7), all variants 
identified in P01, P45 and P46 were excluded. Using these settings, the total number of selected 
variants was 1,961.
ExAC control cohort
To determine the frequency of the encountered missense variants in POLE (p.K284E) 
and POLD1 (p.G321S) in controls, we searched for these specific variants in The Exome 
Aggregation Consortium (ExAC) database (n=60,706) [Version 0.3; July, 2015 accessed]. This 
database contains all germline variants identified in exomes derived from unrelated individuals 
from African, Asian, European or Latino descent without severe pediatric diseases [21]. Coverage 
of the respective genomic positions was high for the majority of the samples included in the 
ExAC database (≥25 read depth). 
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Variant selection and KEGG pathway analysis
 Our control cohort contained exome data (Illumina) derived from 2,329 individuals 
who had, to our knowledge, no suspected form of hereditary cancer (see chapter 4). In this 
dataset, we encountered 483,570 different variants affecting exonic and canonical splice site 
regions that were rare (MAF≤0.01) in our in-house database of exome sequencing variants 
(containing all germline whole-exome sequencing variants identified in 2,037 individuals, see 
chapter 4). We filtered for base substitutions introducing a nonsense mutation or affecting a 
canonical splice site, yielding a total of 7,575 different variant calls in 5,252 genes. 1,451 of 
these genes (2,087 unique variants; 4,711 alleles in total) were involved in at least one KEGG 
pathway (225 KEGG pathways in total). Using a similar approach, we identified 88 unique 
truncating variants (95 alleles in total) in 85 genes associated with one of the 225 KEGG 
pathways in the WES data derived from 48 unrelated adenomatous polyposis patients (variant 
calls in P01 (related to P49) and P46 and P47 (related to P45) were excluded). Subsequently, 
the number of truncating alleles per KEGG pathway were compared between the control and 
patient cohorts. The number of truncating alleles per cohort were compared for 225 different 
KEGG pathways.
Statistical analysis
 To confirm statistically significant differences between the number of pathogenic or 
truncating variants in the patient cohort (48 individuals, three related subjects (P01, P45 and 
P46) were excluded) compared to the control dataset (n=2,329), a two-tailed Fisher Exact test 
was performed. Correction for multiple testing was performed for the candidate gene list (n=5) 
and the KEGG pathway analysis (n=225). 
Results
Whole-exome sequencing reveals germline variants in known cancer predisposing 
genes
 To establish the role of genes associated with high-penetrant cancer predisposition, 
we screened our previously generated whole-exome sequencing (WES) data [8] (chapter 4) 
for the presence of deleterious variants in known cancer predisposing genes (CPGs) [22] and 
detected 31 variants in 23 CPGs (Table 1). Three of these variants are likely to predispose 
to the development of cancer: a nonsense variant in BRCA2 in individual P54 (c.5645C>A, 
p.S1882*, NM_000059) and two novel missense variants in the exonuclease domains of POLD1 
(c.961G>A; p.G321S, NM_002691) and POLE (c.850C>G; p.K284E, NM_006231) in individuals 
P17 and P35, respectively. 
 The BRCA2 p.S1882* variant in P54 was known prior to inclusion of the patients for 
WES but, since this variant unlikely explains the adenomatous polyposis phenotype, this patient 
was nevertheless included in our cohort. She developed breast cancer and endometrial cancer 
at the ages of 39 and 52, respectively. Furthermore, she had a positive family history of breast 
cancer and multiple family members were diagnosed with breast cancer below the age of 50. 
The germline variants in POLD1 (p.G321S) and POLE (p.K284E) are of interest, 
since both are located in the proofreading domains and, therefore, may predispose to the 
development of polymerase proofreading-associated polyposis (PPAP) [7]. The p.K284E variant 
in POLE is highly conserved (PhyloP: 5.026) and predicted to be pathogenic by two out of 
three in-silico prediction tools applied: SIFT: Deleterious (score: 0), Align GVGD: Class C0 (GV: 
353.86 - GD: 0.00), and PolyPhen2: probably damaging (score: 1.000). The missense variant 
in POLD1, p.G321S, affects a highly conserved amino acid (PhyloP: 5.549) and is predicted to 
be pathogenic by all three in-silico tools: SIFT: Deleterious (score: 0), Align GVGD: C55 (GV: 
0.00 - GD: 55.27) and PolyPhen2: possibly damaging (score: 0.880). Both variants are rare 
but not unique: the p.K284E variant in POLE was encountered 5 times in the ExAC database 
(MAF 0.0000413) and the p.G321S allele of POLD1 was called 53 times in this database (MAF 
0.0005148). P17 developed 12 adenomatous polyps and 5 first-degree family members were 
diagnosed with polyposis and/or CRC (Figure 1). P35 developed 8 adenomatous polyps, 20-
30 hyperplastic polyps and 4 serrated adenomas, but exhibited a negative family history of 
polyposis and/or CRC. 
Absence of deleterious germline variants in candidate cancer predisposing genes
 Next, we extracted all rare germline variants (MAF<0.01) called in recently reported 
candidate cancer predisposing genes to substantiate their role in adenomatous polyposis 
predisposition. These included three genes that we identified earlier, namely: FOCAD (chapter 
2), BUB1 and BUB3 (chapter 3) [14, 23], as well as the candidate CRC predisposing genes 
BUB1B and FAN1 [15, 24]. Prior to inclusion for WES, 30 patients were already tested negative 
for pathogenic germline mutations in FOCAD (chapter 2). Protein truncating germline variants 
were not observed in any of the candidate genes, but three and two highly conserved missense 
variants (phyloP ≥3) were encountered in FOCAD and BUB1, respectively (Table 2). However, 
compared to 2,329 controls, the number of rare, highly conserved, missense variants in FOCAD 
and BUB1 is not significantly increased in our cohort of 51 adenomatous polyposis patients 
(PFOCAD = 0.56 and PBUB1 = 0.18 after correcting for multiple (n=5) testing). Based on in-silico 
prediction tools, the five rare, highly conserved, missense variants encountered in FOCAD and 
BUB1 are predicted to be benign (Table 2).
 
Rare homozygous variants in genes not previously associated with adenomatous 
polyposis 
 In line with a recessive inheritance pattern as observed in NTHL1-associated polyposis 
(NAP) due to homozygous germline variants (chapter 4), we filtered for the presence of 
potential pathogenic homozygous variant calls in our adenomatous polyposis cohort (see 
materials and methods). Apart from the homozygous variant calls for p.Q90* in NTHL1, 
ten additional potential homozygous variant calls in nine different adenomatous polyposis 
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patients were found (Table 3). One variant affecting a canonical splice site of AHCTF1 was 
called homozygously in individual P24. AHCTF1 encodes a putative transcription factor and, 
in addition, acts as a kinetochore-associated protein during mitosis [25]. Whereas reduced 
expression of AHCTF1 does not appear to result in significant chromosome segregation defects, 
other mitotic defects have been observed [25]. In subject P05 a homozygous missense variant 
was called in NUP133 (p.T698I). Interestingly, it has been found that during mitosis NUP133 
and AHCTF1 localize in a similar spatio-temporal fashion to the kinetochore. Therefore, NUP133 
and AHCTF1 are suspected to be co-dependent for proper kinetochore targeting [25]. Based on 
in-silico prediction tools, however, the p.T698I missense variant in NUP133 is predicted to be 
probably benign (Table 3). 
A subset of homozygous missense variants were found to be located in genes 
associated with other heritable syndromes. The p.I426L variant in AP4E1 in subject P17 may 
be considered to be benign, since biallelic pathogenic variants in AP4E1 are instead known to 
cause severe intellectual disability [26, 27]. INA is a neural intermediate filament encoding gene 
and has been associated with brain-related phenotypes (e.g. schizophrenia and migraine [28, 
29]). Germline aberrations in PKD2 are known to predispose to autosomal dominant polycystic 
kidney disease type 2 [30]. Also prediction programs annotate the missense variants in AP4E1 
and PKD2 as probably benign, whereas the p.H347R variant in INA is predicted to be deleterious 
(Table 3).
A missense variant (p.L134P) in GPR87 was predicted to be deleterious and called in 
a homozygous state in two related individuals (P45 and P47). This variant, however, was not 
observed (in a homozygous state) in four other affected family members, and polyposis was 
inherited in a dominant rather than a recessive manner in this family (see chapter 7). Finally, 
lack of available information on the functions of ARFIP1, OR4C11 and ZNF507 hampers a proper 
estimation to what extent these genes may predispose to the development of adenomatous 
polyposis and/or CRC.
 
Compound heterozygous variants in potentially novel adenomatous polyposis 
predisposing genes
 In addition to homozygous variant calls, we also screened for potential compound 
heterozygous calls in our cohort of 51 adenomatous polyposis patients, thereby assuming a loss-
of-function scenario. By doing so, we identified 36 potential compound heterozygous variant calls 
in 29 different patients (Table 4). For none of these patients it could be established whether the 
variants are on distinct alleles.
Possible compound heterozygosity was recurrently encountered for the TTN and PLEC 
genes in three and two adenomatous polyposis patients, respectively. The abundance of germline 
variants in TTN can likely be explained by the large size of this gene, which encodes the 34,350 
amino acids sized protein Titin (NM_001256850). The variants encountered in the PLEC gene may 
be considered non-pathogenic, since biallelic pathogenic germline variants in PLEC are known to 
predispose to early childhood onset of muscular dystrophy with epidermolysis bullosa simplex [31], 
a phenotype that was not reported in either of the two adenomatous polyposis patients tested.
Similar to PLEC, biallelic pathogenic germline mutations in a subset of the other genes 
have been strongly associated with other severe and early-onset clinical phenotypes, but not with 
cancer predisposition. Biallelic germline mutations in the TBX6 (congenital scoliosis [32]), COL6A3 
(early-onset isolated dystonia [33]), NBAS (recurrent acute liver failure with onset in infancy 
[34]), CDH23 (Usher syndrome, deafness [35]), RELN (lissencephaly with cerebellar hypoplasia 
[36]) and PDE6A (retinitis pigmentosa [37]) genes, if pathogenic, would have resulted in severe 
clinical phenotypes, which were not observed in our adenomatous polyposis patients. The ABCC2 
(Dubin-Johnson syndrome [38]), MYH6 (Hypertrophic cardiomyopathy [39, 40]), SPTB (hereditary 
spherocytosis [41]) and COL6A6 (deficiencies result in myopathies [42]) genes have been associated 
with less severe syndromes, but patients diagnosed with these syndromes are not known to be at 
an increased risk to develop cancer.
Based on in vivo studies, complete loss-of-function of a subset of genes may not be 
compatible with life. For example, KIF16B, PIEZO1, POLD1, RTTN, TBX6, TENM4 and TTN are 
required for early embryonic development in mice and, teleological, for early embryonic 
mammalian development in general [43-49]. The function of a subset of the remaining genes 
appears to be in conflict with a potential role in colorectal tumorigenesis, i.e., the abundant 
expression of SLC26A11, RIMS2 and NELL1 in the embryonic brain may indicate a crucial role 
in brain development [50-53], whereas SSPO encodes a glycoprotein that is involved in neurite 
outgrowth [54]. Indeed, NELL1 knockout mice show an alteration in cranial morphology and are 
neonatal lethal [55]. Finally, lack of data on the function of C7orf29, DNAH7, DNAH8, RANBP6, 
KIAA2018, SPTBN4 and ZNF76 hampers a functional interpretation of the identified germline 
variants and their potential role in adenomatous polyposis predisposition.
Five candidate genes, HDLBP, MC1R, PPP1R12B, MAML1 and FAT3, have previously been 
associated with tumorigenesis. HDLBP has been identified as a tumor suppressor gene involved in 
sarcoma development using a combined retroviral and transposon insertional mutagenesis screen 
in mice [56]. Germline variants in MC1R have not only been associated with red hair and fair skin 
[57], but also with an increased risk for the development of BRAF mutation-positive melanomas 
[58]. The function of PPP1R12B has not been elucidated yet, but significant down-regulation of 
PPP1R12B has been observed in sporadic colorectal cancers [59]. MAML1 is a transcriptional co-
activator of the NOTCH signaling pathway. Constitutive activation of this pathway has repeatedly 
been observed in several cancers, including CRC [60, 61]. In addition, it has been reported that 
MAML1 acts as a co-activator of β-catenin transcription activation and, as such, is essential for 
colon carcinoma survival [62]. A reduced expression due to biallelic germline aberrations, however, 
seems to be in conflict with a specific adenomatous polyposis and/or CRC predisposing role. 
FAT3 is a member of the Fat cadherin subfamily of proteins and is involved in the Hippo signaling 
pathway [63]. FAT3 is expressed primarily in the developing central nervous system. Knockout mice 
are viable, but exhibit specific cellular changes in the retina [64]. Recently, somatic mutations in 
FAT3 have been observed in acinar cell carcinomas of the pancreas [65] and esophageal squamous 
cell carcinoma [66].
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Recurrent or rare loss-of-function heterozygous variants in potentially novel 
adenomatous polyposis predisposing genes
 In addition to homozygous and compound heterozygous variants, we also filtered for 
heterozygous variants that may predispose to adenomatous polyposis and CRC in a dominant 
manner (see materials and methods). A total of 21 rare variants was recurrently encountered in 
the 48 adenomatous polyposis families (Table 5). Two missense variants, p.T429M in ME2 and 
p.D76N in PDX1, were encountered in three different patients, whereas the other 19 variant were 
identified twice. Recurrent loss-of-function variants were called in ATM (p.E522Fs), C14orf37 
(p.T233fs), CALCR (p.N487fs) and MMP25 (p.R118*). In the past, germline aberrations in ATM 
have already been associated with tumorigenesis. Depletion of ATM in mice has been found to 
result in the development of malignant thymic lymphomas [67] and patients with mild ataxia 
telangiectasia, caused by a partially retained activity of ATM, are at an increased risk to develop 
lymphoid tumors and breast cancer [68]. MMP25 is highly expressed in human colon cancer and 
promotes tumor growth [69], which again is in conflict with a possible adenomatous polyposis 
and/or CRC predisposing role of a germline nonsense variant.
 In 182 genes, at least two rare variants were encountered (Table 6). In 152 of these 
182 genes, only two different variants were identified. Most unique variants (n=10) were 
called in the TTN gene (107,976 bp), probably due to the large coding size of this gene. Five 
unique variants were identified in the glycoprotein encoding SSPO gene. In the OBSCN, RYR3, 
PLEC, COL6A3 and ELMO3 genes four different variant calls were noted. Rare germline loss-
of-function and conserved missense variants were, however, also frequently observed in most 
of these genes in a cohort of 2,329 control exomes: TTN (383 unique variants), SSPO (62), 
OBSCN (84), RYR3 (60), PLEC (97), COL6A3 (26) and ELMO3 (11). The number of unique rare 
germline variants in these genes in adenomatous polyposis patients is probably related to the 
corresponding gene sizes (Figure 2).
 
Potentially novel adenomatous polyposis predisposing genes based on predicted 
protein-protein interactions
 Finally, we filtered for rare base substitutions affecting a canonical splice site or 
introducing a nonsense mutation, and determined if the corresponding genes encode proteins 
which are predicted to interact with the protein products of known polyposis and CRC 
predisposing genes. For the protein products of BRCA2 (p.S1882*), CIAO1 (p.W69*), FANCM 
(p.R658*), GEN1 (p.S870*), OGG1 (p.R131*) and PTPN13 (c.4258+2T>C ) interactions are 
predicted with the encoded proteins of known polyposis or CRC predisposing genes (Figure 
3). We noticed that, next to the previously identified mutations in BRCA2, OGG1 and SMUG1 
(p.R124*) (chapter 4), both GEN1 and FANCM are involved in DNA repair. The nonsense variant 
in the base excision repair gene MPG (p.R118*), reported in chapter 4, was excluded from this 
analysis based on the high frequency of this variant in our in-house database (MAF 0,29). Rare 
base substitutions introducing a nonsense mutation were recurrently encountered in FANCM 
in 2,329 controls (NM_020937; p.Q306*, p.R658*, p.Q1701* and p.R1931* were called 1, 1, 
8 and 4 times, respectively). In contrast, base substitutions affecting a canonical splice site or 
introducing a nonsense mutation were not observed in CIAO1 and GEN1 in the same control 
dataset. It should, however, be noted that a germline deletion introducing a frameshift in 
GEN1 (c.2515_2519delAAGTT) was recurrently encountered in our control dataset (called in 
a heterozygous and homozygous state in 454 and 33 individuals, respectively). One nonsense 
variant in PTPN13, p.Q2482*, was observed in a heterozygous state in two controls, but may 
not affect the function of the protein since this variant only disrupts the translation of the last 
nine amino acids of the protein.
Protein truncating germline variants in genes involved in the base excision repair 
pathway are enriched in adenomatous polyposis patients
 To identify a possible enrichment of deleterious variants in certain cellular pathways, 
we compared the KEGG pathway annotations of rare deleterious variants (canonical splice site- 
and nonsense variants) (MAF≤0.01) encountered in the 48 adenomatous polyposis families 
with similar variants called in WES data derived from 2,329 in-house controls who have, to 
our knowledge, not been diagnosed with polyposis and/or CRC (for details, see materials and 
methods). In total, 95 and 4,711 truncating alleles in genes with a known KEGG annotation 
were encountered in the patient and control cohorts, respectively. These truncating alleles 
correspond to genes that are involved in 225 different KEGG pathways. The number of truncating 
alleles encountered per KEGG pathway strongly correlates between patients and controls (R2= 
0.7286), and in both cohorts most truncating alleles were encountered in genes involved in 
the metabolic pathways (Table 7). After correcting for multiple testing (Bonferrroni correction), 
the base excision repair pathway (hsa03410) appeared to be the only KEGG pathway that 
was significantly enriched for the number of truncating alleles in the adenomatous polyposis 
patients compared to the controls (P = 0.0127) (Figure 4). Four different genes in this pathway 
were found to carry nonsense mutations, i.e., NTHL1 in three individuals (c.268C>T, p.Gln90*, 
NM_002528), and OGG1 (c.391C>T, p.Arg131*, NM_016821), MPG (c.352C>T, p.Arg118*, 
NM_002434) and SMUG1 (c.370C>T, p.Arg124*, NM_014311) in one individual each (Table 
8) (already known prior to the pathway analysis, see chapter 4). In 2,329 controls, truncating 
germline variants in base excision repair genes were encountered in APEX1, LIG3, MBD4, MPG, 
MUTYH, NTHL1, PARP3, PARP4, POLB, POLD1, POLE, POLL, SMUG1 and XRCC1 (Table 9).
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Discussion
 
We have performed a comprehensive analysis of whole-exome sequencing (WES) data 
from a stringently selected cohort of 51 unexplained adenomatous polyposis patients from 
48 families. Next to the truncating variants in base excision repair genes, we identified novel 
germline aberrations in the proofreading domains of POLE and POLD1 in two other patients 
(chapter 4). The data analysis also revealed additional interesting candidate genes, but the 
causative effects of the corresponding germline variants remain to be established. Furthermore, 
we show that, apart from the base excision repair pathway, no other pathway is more frequently 
affected by truncating mutations in the adenomatous polyposis patients tested compared 
to controls. We conclude that in our cohort of 51 individuals who developed adenomatous 
polyposis, four patients can be explained by NTHL1-associated polyposis (NAP; chapter 4), two 
patients may be explained by a pathogenic germline variant in POLE and POLD1, respectively, 
and nine patients carry interesting, putative causative, variants in the AHCTF1, ATM, CIAO1, 
MPG, NUP133, OGG1, PTPN13 and SMUG1 genes. 
Taken together, we conclude that our approach was instrumental in the identification 
of (putative) causative germline variants in a significant subset of a cohort of previously 
unexplained adenomatous polyposis patients.
Previous studies have shown that whole-exome sequencing serves as a useful tool 
to identify causative germline mutations in known CRC predisposing genes [70, 71], but the 
identification of novel predisposing genes appeared challenging [16-19]. The identification of 
NTHL1 as a gene underlying a distinct subset of adenomatous polyposis patients (NAP), and 
the identification of additional promising germline aberrations in our discovery cohort of 51 
patients underlines the importance of stringent patient selection. In contrast to previous studies 
in which CRC patients were included based on age of onset or family history [16-19], which 
results in rather heterogeneous cohorts, we strictly selected APC and MUTYH mutation-negative 
patients who developed adenomatous polyposis, were suspected of a hereditary cause and/
or had a high (familial) CRC incidence. This selection has improved the homogeneity of the 
patient group included in our discovery cohort. Based on the expected low frequency of novel 
polyposis and/or CRC predisposing syndromes (such as PPAP and NAP), patient cohorts need to 
be clinically well-defined and as homogeneous as possible.
Although our WES approach was successful, still a subset of the adenomatous 
polyposis patients remains unexplained (89,6% was not explained by NAP or, possibly, PPAP). 
One reason for this may be that in several cases family members were not available for genetic 
testing. For example, co-segregations analyses may significantly reduce the number of candidate 
variant calls and thus facilitate the identification of relevant, causative variants (chapter 7). This 
approach has recently been successfully applied for the identification of FAN1 as a novel CRC 
predisposing gene [15]. In addition, linkage data may be used to guide the search for shared 
regions. Whereas an initial screening for recurrent rare germline variants was unsuccessful in 
a study of Palles et al., the inclusion of linkage data ultimately resulted in the identification of 
POLE and POLD1 as novel adenomatous polyposis and CRC predisposing genes [7]. Therefore, 
we anticipate that within our cohort at least a subset of the patients could have been explained 
if additional family members would have been available and included for WES.
Since the original finding that germline mutations in the exonuclease domains of POLE 
(p.L424V) and POLD1 (p.S478N) predispose to the development of adenomatous polyposis and 
CRC [7], several other germline missense variants in the same domains have been identified 
in additional polyposis patients [11, 13, 70, 72-74]. For a subset of these variants, including 
p.N363K and p.Y458F in POLE [72, 73] and p.L474P in POLD1 [11], co-segregation analyses 
in families with multiple affected members confirmed their causality. Additionally, somatic 
mutations in the exonuclease domain of POLE are frequently encountered in hypermutated 
tumors [75]. Interestingly, the positions of the hotspot mutations in POLE in endometrial and 
colorectal cancers, i.e., p.P286H/R/S, p.V411L and p.S459F, respectively [75-79], differ from 
the known causative germline variants observed in PPAP patients. Here, we have identified 
rare missense variants in the proofreading domain of POLE (p.K284E) and POLD1 (p.G321S) 
that are predicted to be pathogenic in silico, but have not previously been associated with 
PPAP. Interestingly, the p.K284E germline variant in POLE is located in close proximity to the 
somatic mutation hotspot at amino acid position 286 [77, 78]. Both the p.K284E (POLE) and 
p.G321S (POLD1) variant are rare in the ExAC database (MAF 0.0000413 and MAF 0.0005148, 
respectively), but appear to be more frequent than the p.L424V (POLE) and p.S478N (POLD1) 
variants that thus far explain the majority of PPAP families [7]. Therefore, we anticipate that the 
variants we found will be observed more frequently in patients with polyposis. In case additional 
carriers are not found in large cohorts of polyposis patients, these variants may considered to 
be benign polymorphisms. Unfortunately, co-segregation analyses of these variants could not 
be performed in our families since DNA material of (affected) family members was not available 
for genetic testing. Clearly, additional information regarding the pathogenicity of these variants 
is required before they can be included in a clinical diagnostic setting.
FOCAD (chapter 2), BUB1, BUB3 (chapter 3), BUB1B and FAN1 are novel candidates 
involved in the predisposition to polyposis or CRC [14, 15, 23]. In our cohort, no additional 
pathogenic germline variants in these genes were encountered. This is not surprising because 
of the relatively small cohort size and the clinical selection criteria used. For example, in a 
recent study truncating germline variants in FOCAD were encountered in only two out of 192 
polyposis/CRC patients [80], whereas germline mutations in BUB1, BUB3 and FAN1 have been 
associated with the development of CRC without polyposis [14, 15]. Therefore, the absence of 
pathogenic germline variants in these novel candidate predisposing genes in our cohort does 
not contradict with a possible role of these genes in polyposis/CRC development but, instead, is 
likely related to the size and the clinical characteristics of our discovery cohort. Future research is 
required to more exactly define the predisposing role of germline variants in these genes in the 
development of polyposis/CRC.
We encountered several promising germline variants in a subset of our cohort. 
Interestingly, two homozygous missense variants were identified in genes that are involved 
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in kinetochore targeting during mitosis [25]. Based on the known role of mitotic spindle 
checkpoint defects in CRC development [14, 24], a possible polyposis/CRC predisposing role of 
these genes may be considered. Heterozygous germline mutations in ATM have primarily been 
associated with an increased risk to develop breast cancer [81, 82], but a predisposing role in 
the development of other cancer types, including CRC, has been reported as well [82, 83]. Our 
current cohort is, however, expected to be too small to reveal a strong association between 
heterozygous germline mutations in ATM and the development of adenomatous polyposis. A 
recently reported association between ATM germline aberrations and gastric cancer required, 
for example, 2,500 gastric cancer patients and 205,652 controls to significantly highlight such 
an association [83]. PTPN13 is considered to be a tumor suppressor that is involved in CRC 
development [84] and germline missense variants in this gene have been associated with cancer 
susceptibility [85]. In our case, however, co-segregation analysis was not informative since the 
patient’s sister, who developed polyposis and CRC at the age of 60, was her monozygotic twin 
sister, and no material of the other family members was available for genetic testing. Finally, the 
role of heterozygous nonsense variants in the DNA glycosylase genes MPG, OGG1 and SMUG1 
has not been firmly established yet. For these candidate genes, extensive co-segregation 
analyses and recurrency screenings are still required (see chapter 6).
 Using pathway analysis, we found that genes of the base excision repair (BER) 
pathway with truncating variants were significantly enriched in the adenomatous polyposis 
patient cohort compared to controls. This significant enrichment was at least partially caused by 
the p.Q90* variant in NTHL1 as observed in three NTHL1-associated polyposis families (chapter 
4). MPG, OGG1 and SMUG1 are members of the BER pathway that encode DNA glycosylases 
similar to NTHL1 and MUTYH. The BER pathway represents a multistep process in which eleven 
different DNA glycosylases are involved in the initiating steps of recognition and removal of 
damaged or mismatched nucleotides. Interestingly, only five truncating variant calls in DNA 
glycosylase encoding genes, other than NTHL1 and MUTYH, were found in the control cohort 
(n=2,329). The lack of second pathogenic variants in these genes argues against a recessively 
inherited trait, but small deletions or mutations in non-coding regions on the second allele 
cannot be excluded. Future research is required to establish whether germline aberrations in 
DNA glycosylase genes other than MUTYH and NTHL1 also predispose to the development of 
adenomatous polyposis and CRC.
We applied pathway analyses to find out whether a possible enrichment of mutations in 
functionally related genes may, like the BER genes, underlie phenotypes similar to adenomatous 
polyposis. We noticed, however, that the size of our discovery cohort limits the effectiveness 
of this approach. The number of loss-of-function alleles in the KEGG pathway should be high 
to remain statistically significant after correcting for multiple testing. The average number of 
truncating alleles in our control cohort per KEGG pathway was, for example, 53 (Table 7). 
In case 53 truncating alleles are called in a KEGG pathway in a control dataset, the number 
of truncating alleles in the patient cohort in the same KEGG pathway should be at least 7 to 
obtain a statistical significant enrichment (P < 0,05) after correcting for multiple (n=225) testing. 
Based on the observed frequencies of loss-of-function alleles in our control and patient cohort 
in the WNT signaling pathway (60 vs. 0, see Table 7), even the presence of six FAP families in 
our cohort would not have resulted in an statistical significant enrichment of loss-of-function 
alleles in this pathway. Therefore, these studies suffer from major statistical limitations due to 
the relatively small sizes of the discovery cohorts and the fact that rare syndromes that could 
explain a subset of the patients may not be recognized using such approaches. We anticipate 
that adenomatous polyposis is a genetically heterogeneous disease and that novel underlying 
monogenic syndromes, such as PPAP and NAP, will be rare and unlikely to be detected by 
pathway analyses.
Although WES has been instrumental in revealing the predisposing role of NTHL1 
in adenomatous polyposis (chapter 4), we encountered some limitations that may hamper 
the elucidation of additional predisposing genes. The majority of the variant calls in publicly 
available WES datasets has not been validated and, therefore, these datasets will contain false 
positive variant calls. Especially when large datasets are analyzed (e.g. recurrency screens and 
pathway analyses), the validation of the high number of variant calls is considered to be too 
expensive, laborious and time consuming. In addition, we screened for compound heterozygous 
germline variants in our patient cohort, but we could not discern whether these variants were 
indeed located on different alleles. Finally, we have identified interesting candidate variants, 
but additional data supporting the causative effect of these variants is still limited. Overall, 
the power to detect an association between a rare allele and an increased risk to develop 
adenomatous polyposis and CRC may be hampered by the number of patients included in the 
discovery cohort [86].
 In conclusion, we have shown that WES serves as a valuable tool to identify germline 
aberrations in both known as well as novel (candidate) adenomatous polyposis predisposing 
genes. The NTHL1 variants identified explain 6.3% of the adenomatous polyposis patients, 
whereas 4% are possibly explained by germline mutations in POLE or POLD1. We anticipate that 
adenomatous polyposis is a genetically heterogeneous disease. In order to firmly establish the 
putative predisposing role of rare germline aberrations, additional recurrency screens in large 
patient-control cohorts, functional studies and extensive co-segregation analyses are required. 
The establishment of the predisposing effect of these and other rare germline aberrations is 
required to further improve the clinical management of individual patients and to identify other 
(related) individuals at risk.
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Table 7. Number of truncating variants per KEGG pathway
KEGG pathway # alleles (controls)1 # alleles (polyposis patients)2
Metabolic pathways 1183 22
Base excision repair 60 8
Neuroactive ligand-receptor interaction 230 7
ECM-receptor interaction 128 5
ABC transporters 183 4
Focal adhesion 151 4
Huntington’s disease 140 4
Hematopoietic cell lineage 89 4
Dorso-ventral axis formation 36 4
Purine metabolism 204 3
Cytokine-cytokine receptor interaction 167 3
Complement and coagulation cascades 124 3
Alzheimer’s disease 112 3
Glycolysis / Gluconeogenesis 111 3
Pyruvate metabolism 101 3
Cytosolic DNA-sensing pathway 91 3
Jak-STAT signaling pathway 77 3
Drug metabolism - other enzymes 70 3
Carbohydrate digestion and absorption 45 3
Caffeine metabolism 26 3
Olfactory transduction 311 2
RIG-I-like receptor signaling pathway 146 2
Regulation of actin cytoskeleton 121 2
Pathways in cancer 119 2
Toll-like receptor signaling pathway 112 2
Oxidative phosphorylation 99 2
Pancreatic secretion 98 2
Protein processing in endoplasmic reticulum 96 2
Protein digestion and absorption 92 2
Tight junction 81 2
PPAR signaling pathway 80 2
GnRH signaling pathway 80 2
Malaria 77 2
Hepatitis C 74 2
Phosphatidylinositol signaling system 68 2
Parkinson’s disease 67 2
Starch and sucrose metabolism 66 2
Leishmaniasis 66 2
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Taste transduction 54 2
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 54 2
Pentose phosphate pathway 49 2
Ubiquitin mediated proteolysis 48 2
Adipocytokine signaling pathway 48 2
Long-term depression 48 2
Long-term potentiation 44 2
Cell adhesion molecules (CAMs) 42 2
Propanoate metabolism 41 2
Galactose metabolism 30 2
Cysteine and methionine metabolism 25 2
Other glycan degradation 19 2
Intestinal immune network for IgA production 19 2
Primary immunodeficiency 15 2
Calcium signaling pathway 155 1
Natural killer cell mediated cytotoxicity 128 1
Lysosome 121 1
MAPK signaling pathway 107 1
Endocytosis 101 1
Tyrosine metabolism 96 1
Toxoplasmosis 94 1
Phagosome 93 1
Peroxisome 93 1
Insulin signaling pathway 88 1
Vascular smooth muscle contraction 79 1
Bile secretion 77 1
NOD-like receptor signaling pathway 75 1
Drug metabolism - cytochrome P450 74 1
Cardiac muscle contraction 73 1
Pyrimidine metabolism 72 1
Butanoate metabolism 72 1
Leukocyte transendothelial migration 70 1
Axon guidance 65 1
Fc epsilon RI signaling pathway 63 1
Dilated cardiomyopathy 62 1
Hypertrophic cardiomyopathy (HCM) 61 1
Oocyte meiosis 61 1
Chagas disease (American trypanosomiasis) 59 1
Glycerophospholipid metabolism 58 1
Fat digestion and absorption 56 1
Systemic lupus erythematosus 49 1
Salivary secretion 49 1
Gastric acid secretion 48 1
Amyotrophic lateral sclerosis (ALS) 48 1
T cell receptor signaling pathway 45 1
Viral myocarditis 45 1
Prion diseases 43 1
Regulation of autophagy 40 1
p53 signaling pathway 39 1
Amino sugar and nucleotide sugar metabolism 37 1
Glycerolipid metabolism 36 1
Fc gamma R-mediated phagocytosis 36 1
Steroid biosynthesis 33 1
Steroid hormone biosynthesis 32 1
Basal transcription factors 32 1
Mucin type O-Glycan biosynthesis 32 1
Autoimmune thyroid disease 32 1
Glycosphingolipid biosynthesis - lacto and neolacto series 25 1
One carbon pool by folate 24 1
Asthma 24 1
Fructose and mannose metabolism 23 1
Gap junction 23 1
Sphingolipid metabolism 22 1
Homologous recombination 21 1
Mismatch repair 21 1
mRNA surveillance pathway 18 1
Antigen processing and presentation 17 1
Phototransduction 17 1
Pancreatic cancer 15 1
Aldosterone-regulated sodium reabsorption 14 1
Circadian rhythm - mammal 11 1
Terpenoid backbone biosynthesis 10 1
Amoebiasis 97 0
Arachidonic acid metabolism 81 0
Tryptophan metabolism 76 0
Chemokine signaling pathway 76 0
Table 7. (continued) Table 7. (continued)
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VEGF signaling pathway 67 0
Type II diabetes mellitus 65 0
Wnt signaling pathway 61 0
Retinol metabolism 59 0
Apoptosis 59 0
Spliceosome 55 0
Pentose and glucuronate interconversions 55 0
Adherens junction 55 0
Glycine, serine and threonine metabolism 55 0
Osteoclast differentiation 55 0
Inositol phosphate metabolism 54 0
Melanogenesis 54 0
Metabolism of xenobiotics by cytochrome P450 53 0
Linoleic acid metabolism 51 0
Valine, leucine and isoleucine degradation 50 0
Nicotinate and nicotinamide metabolism 48 0
Ether lipid metabolism 47 0
Small cell lung cancer 47 0
Cell cycle 46 0
Arginine and proline metabolism 45 0
Vibrio cholerae infection 45 0
Epithelial cell signaling in Helicobacter pylori infection 43 0
Fatty acid metabolism 42 0
RNA transport 41 0
B cell receptor signaling pathway 39 0
Other types of O-glycan biosynthesis 36 0
Neurotrophin signaling pathway 36 0
beta-Alanine metabolism 36 0
Pantothenate and CoA biosynthesis 35 0
Progesterone-mediated oocyte maturation 35 0
Collecting duct acid secretion 32 0
Lysine degradation 31 0
Citrate cycle (TCA cycle) 31 0
Glycosaminoglycan degradation 30 0
Basal cell carcinoma 30 0
Glyoxylate and dicarboxylate metabolism 29 0
Notch signaling pathway 29 0
Aminoacyl-tRNA biosynthesis 29 0
Porphyrin and chlorophyll metabolism 29 0
alpha-Linolenic acid metabolism 29 0
Histidine metabolism 27 0
Glutathione metabolism 27 0
Shigellosis 27 0
Hedgehog signaling pathway 26 0
Nucleotide excision repair 26 0
Staphylococcus aureus infection 26 0
Bacterial invasion of epithelial cells 25 0
Phenylalanine metabolism 24 0
DNA replication 24 0
Renal cell carcinoma 22 0
Ascorbate and aldarate metabolism 21 0
Vitamin B6 metabolism 21 0
Nitrogen metabolism 20 0
Pathogenic Escherichia coli infection 20 0
Prostate cancer 20 0
RNA degradation 19 0
African trypanosomiasis 19 0
Vasopressin-regulated water reabsorption 19 0
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis 18 0
TGF-beta signaling pathway 18 0
Alanine, aspartate and glutamate metabolism 18 0
SNARE interactions in vesicular transport 17 0
Riboflavin metabolism 17 0
mTOR signaling pathway 17 0
Proximal tubule bicarbonate reclamation 17 0
Non-homologous end-joining 16 0
Bladder cancer 16 0
ErbB signaling pathway 15 0
Glycosphingolipid biosynthesis - ganglio series 15 0
N-Glycan biosynthesis 15 0
Selenocompound metabolism 14 0
Colorectal cancer 14 0
Glycosphingolipid biosynthesis - globo series 13 0
Endometrial cancer 13 0
Glycosaminoglycan biosynthesis - heparan sulfate 12 0
Phenylalanine, tyrosine and tryptophan biosynthesis 12 0
Table 7. (continued) Table 7. (continued)
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Primary bile acid biosynthesis 11 0
Chronic myeloid leukemia 11 0
Melanoma 11 0
Glioma 11 0
Biosynthesis of unsaturated fatty acids 10 0
Sulfur metabolism 10 0
Acute myeloid leukemia 10 0
Renin-angiotensin system 9 0
Valine, leucine and isoleucine biosynthesis 9 0
Taurine and hypotaurine metabolism 9 0
RNA polymerase 9 0
Type I diabetes mellitus 7 0
Thyroid cancer 7 0
Non-small cell lung cancer 7 0
Maturity onset diabetes of the young 6 0
Synthesis and degradation of ketone bodies 6 0
Fatty acid biosynthesis 6 0
Graft-versus-host disease 6 0
Folate biosynthesis 5 0
Glycosaminoglycan biosynthesis - keratan sulfate 5 0
Sulfur relay system 5 0
Cyanoamino acid metabolism 5 0
D-Glutamine and D-glutamate metabolism 5 0
Fatty acid elongation in mitochondria 3 0
Ubiquinone and other terpenoid-quinone biosynthesis 3 0
D-Arginine and D-ornithine metabolism 3 0
Lipoic acid metabolism 2 0
Glycosaminoglycan biosynthesis - chondroitin sulfate 2 0
Lysine biosynthesis 2 0
Proteasome 2 0
Allograft rejection 2 0
Butirosin and neomycin biosynthesis 2 0
Protein export 1 0
Biotin metabolism 1 0
Ribosome 1 0
1 number of truncating alleles observed in whole-exome data derived from 2,329 controls. 
2 number of truncating alleles observed in whole-exome data derived from 48 adenomatous polyposis 
patients.
Table 8. Truncating alleles in the base excision repair pathway (KEGG hsa03410) in adenomatous 
polyposis patients
Subject Gene mRNA 
accession 
number
mRNA 
change
Protein 
change
MAF Coverage %Var. 
reads
Mutation 
type
Number of 
alleles1
P57 MPG NM_002434 c.352C>T p.R118* 0.0029 101 47 NS 1
P07 NTHL1 NM_002528 c.268C>T p.Q90* 0.0019 39 85 NS 1
P23 NTHL1 NM_002528 c.268C>T p.Q90* 0.0019 119 99 NS 2
P49 NTHL1 NM_002528 c.268C>T p.Q90* 0.0019 168 100 NS 2
P54 OGG1 NM_002542 c.391C>T p.R131* 0.0000 92 49 NS 1
P09 SMUG1 NM_014311 c.370C>T p.R124* 0.0000 115 49 NS 1
 
Var.: variant, NS: nonsense variant. 1 Variant calls ≥90% were considered homozygous and carriers expected 
to carry two alleles of the encoded variant.
Table 9. Truncating alleles in the base excision repair pathway in controls
Gene mRNA accession number mRNA change Protein change Number of alleles1
APEX1 NM_080648 c.217C>T p.R73* 1
APEX1 NM_080648 c.945C>A p.Y315* 2
LIG3 NM_013975 c.799C>T p.R267* 1
MBD4 NM_003925 c.1688A>T p.L563* 1
MPG NM_002434 c.352C>T p.R118* 1
MUTYH NM_012222 c.934-2A>G p.? 2
MUTYH NM_001128425 c.739G>A p.R247* 1
MUTYH NM_001128425 c.1105C>A p.E369* 2
NTHL1 NM_002528 c.268G>A p.Q90* 17
PARP3 NM_001003931 c.1039C>T p.Q347* 6
PARP3 NM_001003931 c.1462C>T p.Q488* 1
PARP4 NM_006437 c.3667-1G>A p.? 7
PARP4 NM_006437 c.2134-1G>A p.? 1
PARP4 NM_006437 c.376C>A p.E126* 2
PARP4 NM_006437 c.3712G>A p.R1238* 1
POLB NM_002690 c.262-2A>G p.? 1
POLD1 NM_002691 c.2953+1G>A p.? 1
POLD1 NM_001256849 c.583C>T p.R195* 1
POLE NM_006231 c.424-2A>G p.? 1
POLE NM_006231 c.1230C>T p.W410* 2
POLE NM_006231 c.3958G>A p.R1320* 1
POLL NM_001174084 c.1255G>A p.R419* 1
SMUG1 NM_014311 c.7G>A p.Q3* 2
SMUG1 NM_014311 c.752C>T p.W251* 1
XRCC1 NM_006297 c.90G>T p.Y30* 1
XRCC1 NM_006297 c.1690G>A p.R564* 2
1 Only encountered in a heterozygous state.
Table 7. (continued)
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Figure 1. Anonymized pedigree of the heterozygous index-patient of the p.K284E variant in 
POLD1. Left side half-filled symbols: polyposis. Right side half-filled symbols: colorectal cancer. C: colorectal 
cancer, numbers represent age at diagnosis. The index patient is marked by the arrow.
 
Figure 2. Correlation between gene size and the frequency of rare germline variants. Depicted 
are the gene size (based on the encoded protein) and number of variants encountered in 2,329 controls. 
The image is based on information regarding 14,719 genes with at least one rare germline variant in 
the whole-exome dataset of 2,329 controls. Red dots represent all genes with more than three different 
rare germline variants in the adenomatous polyposis cohort, see text for more details. Note: TTN is not 
depicted due to the large number of unique germline variants encountered in the control dataset (n=383). 
Figure 3. Predicted protein interactions with known polyposis and colorectal cancer 
predisposing genes. Using the STRING-10 software package [87], known and predicted 
interactions of genes with rare loss-of-function germline variants in adenomatous polyposis 
patients with known polyposis/CRC predisposing genes were visualized. Known polyposis and 
CRC predisposing genes: APC, AXIN2, BMPR1A, MUTYH, POLD1, POLE, SMAD4, STK11, MLH1, 
MSH2, MSH6, PMS2. Colored lines represent types of evidence for interactions/prediction 
method. Green line: neighborhood. Red line: gene fusion. Dark-blue line: co-occurrence. Black 
line: co-expression. Purple line: experiments. Light-blue line: databases. Interactions based on 
text mining were not included and the required confidence score was high (0,700).
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Figure 4. Correlation between truncating alleles encountered in KEGG pathways in 
adenomatous polyposis patients and controls. Black dot and grey dots: KEGG pathways 
significantly (black) or not significantly (grey) enriched for the number of truncating alleles in 
48 unrelated adenomatous polyposis patients compared to 2,329 control exomes. Note: the 
dot corresponding to the number of mutations identified in the metabolic pathway in patients 
(n=22) and controls (n=1,183) is not depicted. For details, see main text.
Supplementary Figure 1. Number of protein altering variant calls encountered in 
whole-exome sequencing data of 51 adenomatous polyposis patients. CSS: variant 
calls affecting a canonical splice site, NS: nonsense variant calls, FS: frameshift variant calls, 
InDel: in-frame insertion and deletion variant calls, MSS: missense variant calls. X-axis: number 
of corresponding variant calls encountered per sample. Y-axis: P numbers representing 51 
adenomatous polyposis patients included for WES. Note: the number of insertions, deletions 
and frameshifts called in P01 to P09 is lower compared to the other samples due to the different 
sequencing platform applied for these samples (5500xl (Life technology) vs. HiSeq (Illumina) 
sequencers; see materials and methods).
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Abstract
Biallelic germline aberrations in the DNA glycosylase gene MUTYH predispose to the 
development of adenomatous polyposis and colorectal cancer. Very recently, we found that 
biallelic germline aberrations in a second DNA glycosylase gene, NTHL1, also predispose to the 
development of adenomatous polyposis and colorectal cancer (chapter 4). DNA glycosylase 
genes are involved in the initiating steps of the base excision repair pathway and recognize 
and remove damaged or mismatched nucleotides from the DNA, thereby preventing the 
accumulation of base substitutions. Next to MUTYH and NTHL1, nine other DNA glycosylase 
genes are known to be involved in the base excision repair pathway in humans. Here, we aimed 
to further define the prevalence of NTHL1-associated adenomatous polyposis, as well as the 
putative involvement of other DNA glycosylase genes in adenomatous polyposis predisposition. 
To this end, we searched for germline aberrations in the DNA glycosylase genes MBD4, MPG, 
NEIL1, NEIL2, NEIL3, NTHL1, OGG1, SMUG1, TDG and UNG in a cohort of 701 APC and MUTYH 
mutation-negative adenomatous polyposis patients using a targeted next generation sequencing 
approach. We identified one novel NTHL1-associated polyposis family, which confirms that 
biallelic germline aberrations in NTHL1 explain at least a subset of the adenomatous polyposis 
cases. Biallelic germline mutations were not observed in the other DNA glycosylase genes, but 
we encountered several heterozygous truncating mutations in MBD4, NEIL1, OGG1 and UNG. 
These data suggests that biallelic aberrations in DNA glycosylase genes other than MUTYH and 
NTHL1 are rare in polyposis patients. Therefore, larger well-selected patient cohorts need to be 
screened in order to define the exact role of the various DNA glycosylase genes in adenomatous 
polyposis and colorectal cancer predisposition.
Introduction
 Proper functioning of the base excision repair (BER) pathway is crucial to recognize 
and replace damaged nucleotides from the DNA backbone which may induce base substitutions 
and, therefore, hamper genomic stability. The first step in the BER pathway is the recognition 
and removal of damaged bases and is initiated by DNA glycosylases. Germline defects in DNA 
glycosylase genes can predispose to the development of adenomatous polyposis and colorectal 
cancer (CRC). For example, biallelic pathogenic germline aberrations in MUTYH have been 
found to underlie the development of MUTYH-associated polyposis (MAP), a syndrome that 
is associated with the occurrence of predominantly C:G to A:T transversions in adenomas and 
carcinomas [1]. Recently, we found that a homozygous germline nonsense mutation in another 
base excision repair gene, NTHL1, also predisposes to the development of adenomatous 
polyposis and CRC. We observed that adenomas and carcinomas derived from these patients 
predominantly accumulate C:G to T:A transitions (chapter 4). For this novel syndrome we have 
proposed the term NTHL1 -associated polyposis (NAP). The identification of NTHL1 as a novel 
adenomatous polyposis and CRC predisposing gene has substantiated the role of the base 
excision repair pathway in adenomatous polyposis and CRC predisposition. Our additional 
detection of truncating mutations in three other base excision repair genes (MPG, OGG1 and 
SMUG1) suggests that this role might be even broader (chapter 5).
 The base excision repair pathway represents a multistep process that is involved in the 
correction of small base lesions induced by alkylation, oxidative damage or deamination [2-5]. 
The initiating step of this pathway is the recognition and removal of damaged bases by DNA 
glycosylases, thereby introducing an apurinic or apyrmidinic (AP) site. Subsequently, the DNA 
backbone is cleaved and processed to produce a single-nucleotide gap. After incorporation 
of the correct nucleotide (short-patch BER pathway) or elongation of multiple nucleotides 
(long-patch BER pathway) by a DNA polymerase, the BER pathway is completed by sealing 
the remaining nick through a DNA ligase [6]. The human genome contains, next to MUTYH 
and NTHL1, nine additional genes encoding for DNA glycosylases, i.e., MBD4, MPG, NEIL1, 
NEIL2, NEIL3, OGG1, SMUG1, TDG and UNG. Each of these DNA glycosylases is involved in the 
recognition and removal of different base lesions [7]. 
 In order to (i) determine the prevalence of NAP and (ii) to establish whether other BER 
genes may also predispose to the development of polyposis and CRC, we set out to screen for 
germline aberrations in DNA glycosylase genes in a cohort of 701 selected polyposis patients 
using targeted next generation sequencing. Four genes, MPG, NTHL1, OGG1 and SMUG1, 
were sequenced in the entire cohort, and in a subset of the patients (n = 427) we included six 
other DNA glycosylase genes: MBD4, NEIL1, NEIL2, NEIL3, TDG and UNG. We identified one 
index patient who carried the p.Q90* nonsense variant [8] in NTHL1 in a homozygous state. 
This patient developed adenomatous polyposis, two colorectal carcinomas and a recurrent 
thyroid cancer. In addition, we identified five individuals from four families with the p.Q90* 
nonsense variant in a heterozygous state and several other individuals with heterozygous 
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protein truncating mutations in MBD4, NEIL1, OGG1 and UNG. Whether these mutations are 
associated with the phenotype of these patients, either alone or in combination with another 
yet to be identified mutation, still needs to be verified. 
Materials and Methods
Patient and control cohorts
 We included 701 polyposis patients without germline mutations in APC or MUTYH 
explaining the polyposis phenotype from three different countries, i.e., the Netherlands (n = 
316), Germany (n = 103) and the United Kingdom (n = 282). All patients provided written 
informed consent. This study was approved by the medical ethics committee (CMO, study 
numbers 2014/032 and 2015/1748)/institutional board of the Radboudumc. The control 
dataset used consists of whole-exome sequencing data derived from 60,706 individuals listed in 
the ExAC database (Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.
broadinstitute.org) [01/06/2015 accessed]. 
Molecular Inversion Probe (MIP) sequencing
DNA was isolated from peripheral blood leukocytes of all 701 polyposis patients 
included for targeted resequencing. Germline DNA derived from these polyposis patients 
was screened for pathogenic variants in MPG (NM_002434), NTHL1 (NM_002528), OGG1 
(NM_016821) and SMUG1 (NM_001243788). In addition, 429 of these patients were also 
tested for germline aberrations in the DNA glycosylase genes MBD4 (NM_003925), NEIL1 
(NM_024608), NEIL2 (NM_145043), NEIL3 (NM_018248), TDG (NM_003211) and UNG 
(NM_080911) (Table 1). Targeted resequencing was performed using Molecular Inversion Probe 
(MIP)-based sequencing [9] (Supplementary Table 1). A total of 271 MIPs was designed as 
previously published [9, 10] with minor modifications, covering all coding regions and intron-
exon boundaries of the respective genes (sequences available upon request). Further details 
regarding library enrichment and sequencing are provided in the material and methods section 
of chapter 4. Due to technical issues (e.g. DNA quality), no sequencing data were obtained 
for a limited number of samples. These samples were excluded for further analyses. Sufficient 
coverage for variant calling was obtained for 695 (MPG, NTHL1, OGG1, SMUG1) and 427 
(MBD4, NEIL1, NEIL2, NEIL3, TDG, UNG) samples, respectively. 
Data analysis
 Fastq files, containing all reads split per barcode, were analyzed using SeqNext (JSI 
medical systems; version 4.2.2, build 502). Reads fulfilling predetermined quality settings 
(max. 5% mismatches; min. 95% matching bases) were mapped to the regions of interest 
(NM002434; NM002528; NM016821; NM001243788; NM_003925; NM024608; NM145043; 
NM018248; NM003211 and NM080911). At least 40-fold absolute coverage, 30% variant 
reads and 30 variant reads were required for variant calling. All variants called in ≤10% of 
all samples and resulting in missense mutations, nonsense mutations, frame-shift mutations 
(insertions/deletions), or those affecting canonical splice sites were included for further 
analyses. We repeatedly noticed that insertions and deletions with ≤300 variant reads could 
not be validated using Sanger sequencing (based on 19 selected variant calls fulfilling these 
criteria ) and, consequently, we excluded insertions and deletions with ≤300 variant reads from 
our analysis. Next, we filtered for loss-of-function mutations (nonsense, insertions/deletions 
introducing a frameshift or variants affecting the canonical splice site), potential homozygous 
variants (variants with ≥90% variant reads) and compound heterozygous variant calls (subjects 
with at least two variant calls in the same gene). Primer sequences used for validation of variant 
calls using Sanger sequencing are available upon request.
Statistical analyses
 A χ2 test with Yates correction was performed to determine significant differences 
between observed frequencies of variants encountered in polyposis patients and controls. 
Statistical enrichment of pathogenic variants was determined based on the total number of 
alleles included in the corresponding cohort.
Results
Identification of germline loss-of-function mutations in DNA glycosylase genes in 
polyposis patients 
To assure proper variant calling, we assessed the coverage of the targeted MIP 
sequencing data per gene. Mean read depth was variable, but high for all targeted protein 
coding exons of MBD4, MPG, NEIL1, NEIL2, NEIL3, NTHL1, OGG1, SMUG1, TDG and UNG 
(Figure 1). At least 40-fold coverage was required for variant calling (see materials and methods). 
On average, 98,7% (MBD4), 97,1% (MPG), 94,9% (NEIL1), 98,7% (NEIL2), 98,8% (NEIL3), 
92,4%(NTHL1), 99,9% (OGG1), 99,8% (SMUG1), 97,1% (TDG) and 93,8% (UNG) of the bases 
in the coding regions (including the 20 bases flanking the exonic region) were covered at least 
40-fold. Sufficient coverage for variant calling was obtained for 695 (MPG, NTHL1, OGG1, 
SMUG1) and 427 (MBD4, NEIL1, NEIL2, NEIL3, TDG, UNG) adenomatous polyposis patients, 
respectively. 
Using next generation sequencing, we previously identified nonsense mutations in 
MPG, NTHL1, OGG1 and SMUG1 in 51 adenomatous polyposis patients (Chapters 4 and 5). 
Here, we encountered additional variant calls with a potential loss-of-function effect (nonsense 
mutations, insertions/deletions introducing a frameshift or variants affecting a canonical splice 
site) in five DNA glycosylase genes (i.e., MBD4, NEIL1, NTHL1, OGG1 and UNG) in our selected 
cohort of APC and MUTYH mutation-negative adenomatous polyposis patients (Table 2). 
One of the mutations that we encountered represented a homozygous c.268C>T 
6152 CHAPTER 6 153GERMLINE ABERRATIONS IN BER GENES IN POLYPOSIS AND CRC PATIENTS
variant in NTHL1, encoding p.Q90*, in index-patient L6124 that was subsequently confirmed 
by Sanger sequencing. This is the same variant that we previously identified in a homozygous 
state in three other families with adenomatous polyposis (chapter 4) [8]. Index-patient L6124 
developed colorectal cancer twice at the age of 59. Two of his brothers also developed polyposis 
and colorectal cancer and co-segregation analysis revealed that both carried the p.Q90* 
variant in NTHL1 in a homozygous state (II-7 and II-9; Figure 2). In line with the expected 
recessive inheritance pattern, polyposis and colorectal cancer was not observed in any of the 
other generations in this family. In addition to colorectal cancer, the index-patient developed 
a recurrent thyroid cancer at the age of 70, and his brother (II-7) developed kidney cancer 
(urothelial cell carcinoma) at the age of 61. One sister (II-3) carried the p.Q90* variant in a 
heterozygous state, whereas the p.Q90* variant was not detected in DNA derived from ascites 
fluid from another brother (II-5). Both did not develop polyposis and/or CRC but, instead, other 
tumor types were encountered. Sister II-3 was diagnosed with kidney and bladder cancer at 
the ages of 61 and 64, respectively, and brother II-5 developed liver cancer. Further research is 
required to determine whether these tumors occurred sporadically or whether other (genetic/
environmental) factors within this family have contributed to the development of these tumors.
The p.Q90* variant in NTHL1 was encountered in a heterozygous state in five polyposis 
patients from four different families, all of English descent. Compared to the general population 
in the UK, the frequency of the p.Q90* variant was highly enriched in our UK polyposis cohort 
(Table 1) (4/552 vs. 11/7562; P=0.011) [11]. One of the patients was particularly interesting 
because she had a brother and a sister diagnosed with adenomas, and co-segregation analysis 
revealed that all three sibs were heterozygous for the p.Q90* variant. However, subsequent 
Sanger sequencing of the open reading frame of NTHL1 in the five p.Q90* variant-positive 
patients failed to reveal a second mutation in the other allele and, therefore, NTHL1 -associated 
polyposis (NAP) could not be confirmed in these patients yet. 
Next to the p.Q90* variant in NTHL1 in patient L6124, another homozygous loss-of-
function variant was called in patient O290, i.e., a c.434+2T>C variant in NEIL1, affecting a 
canonical splice donor site. However, Sanger sequencing revealed that this variant is present 
in a heterozygous state. The c.434+2T>C variant in NEIL1 is also observed in ten additional 
polyposis patients in a heterozygous state (Table 2), but the number of heterozygous carriers 
is not significantly enriched in our patient cohort compared to the European population in the 
ExAC database (11/427 vs. 663/30,351; P =0.70). 
In one glycosylase gene, MBD4, we encountered two different loss-of-function variants 
in our adenomatous polyposis cohort (Table 2). In patient O72 we identified a p.W479* variant 
(c.1437G>A). This patient developed 11 tubular adenomas at the age of 69 and has a strong 
family history of CRC. The mother and father of this patient died of CRC at ages 58 and 84, 
respectively, whereas one brother developed CRC, two brothers developed stomach cancer 
and one brother developed three tubular adenomas. A second p.R546* variant (c.1636C>T) 
was identified in another patient, O121, with five adenomas at the age of 59. MBD4 loss-
of-function variants are rare in the ExAC database (cumulative minor allele frequency of loss-
of-function variants is 0.000346, excluding insertions/deletions called in the poly-A stretch of 
ten adenines at chr3:129,155,557-129,155,548). Based on targeted MIP sequencing data, no 
additional variants in this gene (i.e., second allele) were observed in these patients. Nevertheless, 
truncating variants in MBD4 are significantly enriched in our cohort compared to those listed in 
the ExAC database (2/854 vs. 42/121,412; P=0.03).
In patient P14015, who developed polyposis at the age of 41 years, a germline variant 
affecting a canonical splice donor site in UNG was detected (c.132+2T>C). This variant is not 
present in the ExAC database. Although truncating germline variants in UNG are rare in the 
ExAC database (n=27), the identification of one truncating canonical splice site mutation in 
UNG in our cohort does not significantly differ from this control dataset (1/854 vs. 27/121,412; 
P=0.49). 
Finally, we identified one heterozygous p.R131* nonsense variant in OGG1 (c.391C>T) 
in patient L6198. Interestingly, the same variant was observed in a polyposis patient previously 
subjected to whole-exome sequencing (patient P54 ,chapter 4 and chapter 5), whereas this 
variant is only listed once in the ExAC database. Similar to UNG, the total number of loss-of-
function alleles observed in OGG1 is low in the ExAC database (n = 37), but the number of 
truncating alleles we encountered in polyposis patients (including the 51 patients included for 
WES, chapter 5) does not significantly differ from this control dataset (2/1,492 vs. 37/121,412; 
P=0.13). Again, a second germline variant in OGG1 was not observed in these two adenomatous 
polyposis patients, and targeted sequencing of polyp and tumor material of P54 did not reveal 
a somatic (second) hit in OGG1 (data not shown).
Compound heterozygous and homozygous variant calls
 Next, we included missense variants in our analysis, which are more abundant in 
the population than loss-of-function variants, and searched for compound heterozygous and 
homozygous variant calls. We identified two germline variants in the same gene in 17 polyposis 
patients, suggestive of a possible recessive inheritance pattern due to compound heterozygosity 
(Table 3). In fifteen patients, at least one of these variants was frequently encountered in one 
of the populations included in the ExAC database (MAF >0.05). Noteworthy, two combinations 
of missense variants were recurrently called in multiple samples (p.R103Q/p.R257L in NEIL1 and 
p.R38C/p.Q172H in NEIL3), suggesting that both missense variants are located in cis. Finally, 
two germline variants were called in NEIL1 in one subject: one variant affecting a canonical 
splice site (c.434+2T>C) and one missense variant (p.Q214R, c.641A>G). The variant affecting 
the canonical splice site was recurrently observed in both polyposis patients and controls (see 
above) and the missense variant, although affecting a conserved nucleotide (phyloP = 3.0), is 
predicted to be benign (AlignGVGD: class C0; PolyPhen-2: possibly damaging, score 0.739 and 
SIFT: tolerated, score 0.13).
 A total of 7 missense variants were called in a homozygous state (≥90% variant 
reads) (Table 4). Four variants were commonly encountered in a homozygous state in the 
ExAC database or were predicted to be benign. Variants in NEIL1 (p.P190A, c.568C>G), NEIL3 
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(p.C156G, c.466T>G) and UNG (p.T126I, c.377C>T) were predicted to be possibly damaging, 
but not observed in the ExAC database. However, the number of reads at these positions was 
low (range 47-127), suggestive for false positive variant calls. Indeed, the variant in NEIL1 
(p.P190A) could not be confirmed by Sanger sequencing, but material of the other two samples 
was not available for validation. 
Discussion
Upon the identification of MUTYH as a recessive adenomatous polyposis and CRC 
predisposing gene in 2002 [1], several targeted screening efforts aimed at the identification of 
germline mutations in the other DNA glycosylase genes in polyposis and/or CRC patients have 
been undertaken, but the effect of such variants has so far been reported to be limited [12-18]. 
Therefore, it has been suggested that the role of DNA glycosylases other than MUTYH in the 
development of colorectal cancer may be ignored [12, 17]. However, since we recently found 
that biallelic pathogenic germline mutations in NTHL1, similar to MUTYH, predispose to the 
development of adenomatous polyposis [8], this suggestion could be considered as premature. 
Therefore, we substantiated the role of NTHL1 in the predisposition to adenomatous polyposis 
and established the frequency of germline aberrations in DNA glycosylase genes, other than 
MUTYH and NTHL1, in a cohort of 701 unexplained adenomatous polyposis patients. We 
encountered one NAP index-patient within this cohort, which indicates that biallelic pathogenic 
germline NTHL1 mutations are recurrent, but exhibit a low prevalence. Loss-of-function 
mutations in DNA glycosylase genes other than MUTYH and NTHL1 were found to be rare 
and were only encountered in a heterozygous state. As of yet, our results do not support the 
hypothesis that germline mutations in DNA glycosylase genes other than MUTYH and NTHL1 
underlie the development of polyposis in a recessive manner, suggesting that they are very rare 
or do not exist. 
The identification of a novel NTHL1-associated polyposis (NAP) family through 
our screen confirms that biallelic germline aberrations in the NTHL1 gene predispose to the 
development of adenomatous polyposis and colorectal cancer. In line with our previous 
observation, it appears that individuals who carry the p.Q90* variant in a homozygous state 
are also prone to develop other types of cancer. Noteworthy, an increased incidence of extra-
intestinal malignancies has also been observed in MAP patients [19]. In the current family, NAP 
patients II-7 and II-11 developed kidney cancer and thyroid cancer, respectively (Figure 2). 
However, we cannot exclude that other (genetic/environmental/age-related) factors have played 
a role in the development of these tumors and not all malignancies identified in NAP patients 
may necessarily be caused by a base excision repair defect. To establish such a correlation, 
we previously determined the mutation spectra of polyps and colorectal tumors derived from 
NAP patients, and noticed that they are significantly enriched for C:G>T:A transitions. Similar 
strategies are required to reveal whether such an enrichment can also be observed in the various 
extra-colonic tumors encountered in NAP patients, including the ones observed in the new 
family described here. An enrichment of C:G>T:A transitions in tumors of non-colonic origin, 
combined with the frequent occurrence of such tumors in the NAP patients identified so far, 
would strongly indicate that NAP patients are not only at increased risk to develop adenomatous 
polyposis and/or colorectal cancer, but also to the development of other types of cancer.
In our previous study, we anticipated that the frequency of NAP may be higher in 
Dutch polyposis index-patients due to the relatively high frequency of the NTHL1 p.Q90* variant 
in the Netherlands [8] (chapter 4). Indeed, the single NAP patient identified in this study was, 
again, of Dutch descent and carried the p.Q90* variant in a homozygous state. Thus far, we 
have not identified any NTHL1 p.Q90* homozygous patients from outside the Netherlands, 
despite the inclusion of cohorts of substantial size from Germany and the United Kingdom. 
In addition, no other strong loss-of-function variants in NTHL1 than the p.Q90* variant were 
encountered in any of the tested cohorts. These results suggest that the prevalence of NAP may 
strongly correlate with the frequency of the p.Q90* variant in the population and, consequently, 
may indeed be lower in Germany and the United Kingdom compared to the Netherlands. 
The NTHL1 p.Q90* variant was observed in a heterozygous state in five polyposis 
patients from four different families included from the United Kingdom. This observation was 
remarkable since the frequency of the p.Q90* variant is very low in the United Kingdom (MAF 
0.001455), indicating a significant enrichment in the polyposis cohort from the United Kingdom 
(P=0.011). Furthermore, the co-segregation in one of these families with three affected sibs 
strongly suggests an association with the polyposis phenotype. Since no other pathogenic 
germline mutations were identified in any of these patients, this co-segregation and apparent 
enrichment remains to be explained. Currently, ongoing research is performed to establish 
whether (i) mutation spectra in the tumors of these patients are indicative of an underlying base 
excision repair defect and (ii) other germline aberrations affecting NTHL1 on the remaining allele 
(i.e., non-coding regions and/or copy number variations) can be detected.
The identification of heterozygous loss-of-function germline variants in MBD4, NEIL1, 
OGG1, and UNG in our cohort of adenomatous polyposis patients is interesting, but whether 
these variants are involved in the development of polyposis still remains to be established. 
One explanation could be that heterozygous carriers of loss-of-function variants already have 
a (minor) increased risk to develop polyposis. However, based on previous risk analyses for 
pathogenic germline variants in MUTYH, which revealed no, or only limited increased risk for 
monoallelic carriers [20-23], we consider this hypothesis unlikely. Furthermore, heterozygous 
loss-of-function variants in DNA glycosylase genes are frequently encountered in the ExAC 
database, which also questions a potential causative effect for heterozygote variants in the 
development of polyposis. Nevertheless, it could still be that, similar to what we described 
above for NTHL1 heterozygotes, a yet undiscovered pathogenic mutation (outside the targeted 
regions of the respective genes) is present on the other allele. Interestingly, such a scenario 
has recently been described for several other syndromes [24, 25]. Whole-genome sequencing 
and haplotype analysis could reveal the presence of pathogenic variants in the regions outside 
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the open reading frame, and whether polyposis patients with a heterozygous loss-of-function 
mutation in the same gene share the same haplotype on the other allele. In addition, future 
research will reveal whether the somatic mutation spectra observed in polyps and tumors derived 
from these patients are in line with a germline defect in the base excision repair pathway. 
Here, we have sequenced a large cohort of adenomatous polyposis patients for 
the presence of germline aberrations in DNA glycosylase genes involved in the base excision 
repair pathway. We identified one index-patient who carried the NTHL1 p.Q90* variant in a 
homozygous state, and subsequent pedigree and co-segregation analyses confirmed a recessive 
inheritance pattern and a complete co-segregation of the homozygous p.Q90* variant with the 
development of polyposis and/or colorectal cancer. Biallelic pathogenic germline variants were 
not observed in the other DNA glycosylase genes, which suggests that such aberrations (next to 
MUTYH and NTHL1) are rare. We anticipate that even larger cohorts of adenomatous polyposis 
patients should be screened to exactly define the putative role of other DNA glycosylase genes 
in adenomatous polyposis and CRC predisposition.
Table 1. Patient cohorts included for germline DNA testing of DNA glycosylase genes
Cohort name Origin # samples DNA glycosylase genes sequenced
Nijmegen Netherlands 147 MBD4, MPG, NEIL1, NEIL2, NEIL3, NTHL1, OGG1, SMUG1, TDG, UNG*
Leiden Netherlands 150 MPG, NTHL1, OGG1, SMUG1
Groningen Netherlands 19 MPG, NTHL1, OGG1, SMUG1
Dresden Germany 103 MPG, NTHL1, OGG1, SMUG1
Oxford United Kingdom 282 MBD4, MPG, NEIL1, NEIL2, NEIL3, NTHL1, OGG1, SMUG1, TDG, UNG
 
* The 147 polyposis patients included in the Nijmegen cohort were screened for germline aberrations in the 
NTHL1 gene using Sanger sequencing prior to this study (chapter 4).
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Figure 1. Mean read depth per exon. Y-axis: fold coverage, x-axis: exons included for targeted sequencing. 
Boxes represent the interquartile range (IQR), the gray and black parts of the box represent the Q1-median 
and median-Q3 region, respectively. Whiskers indicate the 5th to the 95th percentile.
Figure 2. Pedigree of NTHL1-associated polyposis patient L6124. Filled symbols indicate the 
development of polyposis. Symbols with dots represent (obligate) carriers of the p.Q90* variant in NTHL1. 
C: colon cancer, St: stomach cancer, K: kidney cancer (urothelial cell carcinoma), Bl: bladder cancer, Li: liver 
cancer and Thy: thyroid cancer. Numbers correspond to age of onset. Note that the index patient L6124 
(II-11; indicated by the arrow) developed colon cancer twice at the age of 59. All patients with polyposis (II-
7, II-9 and II-11) carried the p.Q90* variant in NTHL1 in a homozygous state (+/+), whereas II-3 carried the 
variant in a heterozygous state (+/—) and II-5 only carried the wild type allele (—/—).
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nt
in
ue
d)
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M
PG
16
13
31
17
13
32
28
+
ac
tt
ct
gc
at
ga
ac
at
ct
cc
ag
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
tg
ga
ga
cc
ga
gg
ca
ta
c
M
PG
16
13
30
60
13
31
71
-
ga
ct
ag
ga
cc
tg
tg
gg
ca
gt
ca
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tt
ca
tg
aa
ca
tg
cc
tc
gg
t
M
PG
16
13
32
28
13
33
39
-
ca
tg
cc
gt
aa
at
ga
tg
ta
ca
cg
tC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
tc
aa
at
gc
tg
gc
cc
ca
M
PG
16
13
52
88
13
53
99
+
gg
ga
cg
gg
gc
tt
gc
gt
ct
tg
ct
gC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Ta
ga
gc
ag
gt
cc
ct
gg
cc
M
PG
16
13
54
54
13
55
65
+
ga
gc
tt
tg
ac
ca
ga
gg
ga
cc
tg
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
cc
tg
ga
ag
gt
ct
gg
ag
a
M
PG
16
13
53
47
13
54
58
-
cc
ct
ag
ta
ca
ca
tc
ca
ga
ca
tc
ct
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tt
gc
tg
cg
aa
gc
tg
ac
g
M
PG
16
13
56
14
13
57
25
+
cc
ct
gg
gt
ca
gt
gt
gg
tc
ga
cC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Ta
tg
aa
gc
tg
ta
tg
gc
tg
ga
M
PG
16
13
55
21
13
56
32
-
ag
ct
cg
cg
gt
cc
tt
ga
gg
ac
ac
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
ac
ta
ca
gc
cg
gc
tc
ac
t
M
PG
16
13
57
23
13
58
34
-
gc
cc
cg
ga
ca
ta
ga
ag
cg
ga
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Ta
ag
gc
ac
ag
tt
tt
ct
ag
aa
a
M
PG
16
20
89
95
6
20
90
06
7
+
gt
ca
gt
gc
tg
ac
ag
ag
gg
cg
gC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
gc
gg
cc
gg
gc
ag
ag
gg
ct
M
PG
16
20
89
84
5
20
89
95
6
-
ga
at
aa
ag
ct
tt
gg
tg
tg
tt
tg
ca
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
ac
gc
ct
gc
ct
ca
ac
c
M
PG
16
20
90
01
8
20
90
12
9
+
at
ac
ct
ag
gc
ag
cc
at
tc
ct
cc
ag
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ct
gg
cc
ga
ag
cc
ca
c
M
PG
16
20
90
01
8
20
90
12
9
+
at
ac
ct
ag
gc
ag
cc
ac
tc
ct
cc
ag
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ct
gg
cc
ga
ag
cc
ca
c
M
PG
16
20
90
12
4
20
90
23
5
+
ac
tg
ct
gc
tg
gg
ag
gc
ca
ag
cg
gg
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
ta
gg
aa
gc
cc
cc
ca
c
M
PG
16
20
90
01
4
20
90
12
5
-
gc
tt
cg
gc
ca
gc
ag
ac
ct
gt
cC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tt
gg
ct
gc
ct
ag
gt
at
ga
gt
M
PG
16
20
90
19
1
20
90
30
2
+
cg
cc
ca
ga
gg
cg
ag
tc
tg
cc
aC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tt
gg
gg
ac
tt
gg
tt
gc
ct
tc
M
PG
16
20
90
08
0
20
90
19
1
-
gt
ca
gc
ac
tg
ac
cc
ag
cc
cc
ca
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Ta
ca
gg
ct
ga
gg
tg
ga
cc
a
M
PG
16
20
93
51
2
20
93
62
3
+
cc
aa
ca
cc
cg
gc
ag
cg
cc
ac
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
tc
ac
ag
gt
ca
ca
ag
ga
tg
t
M
PG
16
20
93
72
5
20
93
83
6
+
ga
cg
tg
tg
ca
ag
ct
ca
gc
cc
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tt
gc
tt
ga
tg
ta
tt
tc
ac
ct
t
M
PG
16
20
93
62
1
20
93
73
2
-
ca
ag
at
gg
ca
ca
cc
tg
gc
ta
tg
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
tg
aa
cc
ca
cc
cc
tg
tc
t
M
PG
16
20
94
51
8
20
94
62
9
+
cc
ct
cc
ag
aa
ac
cg
ac
gg
gg
ta
gC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ct
tc
ag
gg
gg
ac
cc
cc
M
PG
16
20
94
70
6
20
94
81
7
+
ag
gg
ac
cg
gg
gt
gg
cg
gc
gg
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Ta
gg
at
gc
tg
tc
ca
cc
gt
ca
g
M
PG
16
20
94
61
0
20
94
72
1
-
gg
gg
gc
cg
gg
tg
gc
ag
tg
gc
ct
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
gc
gg
gc
gc
ca
tg
ca
gc
g
M
PG
16
20
94
79
9
20
94
91
0
-
cg
ca
gg
ta
cc
ag
gt
gc
tg
ct
gt
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
gg
ag
gc
tg
at
gc
ct
ca
a
M
PG
16
20
96
09
8
20
96
20
9
+
ga
tg
tt
ga
cc
ag
ct
gt
tg
ct
gc
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ac
ct
tg
ct
aa
ga
tg
gg
g
M
PG
16
20
96
03
5
20
96
14
6
-
gc
ag
ac
ag
ca
cc
tt
gg
ga
gg
aC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ac
tg
ag
ca
ct
gc
ta
tg
ac
M
PG
16
20
96
29
9
20
96
41
0
+
aa
gg
ta
gg
gt
ag
gg
gt
gc
ca
tc
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
tt
tc
tc
ac
tg
tc
cg
ag
c
M
PG
16
20
96
19
4
20
96
30
5
-
aa
aa
gg
at
gc
ac
ct
gt
gg
ac
ca
tC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Ta
ga
ga
ct
gc
gt
gt
gg
cc
M
PG
16
20
96
35
5
20
96
46
6
-
cc
ac
ag
cc
cc
gt
ga
ag
cg
tc
cg
cg
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
at
ga
tg
ga
ca
gt
tg
t
M
PG
16
20
97
72
8
20
97
83
9
+
ac
ta
ca
ca
tc
cc
gg
cg
gc
cc
at
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
tg
ct
gc
ag
cc
tc
tc
tt
c
M
PG
16
20
97
65
4
20
97
76
5
-
ga
gt
cc
cg
gg
cc
gc
ct
cc
tg
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Ta
gc
ct
gg
ga
cc
cg
gg
gc
tg
g
M
PG
16
20
97
83
4
20
97
94
5
-
ga
gt
cc
gg
ca
tg
ac
cg
cc
tt
ga
gc
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Ta
tt
gc
gc
gg
ag
gg
cc
g
N
EI
L1
15
75
64
01
26
75
64
02
37
+
cc
ag
gt
gt
gg
ag
gg
gg
ca
ag
gt
aC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ag
ga
ca
gg
gt
cg
ca
gc
N
EI
L1
15
75
64
00
20
75
64
01
31
-
ac
gc
cc
cc
tc
cc
cg
gg
aa
cc
cg
cC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
gg
cc
cg
tc
ct
cc
cc
at
N
EI
L1
15
75
64
02
91
75
64
04
02
+
cg
ct
gc
cg
cg
gg
cc
ct
tt
cc
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
cg
tc
gc
ta
ag
tg
cc
cc
ct
t
N
EI
L1
15
75
64
01
93
75
64
03
04
-
ac
gt
ga
gg
ct
cc
aa
at
cc
ta
gt
tC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ga
at
cg
ga
gg
cg
aa
gg
N
EI
L1
15
75
64
11
70
75
64
12
81
+
gt
tt
gt
ga
at
ga
gg
cc
tg
ca
gC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
ta
aa
aa
tg
gg
gc
tg
ac
ag
N
EI
L1
15
75
64
13
47
75
64
14
58
+
gc
ca
ct
gg
cc
ct
gg
tc
tt
cc
gC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ag
aa
gt
cc
tc
tg
tc
ag
cc
N
EI
L1
15
75
64
12
81
75
64
13
92
-
gg
ct
gg
cc
ag
gt
gc
ag
ct
cg
gg
gC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
ct
tg
cc
gc
gg
gc
tg
aa
N
EI
L1
15
75
64
15
43
75
64
16
54
+
gt
ct
tg
ca
gg
ag
ta
cc
ag
ca
gt
tc
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
ac
gc
ca
tg
cc
ca
cc
t
N
EI
L1
15
75
64
14
58
75
64
15
69
-
cc
tg
tt
gg
gg
ct
gg
gc
cc
ca
gg
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Ta
aa
ca
ta
gg
gc
ga
gc
cg
g
N
EI
L1
15
75
64
16
39
75
64
17
50
-
gg
ct
gc
ca
ct
tt
cc
cc
ca
ag
gt
cC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ac
tc
gc
cc
ct
tg
tt
gg
N
EI
L1
15
75
64
45
07
75
64
46
18
+
cc
ac
at
tc
cc
ca
ct
gc
ct
ag
ca
tg
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
cg
gc
cc
at
ct
gc
ga
g
N
EI
L1
15
75
64
44
34
75
64
45
45
-
gg
tg
cg
ta
ag
ac
cc
at
cc
cc
ac
cC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Ta
tc
tc
tg
cc
cg
ca
ga
ta
N
EI
L1
15
75
64
46
46
75
64
47
57
-
ag
cc
at
gc
ta
gg
ca
gt
gg
gg
aa
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ga
ca
cc
ag
tg
tg
cc
ag
c
N
EI
L1
15
75
64
50
26
75
64
51
37
+
gt
tt
gt
ag
cc
ct
ag
ct
ga
ta
cC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tt
at
gt
ca
ct
ca
gt
gc
cc
aa
N
EI
L1
15
75
64
49
17
75
64
50
28
-
gt
ct
gt
ca
gc
ag
gg
cc
at
gt
aa
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tt
ca
cc
ca
ac
tg
ga
cc
ac
t
N
EI
L1
15
75
64
60
78
75
64
61
89
+
cg
ta
cc
at
ct
gg
tt
cc
ag
gt
tg
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
ct
gt
tc
ct
ct
gt
cc
ca
c
Su
p
p
le
m
en
ta
ry
 T
ab
le
 1
. (
co
nt
in
ue
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N
EI
L1
15
75
64
59
67
75
64
60
78
-
gg
gg
cc
ac
ac
tc
tc
cc
tc
ct
ct
gC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
cg
ta
gc
ct
tt
gc
cc
cc
N
EI
L1
15
75
64
61
89
75
64
63
00
-
cc
at
gc
cg
gt
cc
tg
ca
gg
ga
gC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tt
cc
tt
gg
ag
gg
tc
ta
ga
ca
N
EI
L1
15
75
64
65
34
75
64
66
45
-
cc
tt
gg
ag
ag
gc
ag
ga
ct
ca
cC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
aa
gt
cc
tt
tc
tg
ct
ct
ct
N
EI
L1
15
75
64
67
01
75
64
68
12
+
ag
tc
ct
ga
gg
ac
ag
ag
tg
ga
gg
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ca
cc
ct
tc
tc
ca
cc
ct
a
N
EI
L1
15
75
64
68
11
75
64
69
22
-
gc
tg
tg
tg
gc
ct
tg
ga
tt
tc
tt
tC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
tt
ag
gg
cc
ca
cc
ac
tc
N
EI
L1
15
75
64
70
73
75
64
71
84
+
aa
ct
gg
ct
ct
ac
ag
ga
ga
gg
at
gC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ag
ga
ct
gc
aa
cc
ca
gc
N
EI
L1
15
75
64
69
64
75
64
70
75
-
gc
tc
ag
aa
ag
ca
gt
tc
ag
ag
gt
tC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ag
gc
tg
gt
cc
cc
tc
ag
N
EI
L1
15
75
64
71
58
75
64
72
69
-
ga
gg
ct
gc
ct
gt
cg
cc
cc
tt
cC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
aa
ga
tg
gt
ca
gc
ta
ag
ac
N
EI
L1
15
75
64
73
52
75
64
74
63
+
aa
gg
tg
ca
aa
ca
gg
cc
ct
ac
gC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tt
ga
ca
tc
cc
at
cc
tt
gg
aa
N
EI
L1
15
75
64
72
53
75
64
73
64
-
ca
gc
ct
tt
ct
cc
ca
cc
tt
tg
ta
cC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
tc
ct
gc
ta
ag
ag
gc
tg
N
EI
L2
8
11
62
89
00
11
62
90
11
+
gt
ca
gc
ag
gt
gg
tc
aa
ga
ca
gg
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
tt
gg
ca
cc
tg
tt
aa
ag
a
N
EI
L2
8
11
62
90
60
11
62
91
71
+
ag
gg
tg
tc
ac
tt
cc
ct
ga
gt
cc
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
ta
ag
aa
gc
ta
ca
gc
cc
g
N
EI
L2
8
11
62
89
88
11
62
90
99
-
ga
aa
tt
tc
ct
ca
cc
aa
cg
gc
cC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
cc
tt
ca
ga
gg
ag
ta
tt
ac
N
EI
L2
8
11
63
70
83
11
63
71
94
+
aa
ga
ag
tg
ca
ga
ag
ga
ag
gg
gc
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
tc
tg
gg
tc
tg
ta
ag
gc
t
N
EI
L2
8
11
63
72
46
11
63
73
57
+
gc
tg
cg
tg
tc
ag
ct
tt
gg
tt
tg
tt
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
ag
gt
cg
gg
ga
gc
cc
a
N
EI
L2
8
11
63
71
67
11
63
72
78
-
gc
ca
gg
gg
gc
cc
ca
tt
tc
tt
ca
tC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
gg
ga
cg
ag
ct
ct
gc
ag
N
EI
L2
8
11
63
74
32
11
63
75
43
+
ca
ta
ct
ga
gg
ac
gt
cc
ag
tc
tg
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
ca
ag
aa
ag
cc
aa
ca
ag
a
N
EI
L2
8
11
63
73
39
11
63
74
50
-
ca
gg
gg
cg
tc
tc
tc
tc
ca
aa
ta
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
ac
ca
tt
ac
ct
cg
gg
ga
a
N
EI
L2
8
11
64
06
00
11
64
07
11
+
gt
tg
gt
cc
tg
ca
ct
tt
gg
tg
gt
C
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tg
cc
ac
ag
ag
tg
tg
ct
ct
a
N
EI
L2
8
11
64
08
15
11
64
09
26
+
gg
gt
ga
gt
cc
ac
ag
ag
tt
gc
tC
TT
C
A
G
C
TT
C
C
C
G
A
TA
TC
C
G
A
C
G
G
TA
G
TG
Tc
ac
ct
gt
ga
ca
tc
ct
gt
ct
N
EI
L2
8
11
64
07
04
11
64
08
15
-
aa
ag
aa
ca
gg
tc
at
at
gt
ac
ac
aC
TT
C
A
G
C
TT
C
C
C
G
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Abstract
Serrated polyposis syndrome (SPS), the development of multiple serrated polyps in 
the colorectum, is suspected to be a heritable syndrome, but germline aberrations predisposing 
to SPS still remain to be discovered. Here, we report a large family exhibiting an autosomal 
dominant inheritance pattern of SPS. In order to identify a candidate predisposing germline 
aberration, we subjected six affected members of this family to whole-exome sequencing 
(WES) and, in addition, performed co-segregation analysis in six affected and six unaffected 
family members. We found that loss-of-function mutations in two candidate genes that have 
previously been associated with SPS, i.e., PIF1 and RBL1, did not co-segregate with the disease 
in this family. We also noticed that the previously reported p.E49* nonsense variant in PIF1 
appears to be a common SNP present in the general population. Additionally, we searched for 
novel germline aberrations (including copy number variants) shared between the six affected 
family members that could explain the inheritance of SPS in this family, but no overt causative 
aberration could be detected. We anticipate that the causative aberration may be located 
outside the currently analyzed protein-coding region and, therefore, that the application of 
other genomic approaches, such as whole-genome sequencing, is warranted. 
Introduction
The accelerated and consecutive development of polyps in the colon, referred to as polyposis, 
is strongly associated with a heritable genetic predisposition and an increased lifetime risk to 
develop colorectal cancer (CRC). Causative genes have been identified for several polyposis-
associated syndromes, including familial adenomatous polyposis (FAP) [1, 2], MUTYH-associated 
polyposis (MAP) [3], polymerase proofreading-associated polyposis (PPAP) [4], NTHL1-associated 
polyposis (NAP) [5], juvenile polyposis syndrome (JPS) [6, 7], PTEN hamartoma tumor syndrome 
(PHTS) [8] and Peutz-Jeghers syndrome (PJS) [9, 10]. These polyposis syndromes are associated 
with the development of different histological polyp phenotypes: patients may be diagnosed 
with conventional adenomas, serrated polyps, hamartomatous polyps or a mixture of different 
polyp subtypes [11]. The development of multiple serrated polyps (SPs), which have a microscopic 
serrated or saw tooth-like appearance within colonic crypts [12] is known as serrated polyposis 
syndrome (SPS), and has been associated with germline aberrations in the genes GREM1 [13] 
and MUTYH [14]. However, germline mutations in these and other polyposis-associated genes 
appear to be uncommon in individuals with SPS [15] and, as yet, no other high-penetrant genes 
predisposing to SPS have been reported.
Since a genetic test for SPS is not available, diagnosis of SPS is currently made in 
patients that meet one of the following clinical criteria: (i) at least five serrated polyps proximal 
to the sigmoid colon with two or more of these being > 10 mm; (ii) any number of serrated 
polyps proximal to the sigmoid colon in an individual who has a first-degree relative with 
serrated polyposis; or (iii) > 20 serrated polyps of any size distributed throughout the colon [12]. 
SPS patients, as well as close relatives of SPS patients, are at an increased risk of CRC [16-18]. 
Therefore, these individuals are advised to enter presymptomatic screening programs which, 
for other colon cancer syndromes, have shown to enable the early recognition of individuals at 
risk, and reduce cancer incidence and mortality rates [19, 20]. Unfortunately, however, clinical 
management is hampered in cases where germline aberrations are not known [21]. 
In the past decades, genome-wide linkage analyses in families with high-penetrance 
predisposition patterns has been a successful approach to identify novel cancer predisposing 
genes [22]. A previous linkage analysis in a large family in which serrated neoplasia was inherited 
in a dominant fashion and, subsequently, fine-mapping in an additional 10 serrated neoplasia 
families resulted in linkage to chromosome 2q32.2-q33.3. This effort, however, did not result 
in the identification of a candidate susceptibility gene [23]. The introduction of whole-exome 
sequencing (WES) provides new opportunities to reveal the genetic cause of SPS. In a recent 
study, WES was applied to 20 unrelated subjects with multiple sessile serrated adenomas, and 
an association with germline loss-of-function mutations in genes involved in the oncogene-
induced senescence pathway was reported [24]. Noteworthy, these genes with loss-of-function 
mutations are not located in the 2q32.2-q33.3 region. Interpretation of WES data is challenging, 
particularly in isolated cases and small families where extensive co-segregation analyses cannot 
be conducted.
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Here, we report a clinically well-characterized family in which multiple members 
in consecutive generations are affected with serrated polyposis. An autosomal-dominant 
inheritance pattern with a high penetrance of serrated polyps and colorectal cancer has been 
noted in this family. We applied whole-exome sequencing to six affected family members with 
the aim to identify the genetic defect underlying the SPS phenotype in this family. 
Material and methods
Patient material
The study protocol was approved by the local medical ethics committee (NL44839.091.13 and 
local study number 2014/032) and every participant provided written informed consent. Of 
the 13 members of this family included in this study, 8 were diagnosed with serrated polyposis 
or CRC and 2 were unaffected. Three relatives without a known history of polyposis refused 
surveillance colonoscopies, therefore their clinical phenotype is undefined. All patient charts 
were reviewed for endoscopic results and relevant co-morbidities. Polyps were counted toward 
a total polyp count with a definite pathology result. All removed colorectal lesions were 
revised by an expert pathologist (IDN). Even though total polyp counts varied between family 
members, all family members with >10 polyps or ≥ 1 CRC were considered affected, ruling out 
the inclusion of sporadic polyps instead of polyposis. Family members with a low number of 
polyps (range: 1-10) were not counted as affected or unaffected. Peripheral blood was obtained 
for DNA isolation using standard procedures. Six affected family members were included for 
whole-exome sequencing. DNA of other family members was used for co-segregation analysis 
of candidate variants. 
Control cohorts
An in-house database of exome sequencing variants was used as a primary control cohort. This 
cohort contains all germline variants identified in 2,037 exomes derived from individuals who 
have, to our knowledge, not been diagnosed with polyposis and/or CRC. In addition, three 
control databases were used to exclude common genomic polymorphisms: dbSNP142 [25], the 
ExAC browser [26] and a second in-house, diagnostic, exome database. The latter database 
contains data from 2,329 individuals without a suspected hereditary form of cancer, which were 
sequenced using similar conditions (i.e., exome enrichment and sequencing platform (Illumina)) 
as applied for the six serrated polyposis patients in this study.
Whole-exome sequencing and Sanger validation
Exome capturing was performed on purified DNA isolated from peripheral blood leucocytes, 
using an Agilent SureSelectXT Human All Exon v4 enrichment kit (Agilent Technologies). 
Whole-exome sequencing was performed on an Illumina HiSeq platform (2x100bp paired 
end; Illumina). The achieved average coverage on target was high for all six affected patient 
samples [range 69.5-98.1] and at least 99.2% of target regions was covered at least 5-fold 
(supplementary Table 1). Sequencing reads were mapped to the hg19 reference genome 
using Life Technologies Lifescope software version 2.1 and annotations and variant calling were 
performed according to previously described procedures [27]. Prior to our analysis, variants that 
were frequently encountered (i.e., minor allele frequency (MAF) >0.01) in our in-house database 
of exome sequencing variants were excluded. In addition, variants not located in exonic or 
canonical splice-site regions were excluded. PCR and Sanger sequencing were performed using 
standard procedures. Primer sequences are available upon request.
RNA expression analysis
EBV-transformed B-lymphocytes, derived from individuals II-10, II-11, II-12, II-13 and III-
5, were cultured in RPMI-1640 medium (Sigma) supplemented with 10% Fetal Calf Serum 
(PAA laboratories), 50,000 units Penicillin, 50mg Streptomycin (Sigma) and 10mM L-Alanyl-
L-Glutamine (Sigma) at 37°C in a humidified atmosphere with 7,5% CO2. Splitting of cells 
occurred twice a week in a 1:3 ratio. For RNA isolation, 1.0x107 cells were harvested and, 
subsequently, total RNA was isolated using a RNeasy mini kit (Qiagen). Next, 2µg RNA was used 
to synthesize cDNA using random and Oligo (dT) primers (Takara Bio Inc.). cDNA was diluted 
20-fold in MilliQ and, subsequently, 5µl of the diluted sample was mixed with a GoTaq qPCR 
master mix (Promega) and forward and reverse primers. To determine gene expression levels, 
real-time quantitative RT-PCR was performed (Applied Biosystems) using HPRT as an internal 
reference. All primer pairs were designed such that they encompassed large intronic genomic 
regions to avoid amplification of residual genomic DNA in the cDNA samples, and for each gene 
two unique RT-PCR primer pairs were used. Ct values of both primer pairs were used to calculate 
the expression of the corresponding gene (primer sequences available upon request). 
Characterization of polyps and adenocarcinoma
We selected a subset of colorectal polyps from family members and performed PCR and Sanger 
sequencing for KRAS (codon 12 and 13) and BRAF (codon 600) using standard procedures. The 
formalin-fixed, paraffin-embedded adenocarcinoma of family member II-4 was stained with 
monoclonal antibodies against MLH1 (BD Pharmingen 551091, 1:40), PMS2 (BD Pharmingen 
556415, 1:50), MSH2 (Calbiochem NA26, 1:40), and MSH6 (Abcam ab92471, 1:500) and 
developed with Powervision (Labvison). Microsatellite instability of this adenocarcinoma was 
assessed using a panel of microsatellite markers (D2S123, D5S346, D17S250, BAT25, BAT26 
and BAT40).
Results
Clinical characteristics and pedigree information of the SPS family
This large SPS family has been under surveillance at our institution for over 20 years (Figure 
1). A hereditary CRC syndrome was suspected when one sibling (II-4) died of CRC in her early 
thirties. Diagnostic testing of the APC and MUTYH genes was performed in a subset of patients, 
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but no pathogenic germline mutations were identified. It is unclear whether the father (I-1) was 
affected, although he presumably died of colorectal cancer. Of the eleven individuals from the 
second generation, six siblings developed polyps or CRC. Five siblings presented with varying 
polyp counts (range 5-40) when offered a colonoscopy. One sibling has been extensively followed 
with colonoscopy but never developed polyps (now aged 60) while three siblings did not opt for 
colonoscopy surveillance. Two members of the third generation were diagnosed with serrated 
polyps at a relatively young age (Table 1). Currently, all first degree relatives of affected family 
members are offered a colonoscopy every three years starting at age 30, and family members 
presenting with polyps receive a follow-up colonoscopy every 1-3 years depending on polyp 
number and histology according to the Dutch guidelines [28]. No extra-colonic malignancies or 
other important co-morbidities have been noted in this family.
Clinical and molecular characteristics of colorectal lesions
All available colorectal lesions (n=88) were revised by an expert pathologist (IDN). After revision, 
72 of these lesions appeared to be serrated polyps, including 40 hyperplastic polyps, 30 sessile 
serrated adenomas (SSAs), and 2 traditional serrated adenomas (TSAs). Ten lesions were 
classified as conventional adenomas after revision and six could not be classified. The two TSAs 
were discovered in a mother and her daughter (II-2 and III-3) (Figure 2). A neuro-endocrine 
tumor was removed from the colon of family member II-13. The colon carcinoma from family 
member II-4 was a serrated adenocarcinoma with some mucinous components and focal clear 
cell changes (Figure 3). 
Since it has been reported that mutations in KRAS are rare, but the activating p.V600E 
mutation in BRAF is frequently observed in serrated polyps [29-31] we determined, in addition 
to the expert revision, the mutation status of KRAS and BRAF. To this end, we applied targeted 
Sanger sequencing to DNA obtained from polyps derived from II-2 (n=8), II-8 (n=3), II-13 (n=2) and 
III-5 (n=3). The p.V600E mutation in BRAF was observed in 75% of the polyps (supplementary 
Figure 1), whereas none of the polyps carried a mutation in KRAS. In contrast, the activation 
p.G12V mutation in KRAS was encountered in the adenocarcinoma derived from II-4, whereas 
no activating mutation in BRAF was identified in the same sample (Table 2). Staining for MLH1, 
PMS2, MSH2 and MSH6 was normal and no microsatellite instability could be detected. 
Genetic characteristics of affected family members
To identify rare potentially damaging germline aberrations that were shared between all affected 
family members, we performed whole-exome sequencing (WES) on peripheral blood-derived 
DNA from six siblings, i.e., II-2, II-6, II-8, II-13, III-3 and III-5 (Figure 1). The average coverage on 
target was high for all samples [range 69.5-98.1] and, on average, 98.6% of the target regions 
was covered at least 10-fold (supplementary Table 1). No shared copy number variants (CNVs) 
were detected based on the obtained WES data (data not shown). The total numbers of variants 
encountered were comparable between all exomes [range 42,512 – 43,592], resulting in a total 
of 67,028 unique variants. In line with the high-penetrant, autosomal dominant inheritance 
pattern observed in this family, all variants encountered with a minor allele frequency (MAF) 
>0.01 in our in-house database of exome sequencing variants were excluded. To identify the 
causative germline aberration which underlies the development of serrated polyps in the family, 
we applied two filtering strategies on the remaining variants, focusing on previously reported 
and novel variants, respectively (Figure 4). 
In our exome data, a total of 73 truncating variants were called: 24 nonsense variants, 
36 frameshift variants and 9 variants affecting a canonical splice site (supplementary Table 2). 
In a previous study, truncating germline variants in six genes were reported as being associated 
with a serrated polyposis phenotype [24]. In two of these six genes, we encountered a 
truncating germline variant, i.e., a nonsense mutation in PIF1 (c.145C>A; p.E49*;NM_025049) 
and a 4-nucleotide deletion affecting the canonical splice acceptor site in exon 11 of RBL1 
(c.1364-2_1365del; NM_002895). The p.E49* variant in PIF1 has previously been associated 
with the development of SSA/Ps and reported to be rare [24]. To reveal whether one or both of 
these variants were associated with the presence of multiple SSAs in the family under study, we 
performed a co-segregation analysis on 13 available family members. We found that neither of 
the two variants co-segregated with the serrated polyposis phenotype: four affected individuals 
did not carry the PIF1 variant, two of them lacked the RBL1 variant, and both variants were also 
observed in non-affected individuals (Figure 1). Furthermore, we noticed that the p.E49* PIF1 
variant in individual III-3 was not inherited from her affected mother, but from her father who 
was not genetically related to the family, suggesting that the variant may be more frequent than 
expected. We, therefore, examined an additional control exome sequencing dataset consisting 
of 2,329 subjects with, to our knowledge, a negative history of polyposis or CRC (see materials 
and methods). The 4-nucleotide deletion affecting the canonical splice acceptor site in exon 11 
of RBL1 turned out to be rare in this dataset (MAF 0.0013), and other truncating variants in RBL1 
were not observed. In contrast, we encountered 76 heterozygous carriers and one homozygous 
carrier of this specific variant in PIF1 (MAF 0.0167), which indicates that, in contrast to what 
has previously been reported [24], the p.E49* germline variant in PIF1 represents a relatively 
common SNP. 
Identification of novel germline aberrations underlying SPS
Next, we analyzed our exome sequencing data for the presence of pathogenic germline variants 
that could explain the polyposis phenotype in this family. To this end, we focused on all rare 
germline variants shared between the six affected family members that were sequenced. From 
the 3,548 remaining variants detected in one or more of the family members, only variants in 
protein coding regions were included, which resulted in 1,561 unique germline variants. We 
confirmed that the genomic position of these variants were equally covered between the six 
exomes to prevent the exclusion of variants due to reduced coverage in one of the samples in the 
next step (supplementary Figure 2). Furthermore, for those rare variants that were identified 
in five (n=35) or four (n=81) of the six affected individuals, we individually confirmed that 
the coverage at the respective positions in the wild-type individuals was sufficient, to exclude 
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that variants were missed (supplementary Table 3) In total, 28 variants in coding regions 
were exclusively present in all six individuals (Figure 5 and supplementary Table 4). In search 
for protein damaging germline aberrations, synonymous variant calls were excluded (n=7). To 
prevent inclusion of common polymorphisms that were not present in our in-house database of 
exome sequencing variants (see materials and methods) we included three additional databases 
in this filtering strategy: dbSNP142 [25], ExAC [26] and a second in-house exome database. 
Subsequently, we excluded variants with a MAF >0.01 in at least one of these databases (n=8). 
Subsequently, all remaining variants that did not co-segregate with the polyposis phenotype in 
the family were excluded (n=12) (Table 3 and supplementary Table 4). One missense variant 
(p.E333K; c.997G>A) in the BCAT1 gene (NM_001178093) remained after this last filtering 
step. However, the p.E333K missense variant in the BCAT1 gene is predicted to be benign based 
on five different in silico prediction tools (supplementary Table 5). To test whether this variant 
affects RNA expression, we determined the expression of the BCAT1 gene in EBV-transformed 
B-lymphocytes derived from two mutation carriers (II-13 and III-5) and three wild type carriers (II-
10, II-11 and II-12). We noticed that the average RNA expression levels of the BCAT1 gene were 
not altered in mutation carriers (Figure 6). In addition, we noted that the p.E333K variant in the 
BCAT1 gene is encountered relatively frequently in the Finnish population (MAF 0.01097) [26]. 
Discussion 
Here, we present a large family with an autosomal dominant inheritance pattern of SPS, 
illustrated by multiple affected members in at least two consecutive generations. The majority 
of the polyps derived from these patients contained an activating p.V600E mutation in BRAF. 
Using whole-exome sequencing of germline DNA, we identified loss-of-function variants in two 
genes, PIF1 and RBL1, which were previously claimed to be associated with the development 
of serrated adenomas, but these variants did not co-segregate with the development of polyps 
in this family, and the PIF1 turned out to be a relatively common SNP. In addition, we identified 
one variant, p.E333K in BCAT1, which co-segregated with the disease, but an SPS predisposing 
effect of this variant is not anticipated. Therefore, despite the autosomal dominant inheritance 
pattern observed in this large family, no other overt causative germline aberration was detected 
in the protein-coding sequences of the affected individuals.
High-penetrant predisposing germline aberrations have been identified for several 
polyposis syndromes, including FAP [1, 2], MAP [3], PPAP [4], NAP [5], JPS [6, 7], PHTS [8] and PJS 
[9, 10]. However, to date high-penetrant germline aberrations predisposing to the development 
of SPS have not been identified. A possible explanation may be that SPS is genetically 
heterogeneous since currently SPS can only be diagnosed based on clinical and histological 
criteria [12]. Especially since the development of serrated polyps is known to be associated with 
common lifestyle and dietary variables [32], a subset of the patients may in fact be due to these 
non-genetic causes. However, the increased incidence of polyps and the risk to develop CRC in 
first-degree relatives of SPS patients strongly supports a heritable genetic factor [18, 33]. The 
heritability of SPS is further supported by the identification of large families, including the family 
reported here, with multiple individuals who developed SPS. Although some affected family 
members only fulfill the WHO criteria for serrated polyposis because they are a first-degree 
relative of a SPS patient, we considered all family members with >10 polyps as affected [12]. We 
did not include family members from the second generation with less polyps as either affected 
or unaffected to prevent inclusion of sporadic cases. The family members III-3 and III-5 were 
considered affected since they developed polyps at a young age. In addition, III-3 developed 
the same rare TSA as her mother (II-2). Although the exact number of polyps in family member 
II-4 could not be established, she was considered affected due to the presence of polyps and 
the serrated architecture of the adenocarcinoma. It is likely that both the endoscopist and the 
pathologist might have overlooked the easily to-be-missed serrated polyps while focusing on 
the carcinoma [34]. Although microsatellite instability is often described in the serrated pathway, 
the frequency of microsatellite instability in serrated carcinomas does not differ compared to 
conventional adenocarcinomas [35, 36]. In line with previous observations, 75% of the polyps 
derived from the SPS patients in our family contained the p.V600E mutation in BRAF [29-
31], whereas activating BRAF mutations only occur in 4-12% of unselected colorectal tumors 
[37]. This observation supports the hypothesis that a specific serrated polyposis/CRC pathway 
underlies the development of SPS [38]. The identification of additional (large) SPS families will 
not only confirm that heritable germline aberrations can predispose to the development of SPS, 
but may also contribute to the elucidation of these germline aberrations, including its putative 
heterogeneity.
Our WES approach revealed that only the p.E333K variant in BCAT1 co-segregates 
with the polyposis phenotype in this family. However, this variant was predicted to be benign 
and inclusion of additional control databases revealed that this variant, although rare in our 
initial control dataset, was frequently encountered in the Finnish population (MAF 0.01097). 
Overexpression of the c-Myc target gene BCAT1 is associated with the induction of cell 
proliferation in nasopharyngeal carcinomas and gliomas [39, 40]. However, expression levels of 
BCAT1 were not altered in EBV-transformed B-lymphocytes derived from two mutation carriers 
compared to three wild type carriers, further hampering a potential cancer predisposing effect 
of the observed p.E333K variant. The high frequency of this variant and the unaltered expression 
levels of BCAT1 implies that the only co-segregating germline variants observed in this family is 
unlikely to explain the polyposis phenotype.
We noticed that the p.E49* nonsense variant in PIF1, which was previously reported 
to be rare and associated with the development of multiple SSA/Ps [24], in fact represents a 
relatively common SNP in our control cohort (MAF 0.0167), thereby questioning this association. 
The discrepancies between the MAFs of this variant between different data sets may be 
explained by the control cohort used in the previous study, which was based on 4,300 samples 
included in the ESP database [41]. We noticed that the genomic locus encompassing the p.E49* 
germline variant in PIF1 is poorly covered in this database (chr15: 65,116,388- 65,116,413, 
average sample read depth 1.0 ± 0.0) and, therefore, the frequency of the p.E49* variant in PIF1 
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was underestimated. So, although large control datasets are now generally used to determine 
the potential pathogenic effect of germline aberrations, inclusion of additional control cohorts 
with subjects from different ethnicities or sequenced using different sequencing platforms is 
recommended.
We anticipated that the SPS predisposing germline aberration in this family might be 
located within the protein-coding region (exome) of the genome, since previous work has shown 
that Mendelian disorders are often caused by germline aberrations within this part of the genome 
[42]. Indeed, previously we successfully applied WES to reveal the adenomatous polyposis and 
CRC predisposing effect of germline aberrations in NTHL1 [5]. There are several explanations for 
the fact that a causative germline variant could not be identified. Firstly, our current results may 
suggest that no heritable factor is involved in the development of SPS in this family but, as discussed 
above, we consider this hypothesis unlikely. Secondly, sub-optimal targeting may have hampered 
the identification of the causative mutation due to insufficient coverage for proper variant calling 
[43]. Currently, we cannot exclude this possibility, but the majority of the targeted regions (98%) 
of the targets was covered at least 10-fold (supplementary Table 1), which is generally sufficient 
for proper variant calling. Therefore, the number of genes missed in our analysis is low. Thirdly, 
also structural genomic variations (e.g. complex genomic rearrangements and/or small CNVs) or 
genomic aberrations outside the exome may predispose to SPS development. Options to detect 
these aberrations by WES are limited [43, 44]. We applied copy number analyses on our exome 
data, which did not reveal any CNVs, although single-exon deletions may have been missed [45]. 
Also, balanced structural variations, including chromosomal translocations and large inversions 
cannot be detected by WES. Therefore, we anticipate that whole-genome sequencing (WGS) of 
multiple members of our large family will be required to identify the SPS predisposing germline 
aberration, either in exons that were missed by our WES approach or outside the exome.
The advantage of WGS to explain the SPS phenotype in this large family may be illustrated 
by the previous identification of polyposis and CRC predisposing rare germline aberrations that 
would probably not have been detected by WES. For example, deep intronic mutations in MSH2 
and APC are known to predispose to the development of Lynch syndrome and FAP, respectively 
[46, 47]. These intronic regions are not covered by WES. Furthermore, germline deletions affecting 
the 3’ end of EPCAM, resulting in the methylation and inactivation of MSH2, have been shown 
to predispose to the development of Lynch syndrome [48]. These deletions may encompass only 
one or two exons [49], which are difficult to detect by WES. Therefore, rare germline aberrations 
in non-coding regions or CNVs of (single) exons may predispose to the development of SPS and 
WGS is required to identify these aberrations.
In conclusion, we present a large family with an autosomal dominant inheritance pattern 
of serrated polyposis. This inheritance supports the hypothesis that high-penetrant germline 
aberrations may underlie the development of SPS. Since whole-exome sequencing on germline 
DNA from six affected family members failed to detect the causative germline aberrations we 
anticipate that the causative aberration is located outside the exome, and that other approaches, 
e.g. whole-genome sequencing, are needed. 
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Figure 2. Traditional Serrated Adenomas. Patients II-2 (A) and III-3 (B) both presented with a traditional serrated 
adenoma (TSA), a rare subtype of serrated polyp. Alongside the serrated architecture, ectopic crypt formation can 
be observed which is an important feature of TSA. In B there is a remarkable intra-epithelial lymphocytosis (arrows). 
A B
C D
 
Figure 3. Adenocarcinoma of family member II-4. Serrated adenocarcinoma with some mucinous 
components and focal clear cell changes. In both the adenocarcinoma component (a,b) and the mucinous 
component (c), the serrated architecture is present. Clear cell changes can be observed throughout the 
tumour (d). 
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Figure 4. Variant filtering strategy applied on data derived from whole-exome sequencing of six 
related SPS patients. For details, see main text.
Figure 5. Overlapping rare variants in whole-exome sequencing data derived from six related 
affected individuals. The inclusion of six family members reduced the number of rare variants (MAF<1) 
called in all exome sequencing data. A total of 1,561 unique rare variants was called in the six datasets, but 
only a minor subset was present in all six exomes.
Figure 6. Expression of BCAT1 in EBV-transformed B-lymphocytes. Based on real-time PCR data, 
the average level of expression of BCAT1 was not significantly altered in EBV-transformed B-lymphocytes 
derived from patients II-13 and III-5 compared to three controls (P = 0.33; two-sided, unpaired, T-test). For 
details, see materials and methods. 
MaF variant calls in-
house database <0.01
3,548
MaF variant calls <0.01
14
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Table 1. Clinical characteristics of family members
Patient Age at first 
polyp
Total polyps 
observed
Total polyps 
removed
Total
 HPs
Total SSL Total 
TSAs
Total 
adenomas
CRC + age of 
diagnosis
I-1 unknown Unknown Unknown NA NA NA NA ?
I-2 NA 0 0 NA NA NA NA -
II-2 40y 50 42 4 10 1 1 -
II-4 33y >5* >5* NA NA NA NA 33y
II-6 36y 25 18 11 3 0 2 -
II-8 56y 15 14 5 6 0 3 -
II-11 NA 0 0 NA NA NA NA -
II-12 59y 5 2 1 1 0 0 -
II-13 41y 35 24 14 7 0 2 -
III-3 39y 1 1 0 0 1 0 -
III-5 32y 6 6 5 0 0 1 -
HP = Hyperplastic Polyps, SSL = Sessile Serrated Lesion, TSA = Traditional Serrated Adenomas, 
CRC = colorectal cancer, * Exact number of polyps unknown and polyps were unavailable for 
revision (originally diagnosed as hyperplastic polyps).
 
 
Table 2. Characteristics of colorectal neoplasms of family members 
Patient Histology Dysplasia Location BRAF status KRAS status
II-2 SSL No Unclear p.V600E WT
II-2 TSA LGD Unclear WT WT
II-2 SSL No Unclear p.V600E WT
II-2 HP No Unclear p.V600E WT
II-2 SSL No Unclear p.V600E WT
II-2 SSL No Unclear WT WT
II-2 SSL No Unclear WT WT
II-2 SSL No Unclear WT WT
II-4 Adenocarcinoma CRC Proximal colon WT p.G12V
II-8 SSL No Rectum p.V600E WT
II-8 SSL No Rectum p.V600E WT
II-8 SSL No Rectum p.V600E WT
II-13 SSL No Cecum p.V600E WT
II-13 SSL No Transverse colon p.V600E WT
III-5 HP No Distal colon p.V600E WT
III-5 HP No Distal colon p.V600E WT
III-5 HP No Distal colon p.V600E WT
 
SSL = Sessile Serrated Lesion, HP = Hyperplastic polyp, TSA = Traditional Serrated Adenoma, 
CRC = colorectal cancer, LGD = Low Grade Dysplasia, WT = Wildtype
Table 3. Co-segregation analysis of germline variants shared between six polyposis patients
Gene mRNA accession 
number
mRNA 
change
Protein 
change
WES 1 II-4 2 I-2 3 II-11 3 Candidate 
variant 4
 ADCK4 NM_024876 c.645del p.F215fs Yes No Not tested Not tested No
 BCAT1 NM_001178093 c.997C>T p.E333K Yes Yes No No Yes
 CEACAM8 NM_001816 c.364del p.L122fs Yes No Yes Yes No
 CYP2A6 NM_000762 c.361C>G p.G121R Yes No Not tested Not tested No
 FLRT2 NM_013231 c.319C>A p.L107I Yes No Yes Yes No
 GSG1 NM_001080554 c.512A>G p.L171S Yes No Not tested Not tested No
 IGFN1 NM_001164586 c.9682G>A p.G3228S Yes No No No No
 MYOM2 NM_003970 c.3904A>G p.T1302A Yes Yes Yes Yes No
 PTPN21 NM_007039 c.2953del p.V985fs Yes No Yes Yes No
 PZP NM_002864 c.3571G>A p.R1191C Yes No Not tested Not tested No
 RIN3 NM_024832 c.2258A>G p.Y753C Yes No Yes Yes No
 XIRP2 NM_152381 c.9835T>C p.S3279P Yes No Not tested Not tested No
 ZNF780B NM_001005851 c.723G>T p.N241K Yes No Not tested Not tested No
1) Variant is present in II-2, II-6, II-8, II-13, III-3 and III-5.
2) Variant is present in the adenocarcinoma derived from patient II-4.
3) Variant is present in the unaffected family members I-2 or II-11.
4) Variants which are identified in the adenocarcinoma derived from patient II-4 but not observed in 
 I-2 or II-11 are considered candidate germline variants predisposing to polyposis and CRC. 
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Supplementary information
Supplementary Figure 1. BRAF mutation status (p.V600E) in 12 polyps and 1 carcinoma. Polyps 
were derived from II-2, II-8, II-13 and III-15. The adenocarcinoma was derived from II-4. Asterixes indicate 
c.1799T>A transversions, resulting in the activating p.V600E mutation in BRAF.
Supplementary Figure 2. Number of reads covering the base pair position of a variant call 
in the coding region of the genome per exome. Genomic positions of germline variant calls were 
equally covered between the six exomes from patients II-2, II-6, II-8, II-13, III-3 and III-5. A total of 1,561 
unique variants were called. Depicted are the coverage (Y-axis) of the genomic base pair affected by the 
corresponding variant call (X-axis). Note: the coverage could not be established for 53 deletions and 1 
insertion where multiple base pairs were involved. 
Supplementary Table 1. Overview of exome sequencing coverage
Subject NGS Platform Mean target 
coverage
Median target 
coverage
% Targets 
>= 5x
% Targets 
>= 10x
% Targets 
>= 20x
% Targets 
>= 30x
II-2 Illumina Hi Seq 90.44 82 0.995 0.989 0.967 0.929
II-6 Illumina Hi Seq 98.12 90 0.995 0.989 0.971 0.943
II-8 Illumina Hi Seq 76.47 68 0.994 0.985 0.945 0.875
II-13 Illumina Hi Seq 69.49 63 0.992 0.981 0.941 0.869
III-3 Illumina Hi Seq 85.24 79 0.994 0.986 0.963 0.924
III-5 Illumina Hi Seq 71.78 66 0.992 0.983 0.951 0.892
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Supplementary Table 2. Loss-of-function calls in whole-exome sequencing data
Gene mRNA 
accession 
number
mRNA change Protein 
change
Mutation 
type
MAF # of samples
BPIFB3 NM_182658 c.387-1G>T p.? CSS 0.0048 2
CD46 NM_002389 c.901+1G>A p.? CSS 0.0014 4
LYAR NM_017816 c.123-1G>A p.? CSS 0.0000 1
PLA1A NM_015900 c.1013-1G>C p.? CSS 0.0000 3
POLD1 NM_002691 c.2953+1G>A p.? CSS 0.0000 1
RBL1 NM_002895 c.1364-2_1365del p.? CSS 0.0000 4
SPIRE2 NM_032451 c.288+1G>A p.? CSS 0.0024 1
TMEM245 NM_032012 c.1345-2A>G p.? CSS 0.0014 4
ZNF215 NM_013250 c.712+1G>A p.? CSS 0.0062 1
ADCK4 NM_024876 c.645del p.F215fs FS 0.0000 6
AEBP1 NM_001129 c.1147_1150del p.V383fs FS 0.0000 1
ANKLE1 NM_152363 c.69dup p.E24fs FS 0.0076 1
ARHGAP39 NM_025251 c.2583_2586del p.K861fs FS 0.0000 4
C3 NM_000064 c.3619del p.N1208fs FS 0.0000 2
CAMKK2 NM_001270486 c.1615_1618dup p.G539fs FS 0.0067 2
CEACAM8 NM_001816 c.364del p.L122fs FS 0.0010 6
CNKSR1 NM_006314 c.1244del p.P415fs FS 0.0000 2
CNTD2 NM_024877 c.820del p.Y274fs FS 0.0000 1
CYTL1 NM_018659 c.43dup p.A15fs FS 0.0000 3
ESF1 NM_016649 c.2519_2520del p.E840fs FS 0.0067 1
FAM179A NM_199280 c.231_240del p.D78fs FS 0.0043 1
GPLD1 NM_001503 c.2442del p.V815fs FS 0.0081 1
KIF24 NM_194313 c.469del p.T157fs FS 0.0000 1
MESP1 NM_018670 c.159dup p.S54fs FS 0.0019 1
MESP1 NM_018670 c.156_157insCCGAGCCCCGT p.A53fs FS 0.0019 1
MROH6 NM_001100878 c.2027dup p.C677fs FS 0.0033 5
MTCH1 NM_001271641 c.30del p.W11fs FS 0.0067 5
OPN4 NM_001030015 c.403del p.A135fs FS 0.0067 3
PCDH15 NM_001142763 c.5385_5394del p.P1796fs FS 0.0000 3
PILRB NM_178238 c.604_605del p.V202fs FS 0.0000 1
PRDM15 NM_022115 c.262dup p.R88fs FS 0.0072 6
PTPN21 NM_007039 c.2953del p.V985fs FS 0.0005 6
RBM43 NM_198557 c.406del p.I136fs FS 0.0029 1
RNF150 NM_020724 c.1195_1198dup p.S400fs FS 0.0000 1
SAMD1 NM_138352 c.337insG p.A113fs FS 0.0000 1
SCARF2 NM_153334 c.2253dup p.P752fs FS 0.0048 6
SCARF2 NM_153334 c.2248dup p.A750fs FS 0.0086 6
SLAIN1 NM_001242868 c.220_221dup p.L75fs FS 0.0000 3
SLAIN1 NM_001242868 c.230dup p.L78fs FS 0.0000 3
SLC24A1 NM_004727 c.754_755del p.M252fs FS 0.0005 3
SLC27A6 NM_014031 c.61_65del p.K21fs FS 0.0033 2
SLFN5 NM_144975 c.60dup p.V21fs FS 0.0000 3
SPATA31E1 NM_178828 c.138_139del p.F47fs FS 0.0000 1
VWA5B1 NM_001039500 c.3050dup p.T1018fs FS 0.0000 1
VWA8 NM_015058 c.2132_2135del p.T711fs FS 0.0014 1
AK9 NM_001145128 c.5614del p.Ile1872* NS 0.0014 1
APOBEC3H NM_001166003 c.523C>T p.R175* NS 0.0014 2
CPSF1 NM_013291 c.976G>A p.Q326* NS 0.0000 1
CRNKL1 NM_016652 c.148G>A p.Q50* NS 0.0081 1
FCN1 NM_002003 c.515C>T p.W172* NS 0.0000 1
FSCB NM_032135 c.220G>A p.Q74* NS 0.0033 3
G6PC2 NM_021176 c.847C>T p.R283* NS 0.0024 1
GJB4 NM_153212 c.384G>A p.W128* NS 0.0029 3
GPR141 NM_181791 c.465T>G p.Y155* NS 0.0000 1
IGFN1 NM_001164586 c.7381C>T p.R2461* NS 0.0010 1
KCNK16 NM_032115 c.892G>A p.Q298* NS 0.0100 4
MARCH6 NM_005885 c.2524C>T p.Q842* NS 0.0000 1
NIT1 NM_005600 c.198_199del p.Ala68* NS 0.0010 2
NUDT7 NM_001105663 c.111T>A p.Y37* NS 0.0038 1
PDE5A NM_001083 c.2578G>A p.Q860* NS 0.0038 3
PIF1 NM_025049 c.145C>A p.E49* NS 0.0043 3
RAB44 NM_001257357 c.1238C>A p.S413* NS 0.0014 5
SCRN2 NM_138355 c.739G>A p.Q247* NS 0.0000 2
SNX19 NM_014758 c.2419G>A p.Q807* NS 0.0000 1
TADA1 NM_053053 c.598G>A p.R200* NS 0.0029 1
TPRG1L NM_182752 c.490C>T p.R164* NS 0.0052 2
TRIT1 NM_017646 c.979G>A p.R327* NS 0.0048 3
TSNAXIP1 NM_001288990 c.136C>T p.R46* NS 0.0000 1
ZMYND15 NM_001267822 c.784C>T p.R262* NS 0.0005 2
 
CSS: aberration affecting a canonical splice site. FS: insertion or deletion introducing a frameshift in the 
open reading frame. NS: nonsense, germline aberration introducing a premature stopcodon. MAF: Minor 
allele frequency of the corresponding variant in our in-house database of exome sequencing variants. # of 
samples: number of exomes the variant is called. Bold: genes previously associated with the development of 
serrated polyposis. Note: the majority of these variant calls have not been validated using Sanger sequencing.
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Supplementary Table 4. Variants in coding regions shared between all six family members
Gene mRNA accession 
number
mRNA 
change
Protein 
change
Mutation 
type
MAF
in-house
MAF 
dbSNP
MAF 
ExAC
MAF 
in-
house-II
Validation Co-
segregation
ADCK4 NM_024876 c.645del p.F215fs FS 0.000 0.000 0.000 0.000 Confirmed No 1,4
AMH NM_000479 c.1239T>A p.G413G SYN 0.009 0.931 0.823 0.388 Not done Not tested
BCAT1 NM_001178093 c.997C>T p.E333K MSS 0.009 0.003 0.004 0.004 Confirmed Yes
CCDC85C NM_001144995 c.555G>A p.S185S SYN 0.008 0.815 0.945 0.383 Not done Not tested
CEACAM8 NM_001816 c.364del p.L122fs FS 0.001 0.000 0.000 0.000 Confirmed No 1,2,3
CYP2A6 NM_000762 c.361C>G p.G121R MSS 0.000 0.000 0.000 0.000 Confirmed No 1,4
DLEU7 NM_198989 c.248G>A p.A83V MSS 0.010 0.209 0.295 0.140 Not done Not tested
FLRT2 NM_013231 c.319C>A p.L107I MSS 0.007 0.001 0.002 0.004 Confirmed No 1,2,3
GSG1 NM_001080554 c.512A>G p.L171S MSS 0.001 0.000 0.000 0.001 Confirmed No 1,4
IGFN1 NM_001164586 c.9682G>A p.G3228S MSS 0.006 0.004 0.003 0.006 Confirmed No 1
MYOM2 NM_003970 c.3904A>G p.T1302A MSS 0.001 0.000 0.000 0.001 Confirmed No 2,3
PIK3R2 NM_005027 c.700A>C p.S234R MSS 0.006 0.894 0.896 0.298 Not done Not tested
PLEKHG4B NM_052909 c.2364G>A p.S788S SYN 0.003 0.003 0.006 0.007 Confirmed No 3
PNMAL1 NM_018215 c.1095C>T p.K365K SYN 0.001 0.000 0.000 0.001 Not done Not tested
PRDM15 NM_022115 c.262dup p.R88fs FS 0.007 0.952 1.000 0.389 Not done Not tested
PTPN21 NM_007039 c.2953del p.V985fs FS 0.001 0.000 0.000 0.000 Confirmed No 1,2,3
PZP NM_002864 c.3571G>A p.R1191C MSS 0.010 0.001 0.003 0.004 Confirmed No 1,4
RIN3 NM_024832 c.2258A>G p.Y753C MSS 0.000 0.000 0.000 0.001 Confirmed No 1,2,3
SCARF2 NM_153334 c.2253dup p.P752fs FS 0.005 0.967 0.000 0.400 Not done Not tested
SCARF2 NM_153334 c.2248dup p.A750fs FS 0.009 0.899 0.250 0.402 Not done Not tested
SFRP5 NM_003015 c.20C>G p.G7A MSS 0.003 0.734 0.839 0.377 Not done Not tested
SIT1 NM_014450 c.520C>A p.A174S MSS 0.005 0.005 0.011 0.007 Not done Not tested
SPRN NM_001012508 c.183G>A p.G61G SYN 0.000 0.299 0.286 0.085 Not done Not tested
TM6SF1 NM_023003 c.303G>A p.P101P SYN 0.000 0.000 0.000 0.001 Not done Not tested
TMEM158 NM_015444 c.462G>A p.T154T SYN 0.002 0.377 0.500 0.265 Not done Not tested
XIRP2 NM_152381 c.9835T>C p.S3279P MSS 0.005 0.001 0.002 0.002 Confirmed No 1,4
ZNF516 NM_014643 c.1451G>A p.P484L MSS 0.002 0.028 0.046 0.026 Not done Not tested
ZNF780B NM_001005851 c.723G>T p.N241K MSS 0.000 0.000 0.000 0.000 Confirmed No 1,4
 
CSS: aberration affecting a canonical splice site. FS: insertion or deletion introducing a frameshift in 
the open reading frame. NS: nonsense, germline aberration introducing a premature stopcodon. SYN: 
synonymous variant. MAF: Minor allele frequency of the corresponding variant. MAF in-house: MAF in 
our in-house database of exome sequencing variants. MAF dbSNP: MAF in dbSNP142. MAF ExAC: MAF 
in the Exome Aggregation Consortium database. MAF In-house-II: MAF in our in-house diagnostic exome 
database. Validation of a subset of these variants has been done using Sanger sequencing. Co-segregation 
analysis was based on subjects II-4 (affected) and I-2 and II-11 (non-affected). 1 variant not present in the 
adenocarcinoma derived from patient II-4. 2 Variant is present in the unaffected family member I-2. 3 Variant 
is present in the unaffected family member II-11. 4 Segregation of the variant was not determined in samples 
I-2 and II-11.Su
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Supplementary Table 5. Predicted effect of the p.E333K variant in BCAT1 based on in silico 
tools
Prediction tool Predicted damaging effect
PhyloP 1,237; weakly conserved
Align GVGD Class C0; GV: 98.67 - GD: 0.00
SIFT 0,42; tolerated
CADD 1,628; benign
PolyPhen2.0 0,001: benign
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Novel polyposis and CRC predisposing germline aberrations
 During the last two decades, the introduction of novel genome-wide techniques 
has revolutionized the field of human genetics. Initial genome-wide analyses were based on 
karyotyping, but the resolution of this technique is limited to the detection of gross chromosomal 
aberrations (i.e., translocations, inversions, and gains or losses of large genomic regions or whole 
chromosomes). A significant increase in resolution was obtained through the introduction of 
genome-wide microarray technologies, allowing DNA copy number variation (CNV) profiling at 
a resolution of a few kilobases (kb). Sanger sequencing was, however, still required to obtain 
base pair resolutions for determining, for example, the genomic breakpoints of a deletion or to 
identify single base pair substitutions within genes. With the introduction of next-generation 
sequencing (NGS) techniques, genome-wide analyses at the base pair level became feasible. 
Initially, whole-exome sequencing (WES) was employed to sequence the entire coding region of 
the genome at base pair resolution, whereas to date also whole-genome sequencing (WGS) can 
be applied at reasonable costs to sequence the entire genome at this resolution.
 These recent developments in the field of human genetics have already led to the 
elucidation of a vast number of Mendelian disorders, including cancer syndromes [1, 2]. Also, 
novel high-penetrant polyposis and colorectal cancer (CRC) predisposing germline aberrations 
have been identified, some of which appear to be very rare. Through CNV analysis, for example, 
a 40kb duplication that leads to an increased expression of the GREM1 gene and a concomitant 
development of polyposis has recently been identified [3]. In addition, germline missense 
mutations in the proofreading domains of the POLE and POLD1 genes have been identified 
as being the cause of polymerase proofreading-associated polyposis (PPAP) using WGS [4]. 
An additional large number of candidate genes for polyposis and/or CRC predisposition has 
also been proposed based on CNV [5, 6] and NGS [7-12] analyses, respectively, but their 
exact role(s) still remain(s) to be established. Despite the identification and firm validation of 
a dozen high-penetrant polyposis and/or CRC predisposing genes (Chapter 1), a significant 
subset of the cases, highly suspected for a hereditary cause, still remains unexplained [13, 14]. 
The identification of novel causative germline aberrations is, therefore, considered crucial for 
designing proper clinical management strategies and for obtaining reduced mortality rates [15, 
16].
The main goal of this thesis was the identification of novel (high-penetrant) polyposis 
and CRC predisposing genomic aberrations/genes. We have used several cohorts based on 
different selection criteria to identify both non-polyposis and polyposis CRC predisposing genes. 
Here, I will focus on the identification of BUB1 and BUB3 as novel candidate CRC predisposing 
genes, the role of FOCAD as a novel candidate polyposis and CRC predisposing gene, and 
the identification of NTHL1 as a novel adenomatous polyposis and CRC predisposing gene. 
Based on the results obtained, I will elaborate on future directions to recognize novel familial 
polyposis and CRC cases and will discuss novel approaches to identify other polyposis and CRC 
predisposing germline aberrations. Finally, I will discuss the impact of our findings on daily 
clinical healthcare and elaborate on expectations regarding the identification of novel candidate 
polyposis and CRC predisposing genes in the near future.
Copy number profiling to identify novel polyposis and CRC predisposing germline 
aberrations
 It has been suggested that copy number profiling in high-risk families may lead to the 
discovery of cancer-predisposing genes and mechanisms [17]. Indeed, our group has identified 
several novel candidate CRC predisposing genes [5], and has shown that germline deletions 
affecting the 3’ exon of EPCAM induce the epigenetic silencing of MSH2, causing Lynch 
syndrome [18, 19]. Furthermore, it was shown that a 170-kb intragenic duplication of one 
of these genes, PTPRJ, downregulates PTPRJ expression by a similar mechanism of epigenetic 
silencing [20]. Here, we followed up on a previously reported microarray-based CNV screen of 
41 familial and early-onset microsatellite stable (MSS) CRC patients [5] (chapter 2) and applied 
high-resolution genome-wide copy number profiling on DNA derived from another 39 early-
onset CRC patients (onset below the age of 40; chapter 3). Whereas the first screening revealed 
relatively small germline deletions encompassing FOCAD, the second screening resulted in the 
identification of a 1.75 Mb deletion encompassing BUB1.
Role of FOCAD in polyposis and CRC predisposition 
A germline deletion affecting the genomic locus of the FOCAD gene was initially 
observed in a previously reported microarray-based CNV screen of 41 familial and early-onset 
MSS CRC patients [5]. To confirm the potential CRC predisposing role of FOCAD, we screened 
for FOCAD germline deletions in a cohort of 1,232 familial and early-onset CRC patients and 
1,880 controls. In addition, we included CNV data listed in control databases which revealed 
that deletions encompassing the FOCAD gene are significantly enriched in familial and early-
onset CRC patients (P = 0.0067). The absence of second-hit mutations in tumors derived from 
carriers of a germline deletion in FOCAD, the lack of pathogenic single nucleotide variants 
(SNVs) in a cohort of 117 early-onset/familial CRC patients and 33 polyposis patients, and the 
low expression levels of FOCAD in the colon initially hampered the conclusion that FOCAD 
could act as a novel CRC predisposing gene. However, we also found that FOCAD is expressed 
in epithelial cells within the colon and in colon-derived organoids, known to be involved in the 
development of polyps and carcinomas. This information substantiated the notion that FOCAD 
may act as a novel CRC predisposing gene (chapter 2).
Initially, we anticipated that germline deletions affecting the FOCAD locus were 
associated with non-polyposis early-onset and familial CRC predisposition. Our previously 
reported microarray-based CNV screen, which has revealed one deletion affecting the FOCAD 
locus, was performed on a cohort of patients that was selected based on a diagnosis of MSS 
CRC at young age, rather than on the presence of polyposis. In line with this discovery cohort, 
all patients included in our extended screen for germline deletions in this locus were selected 
for familial and early-onset CRC. However, we noticed that all three patients who carried a 
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germline deletion affecting the FOCAD locus had a positive (family) history of polyposis. 
Possibly, the observed number of CNVs and, especially, SNVs affecting FOCAD would be even 
higher if we had screened for these germline aberrations in clinically well-defined cohorts of 
polyposis patients. Indeed, others have shown that germline deletions and deleterious SNVs 
are recurrently encountered in polyposis patients [6]. Based on these results, we now anticipate 
that germline deletions in the FOCAD locus may indeed be associated with the development of 
polyposis and CRC. 
Recently, it was reported that FOCAD could act as a tumor suppressor in gliomas [21]. 
Furthermore, the potential role of FOCAD as a novel candidate polyposis and CRC predisposing 
gene has been established by others, who replicated our results in an independent cohort of 
polyposis and CRC patients. In this latter study, a germline deletion affecting the FOCAD locus 
was encountered in a polyposis patient who developed 100-500 adenomas, a germline SNV 
affecting a canonical FOCAD splice site was observed in a polyposis patient who developed 10-
20 adenomas and CRC, and a nonsense germline FOCAD variant was detected in a polyposis 
patient diagnosed with 51-100 adenomas and CRC [6]. Therefore, based on our findings and 
the aforementioned studies, we conclude that germline aberrations in the potential tumor 
suppressor gene FOCAD are recurrenly encountered in polyposis patients.
 Since germline deletions affecting the FOCAD locus were also observed in the 
unaffected mother of the index patient and in one control sample, we anticipate that the 
encountered deletions in FOCAD act as a moderate-penetrant polyposis and CRC predisposing 
germline factor. Therefore, a subset of the carriers may never develop polyps or CRC in their 
lives. Possibly, FOCAD deletions may act as modifiers of other moderate- to high-penetrant risk 
factors. For example, the patient in our index family carried, next to a deletion affecting FOCAD, 
a pathogenic p.L424V variant in POLE. Since only a limited number of carriers of deletions 
affecting FOCAD have been identified so far, an accurate estimation of the lifetime risk of 
polyposis and CRC cannot yet be established.
Role of BUB1 and BUB3 in CRC predisposition
 Through CNV analysis, we identified a germline deletion, encompassing 10 genes 
including BUB1, in a patient who developed CRC at the age of 37. In contrast to FOCAD, for 
which the function was initially unknown, the role of BUB1 in the mitotic spindle assembly 
checkpoint was well-established. Concordantly, we indeed observed an increased level of 
aneuploidy in lymphocyte-derived metaphases of this BUB1 deletion patient [22]. Others found 
that a homozygous deleterious mutation in another component of this checkpoint, BUB1B, was 
associated with aneuploidy and an increased susceptibility to develop gastrointestinal neoplasias 
[23]. Using WES on a cohort of 33 early-onset CRC patients, two truncating heterozygous 
germline variants in BUB1 were identified, suggesting that germline aberrations in BUB1 may 
predispose to the development of CRC in a haploinsufficient manner. To confirm this hypothesis, 
we generated a monoallelic BUB1 knockout HCT116 cell line and revealed that the number of 
aneuploidies was indeed significantly increased compared to the maternal cell line (chapter 3). 
So, by providing functional data, we showed that a monoallelic disruption of BUB1 results in 
haploinsufficiency and aneuploidy, supporting the hypothesis that BUB1 may act as a novel CRC 
predisposing gene.
 Next to the development of early-onset CRC, two subjects, patient 1 (BUB1, allelic 
loss due to a germline deletion of 1,7 Mb) and patient 4 (BUB3, c.790T>C, p.F264L) showed 
additional phenotypical characteristics. Both patients presented mild dysmorphic features, 
including an asymmetrical face and (mild) microcephaly, and both had miscarriages (one and 
thirteen, respectively). These observations imply that germline aberrations in BUB1 and BUB3 not 
only predispose to the development of early-onset CRC, but also to other clinical characteristics. 
Possibly, patients at an increased risk for early-onset CRC due to germline aberrations in the 
spindle assembly checkpoint can be identified by these additional clinical features in the future.
 We anticipate that, similar to FOCAD (chapter 2), the observed germline aberrations in 
BUB1 and BUB3 act as moderate-penetrant CRC predisposing germline factors. We noticed that 
one sibling of patient 2, who also carried the germline nonsense mutation in BUB1 (c.46C>T, 
p.Gln16*), did not develop CRC. Furthermore, patient 2 also carried a canonical splice site 
mutation in MLH1 (c.453+1G>T), which was not observed in this unaffected sibling. Therefore, 
also here it might be that the germline mutation in BUB1 has acted as a moderator, for example 
by increasing the chance of loss of the wildtype MLH1 allele or by accelerating the effect of 
the mismatch repair defect. Again, large numbers of individuals who carry deleterious germline 
aberrations in BUB1 or BUB3 should be tested to allow a better estimate of the effect of such 
germline aberrations on the lifetime risk of CRC.
 These two studies (chapter 2 and chapter 3) confirm that plausible candidate CRC 
predisposing genes can be identified using CNV analysis. To establish the potential role of these 
genes in CRC predisposition, we performed functional studies, including RNA expression studies 
(FOCAD) and karyotyping of a monoallelic knockout cell model (BUB1 and BUB3), to obtain 
supporting evidence for their role in CRC development. Such functional data are considered 
crucial for the identification of plausible novel CRC predisposing genes, especially since 
previously performed CNV [5, 6] and WES [9-12] studies have resulted in an avalanche of novel, 
but non-validated, candidate CRC predisposing genes. I anticipate that, next to these functional 
studies, also well-established genetic studies (e.g. recurrency and co-segregation screens) will be 
required.
Identification, incidence and tumor spectrum of NTHL1-associated polyposis 
 We applied WES on a stringently selected cohort of 51 adenomatous polyposis patients 
from 48 families and revealed that a homozygous nonsense germline mutation, p.Q90*, in 
NTHL1 was the underlying cause in three families (chapter 4). For this novel syndrome we 
proposed the term NTHL1-associated polyposis (NAP). Subsequently, we identified a fourth NAP 
family using Molecular Inversion Probe (MIP)-based sequencing (chapter 6), whereas a fifth 
family was recently identified by others (K. Neveling and D. Schindler, personal communication). 
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In total, we identified 10 individuals carrying the NTHL1 p.Q90* variant in a homozygous state. 
The exact penetrance of this variant still remains to be established but, based on our small 
patient cohort, the penetrance appears to be high. All ten patients developed adenomatous 
polyposis and seven patients developed CRC. In addition, these patients appear to be at an 
increased risk to develop other types of cancer, including endometrial cancer.
 Additional research will be required to establish the incidence of NAP. Up till now, we 
have sequenced over 700 polyposis patients for germline aberrations in NTHL1 and identified 
one novel NAP family which was explained by the p.Q90* variant (chapter 6), similar to the 
previously identified three NAP families (chapter 4). Interestingly, other (predicted deleterious) 
germline variants in NTHL1 were not encountered in this cohort, which indicates that such 
variants may explain an even smaller subset of polyposis patients in the Dutch population. 
In chapter 4, we analyzed whether, similar to MAP, missense variants may contribute to the 
development of NAP. Based on in-silico prediction tools, the p.I176T variant was found to be 
potentially deleterious. In addition, the p.I176T and pQ90*variants appeared to be present with 
similar frequencies in the Dutch population. However, whereas the p.Q90* mutation solely 
explained four independent polyposis families, the p.I176T variant was not encountered in any 
of the polyposis patients tested (chapter 4 and chapter 6), suggesting that this variant is less 
pathogenic compared to p.Q90*, and may not contribute to the development of NAP. When 
future research indeed confirms that the p.Q90* variant is the major contributor to NAP in 
the Dutch population, the recessive nature of NAP will allow us to make a prediction of the 
expected number of patients in the Netherlands. Based on the estimated minor allele frequency 
(MAF) of this variant (MAF = 0.0036) we used the Hardy-Weinberg equilibrium to estimate that 
homozygosity will occur once in every 75,076 individuals, which would suggest that at least 200 
NAP patients remain to be identified in the Netherlands. 
Since NTHL1 variants appear to be enriched or even unique for specific populations, 
other (rare) deleterious germline variants are likely to underlie NAP worldwide. Based on data 
in the publicly available ExAC database [24], the frequency of the p.Q90* variant in NTHL1 is 
expected to be lower in most other ancestry groups outside the Netherlands. Therefore, the 
incidence of homozygous carriers of the p.Q90* variant in NTHL1 (i.e., patients) will be lower in 
these groups compared to the Dutch population. Next to the p.Q90* variant, seven other loss-
of-function variants are recurrently encountered in the ExAC database [24] (see chapter 4). As 
expected, the MAF of these loss-of-function variants is lower than the MAF of the p.Q90* variant 
in the Netherlands, but also varies between different populations. Therefore, we anticipate that 
other deleterious variants in NTHL1 may be enriched in specific ethnic cohorts and that the 
expected incidence of NAP in these populations may turn out to be significantly higher than 
what would be expected based on the MAF of the p.Q90* mutation alone. Noteworthy, we 
already found that two affected siblings of the fifth (consanguineous) NAP family carried a 
nonsense mutation different from the p.Q90* mutation in a homozygous state. Very recently, 
a CRC patient has been identified who carried the p.Q287* nonsense variant in NTHL1 in 
a homozygous state and another study has described that a patient with multiple colorectal 
adenomas and CRC carried the p.Q90* variant in trans with a mutation affecting a canonical 
splice site (c.709+1G→A) [25, 26]. Therefore, we recommend that the entire open reading 
frame of NTHL1 should be screened for germline mutations in polyposis patients rather than 
limiting such screens to the genomic locus of the p.Q90* variant. Further research is required 
to identify additional deleterious germline mutations in NTHL1 and to determine the frequency 
of these variants in different ethnic populations. Once this information is available, a proper 
estimation of the worldwide incidence of NAP can be made.
The tumor spectrum of NAP
 A subset of the identified NAP patients developed other carcinomas next to colorectal 
carcinomas, including basal cell-, breast-, duodenal-, endometrial- and pancreatic carcinomas. 
Considering the low number of patients that have been identified thus far, it is obvious that more 
studies are needed to establish which of these tumors are associated with NTHL1 deficiency, 
and which are not. This knowledge should eventually lead to a better estimate of the tumor 
spectrum associated with NAP. Nevertheless, it seems likely that the tumor spectrum will turn 
out to be broader than colorectal carcinomas alone, as has also been observed for other CRC 
syndromes associated with DNA repair defects. For example, Lynch syndrome patients are at 
an increased risk of cancer of the small bowel, urinary tract, stomach and ovaries [27]. Similar 
to what we observed for the female NAP patients (chapter 4), an increased lifetime risk of 
endometrium carcinomas has also been reported for Lynch syndrome and PPAP, but not for MAP 
[4, 28]. Furthermore, it has been postulated that PPAP patients may, next to endometrial cancer, 
be at an increased lifetime risk to develop brain tumors and cutaneous melanomas [4, 29]. MAP 
patients, however, do appear to have an increased lifetime risk to develop duodenal, ovarian, 
bladder, skin and, possibly, breast cancer [30]. The wide tumor spectrum in Lynch syndrome, 
PPAP and MAP is probably related to the important function of the respective DNA repair 
systems in the human tissues affected. We anticipate that NTHL1 deficiency may result in a 
broad spectrum of tumors. The identification of large numbers of NAP patients will be essential 
to further define the tumor spectrum of NAP. In addition, the observed somatic mutation bias 
towards C:G to T:A transitions in colorectal polyps and carcinomas derived from NAP patients 
(chapter 4) may be of help to establish whether functional loss of NTHL1 also contributed to 
the development of (non-colonic) tumors in these NAP patients since, in the latter scenario, an 
enrichment of somatic C:G to T:A transitions in these tumors is expected. Knowledge of the 
exact risks for all cancer types is crucial for proper genetic counseling and clinical management 
of NAP patients.
Missing heritability of polyposis and CRC
With the identification of NTHL1 as the gene underlying NAP, as described in 
this thesis, a total of five adenomatous polyposis and CRC predisposing syndromes is now 
recognized. In retrospect, the incidences of the syndromes appear to correlate with the time of 
the identification of its causative genes. The first adenomatous polyposis and CRC predisposing 
8208 CHAPTER 8 209General discussion
gene, APC, was identified in 1991 and its associated syndrome, familial adenomatous polyposis 
(FAP), is the second most common inherited CRC syndrome after Lynch syndrome [31]. The 
incidence of MUTYH-associated polyposis (MAP), for which the gene was identified in 2002, is 
lower than FAP, but expected to be higher than PPAP, for which the genes POLD1 and POLE have 
been identified in 2013 (chapter 1). Based on the above-mentioned calculations on the NAP 
incidence in the Netherlands, it may well be that the worldwide incidence of NAP is lower than the 
previously identified adenomatous polyposis and CRC predisposing syndromes, and this is likely 
also true for the incidence of novel, yet to be identified, high-penetrant adenomatous polyposis 
and CRC syndromes (Figure 1). The increasing number of high-penetrant predisposing genes 
identified indicates that the genetic predisposition to CRC is heterogeneous in nature. Despite 
the elucidation of these high-penetrant predisposing genes, a significant subset of hereditary 
polyposis and CRC cases still remains unexplained. There are several possible reasons why the 
elucidation of the still missing heritability of polyposis and CRC appears so difficult. Here, I will 
discuss some of these reasons, including a) the heterogeneity of hereditary CRC, b) the low 
prevalence of novel causative mutations and c) the role of low- to moderate-penetrant variants.
a. Heterogeneity of hereditary CRC
The previous identification of multiple high-penetrant polyposis and CRC predisposing 
genes has already revealed the heterogeneous genetic nature of CRC (Chapter 1). This notion 
is further illustrated by the recent identification of novel predisposing genes, including POLE, 
POLD1 and NTHL1, which together explain only a limited additional subset of unexplained 
CRC cases highly suspected for a hereditary cause [4, 14, 32-35]. Obviously, this genetic 
heterogeneity has seriously hampered the identification of novel high-penetrant polyposis and 
CRC predisposing genes in several WES-based studies [9-11, 36, 37].
Taking this into account, the identification of three families with homozygous NTHL1 
mutations in a cohort of 48 families was relatively surprising since previous studies were 
unsuccessful in finding an association for this gene with polyposis [9-11, 36-38] (Chapter 4). 
We believe that this discrepancy can at least be partly explained by the fact that we have 
attempted to decrease the heterogeneity of our cohort by including patients who all developed 
the same histological subtype of polyps in the colon and rectum, namely conventional 
adenomas. Next to the stringent clinical selection criteria, also the matching ethnicity of our 
patients may have increased the homogeneity of our discovery cohort. All patients were referred 
to the Radboudumc Nijmegen for genetic diagnosis and, therefore, most of these patients are 
of Dutch decent. The biased inclusion towards Dutch adenomatous polyposis patients has, in 
retrospect, increased the chance to encounter multiple NAP patients in our cohort due to the 
apparent higher prevalence of the NTHL1 p.Q90* variant in the Dutch population (Chapter 
4). This potentially increased incidence of NAP in the Netherlands was substantiated by our 
subsequently applied targeted next generation sequencing approach. A total of 701 APC and 
MUTYH mutation-negative adenomatous polyposis patients from the Netherlands, Germany 
and the United Kingdom were assessed for the presence of germline aberrations in NTHL1 by 
targeted sequencing, but NAP was only revealed in one additional patient of Dutch descent 
(chapter 6). Although we have no doubt that NTHL1-associated polyposis patients will be 
diagnosed outside the Netherlands in the future, the incidence in our country may be higher. 
Therefore, matching ethnicities of patients may have further increased the homogeneity of our 
discovery cohort and facilitated the identification of NAP. In conclusion, the heterogeneous 
nature of CRC predisposition requires well defined inclusion criteria to enable the identification 
of novel predisposing germline aberrations.
b. Low prevalence of novel causative mutations
As discussed in chapter 1, supportive evidence for a causative role of a candidate 
polyposis and CRC predisposing gene can be established through its frequent occurrence in 
patients and families, and its (near) absence in controls. This approach has successfully been 
applied for several CRC syndromes, including FAP [39, 40], MAP [41, 42], PPAP [4, 43] and 
Lynch syndrome [44]. Similarly, the causative effect of the p.Q90* variant in NTHL1 (NAP) was 
established based on the identification of three independent families in our initial cohort study 
[35] (chapter 4) and its confirmation in an extended targeted screening effort (chapter 6). 
However, such an approach may not be suitable for extremely rare variants (see above). The 
observation that a germline mutation in RPS20 was encountered in a single CRC family [45] was 
considered to be insufficient to prove causality [46]. The observation that this variant is absent in 
large exome sequencing datasets, including the ExAC database [24], favors the hypothesis that 
this variant may represent a private variant in this family. Consequently, it should be considered 
that the same variant, or other pathogenic variants in the same gene, will not be found in other, 
unrelated, CRC patients. Previously, our group encountered a similar scenario in familial renal 
cell carcinoma cases caused by chromosome 3 translocations [47]. A subset of the rare germline 
variants detected in our discovery cohort (chapter 5) could, therefore, still be causative, but 
evidence for their causality will be much more difficult to obtain. To establish the causative 
effect of such variants, extensive resequencing of the entire open reading frame of the genes of 
interest in large patient and control cohorts should be performed, but if no additional families 
are identified, functional data supporting a potential causative role is required. 
c. Low to moderate penetrant variants
 In this thesis, we focused on the identification of rare high-penetrant germline 
aberrations predisposing to polyposis and CRC. However, it has been established that common 
germline variants can also affect the life-time risk to develop CRC in a moderate manner. In 
general, the prevalence of validated risk alleles in the general population is correlated with the 
corresponding relative risk to develop cancer. High-penetrant polyposis and CRC predisposing 
alleles are, as discussed above, rare in the population, whereas the frequency of alleles with 
an established minor predisposing effect is often found to be higher (MAF > 0,05) (Figure 2) 
[48, 49]. Low-penetrant predisposing alleles may also be rare, but those variants are hard to 
detect. The common polymorphisms with an established minor predisposing effect may explain 
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a subset of the hereditary CRC cases and, likely, a combination of multiple low- to moderate-
penetrant germline factors may contribute to the development of (adenomatous) polyposis (i.e., 
should be considered as a multi-factorial disorder). In fact, we anticipate that the encountered 
deletions in FOCAD may act as moderately penetrant predisposing germline factors, and that 
additional germline aberrations may have contributed to the development of polyposis in these 
patients (chapter 2). 
In contrast to the CNV- and WES-based approaches to identify novel high- and 
moderate penetrant CRC risk factors discussed above, the identification of low-penetrant risk 
factors requires a different approach. Genome-wide association studies (GWAS) are commonly 
used to identify such low-penetrant risk factors. In these studies, a large number of common 
genetic polymorphisms (usually single nucleotide polymorphisms, SNPs) is tested for a statistically 
significant association with a specific phenotype, including polyposis and CRC. Due to the low-
penetrant effect and the necessity to correct for multiple testing (i.e., Bonferroni correction), 
thousands of patients and controls are usually required to establish a positive association [50]. 
In addition, proper meta-analyses should be carried out to replicate the initial findings and to 
confirm a true correlation between a genetic polymorphism and clinical phenotype [51]. The 
latter appears to be a main bottleneck for GWAS [52]. Therefore, cautiousness is required until 
the correlation between a genetic polymorphism and a clinical phenotype has been confirmed 
in large, independent, replication studies.
A subset of common polymorphisms associated with a (slightly) increased risk to 
develop CRC has been replicated and, therefore, their involvement is now confirmed. To date, a 
total of 23 common European SNPs (MAF range: 0,08 – 0,91) has convincingly been associated 
with an increased risk to develop CRC [53]. As expected, the relative risk per allele is low (range: 
1,05 – 1,23), but it has been estimated that together these SNPs account for approximately 
8% of the hereditary CRC risk [53]. In addition to these SNPs, other genetic factors (modifiers) 
have been described that may affect the penetrance of other predisposing germline aberrations. 
For example, two genomic loci, 8q23.3 and 11q23.1, have been associated with an increased 
risk for Lynch syndrome patients to develop CRC [54, 55]. The large number of common, low-
penetrant, germline variants that affect the life-time risk to develop CRC strongly underlines the 
above described heterogeneity of CRC predisposition and development.
 Finally, non-genetic factors can affect the life-time risk to develop CRC as well, such 
as environmental and life-style factors [56-58], which adds to the multi-factorial nature of the 
disease (see above) and further complicates the challenge to genetically explain all heritable 
polyposis and CRC cases. Several GWAS studies have already aimed at linking combinations 
of common genetic polymorphisms and life-style factors with an increased risk to develop 
CRC. For example, associations between genetic polymorphisms and smoking [59], vegetable 
consumption [60] and alcohol consumption [61] have been reported. Whereas the role of 
environmental factors is convincingly illustrated by, for example, migrant studies [62-64], the 
additional effect of common germline polymorphisms on CRC risk may, as yet, be considered 
suggestive. The reason is that these studies are frequently hampered by a limited number of 
included patients and controls, and the notion that meta-analyses that replicate the initial 
findings are frequently lacking.
Despite our success in identifying new polyposis and CRC predisposing genes, 
a large subset of the polyposis patients included for WES in our study remains unexplained 
(chapter 5). It is not unlikely that a high-penetrant germline aberration outside the coding 
sequence may be present in a (small) subset of these patients but, in addition to that, we expect 
that several multiple low- to moderate penetrant germline variants have contributed to the 
development of polyposis in other patients, variants that are missed due to the variant filtering 
approach that we applied. Low- to moderate penetrant germline aberrations are expected 
to be common in the general population (Figure 2). Since we searched for high-penetrant 
adenomatous polyposis predisposing germline aberrations, we stringently filtered for variants 
that are rare or absent in large control cohorts (chapter 5). Consequently, potential low- to 
moderate penetrant factors, expected to be more common in the population, were probably 
discarded in this study. Although the contribution of low- to moderate-penetrant variants in 
high-penetrant predisposing syndromes like adenomatous polyposis is still poorly understood, 
we already suggested that other germline aberrations affecting FOCAD (chapter 2) may act as 
moderate-penetrant polyposis predisposing germline factors. More extensive future studies will 
be required to establish whether a subset of the adenomatous polyposis cases can be explained 
by a combination of low- to moderate-penetrant germline aberrations.
In summary, it appears that all the aspects mentioned above have so far hampered the 
straightforward elucidation of polyposis and CRC predisposition in selected patient cohorts. In 
the end, I propose that all these variables should be included in a weighed fashion to explain the 
predisposition to polyposis, CRC, or other cancers in each person individually.
Extended role of the BER pathway in adenomatous polyposis and CRC predisposition
The identification of the DNA glycosylase gene NTHL1, next to MUTYH, further emphasizes 
the important role of the BER pathway in adenomatous polyposis and CRC predisposition, and 
suggests that (at least a subset of) the nine other DNA glycosylase genes might be involved as 
well. The BER pathway encompasses a multistep repair process that starts with the recognition 
and removal of damaged bases by glycosylases, which results in apurinic or apyrmidinic (AP) 
sites. Next, the DNA backbone is cleaved and processed by either the glycosylase (only applies 
to bi-functional glycosylases) or an AP endonuclease, and the resulting nick is processed by an 
AP endonuclease to create a single-nucleotide gap in the DNA. The BER pathway continues 
with incorporation of the correct nucleotide (short-patch BER pathway) or elongation with 
multiple nucleotides (long-patch BER pathway) through a DNA polymerase. Finally, the DNA 
repair process is completed by sealing of the remaining nick through a DNA ligase (Figure 3). 
Next to NTHL1 and MUTYH, nine other DNA glycosylases are known to be present in 
humans (Figure 3). Previous targeted sequencing approaches of other DNA glycosylase genes 
did not reveal any (biallelic) deleterious germline variants in polyposis and CRC patients. Based 
on these results, it was suggested that the effect of germline variants in BER DNA glycosylase 
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genes other than MUTYH on the development of polyposis and CRC could be ignored [65-
71]. Our recent finding that biallelic pathogenic germline variants in NTHL1 predispose to the 
development of adenomatous polyposis and CRC [35] shows that this suggestion is at least 
premature. Therefore, we carried out a targeted sequencing approach to determine whether 
deleterious germline variants in other DNA glycosylase genes may recurrently be encountered in 
polyposis patients (chapter 6). 
Based on our targeted sequencing approach, a predisposing role for DNA glycosylase 
genes other than MUTYH and NTHL1 could not be established. A plausible explanation for 
this could be that such variants may be extremely rare in the general population (Figure 4). 
Very low frequencies of pathogenic variants in the other DNA glycosylase genes may hamper 
the elucidation of individuals carrying deleterious variants in a compound heterozygous or 
homozygous state. The majority of these variants have a low frequency (MAF <0.0005) and, 
assuming that they are in Hardy-Weinberg equilibrium, homozygous carriers are expected to be 
extremely rare (<1 in 4.000.000 individuals per variant). Based on these data, it is anticipated 
that considerably larger cohorts of polyposis patients are required to identify loss-of-function 
mutations in a compound heterozygous or homozygous state in either one of the remaining 
DNA glycosylase genes.
An alternative explanation may be that deficiency for some of the DNA glycosylases 
may simply not result in polyposis and CRC predisposition. It has been well established that 
DNA glycosylases share several targets, resulting in a (partial) redundancy in substrate specificity 
[72]. For example, at least four DNA glycosylases, i.e. MBD4, SMUG1, TDG and UNG, can 
remove uracil from double stranded DNA [73]. This redundancy, possibly combined with other 
DNA repair mechanisms, may explain the absence of a severe phenotype in DNA glycosylase 
deficient mice [74]. Some DNA glycosylases may have sufficient back-up mechanisms in human 
colonic cells so that biallelic germline inactivation does not predispose to the development of 
polyposis and CRC in a high-penetrant manner. Furthermore, low expression levels of certain 
glycosylase genes in the colon may question their role in polyposis and CRC predisposition. For 
example, RNA expression levels of the glycosylase gene NEIL2 are very low in the human colon 
[75], which may conflict with a possible polyposis and CRC predisposing role. Next, not all DNA 
glycosylases recognize a type of DNA damage that is abundantly present in the colon (e.g. 
8-oxo-guanine, recognized by OGG1). Deficiencies of these DNA glycosylases may not result 
in extensive mutagenic effects and, subsequently, may not initiate the development of polyps. 
Obviously, some of these DNA glycosylases may give rise to phenotypes in other tissues when 
mutated, and could, therefore, still play a role in the predisposition to other cancer types. 
Heterozygous DNA glycosylase gene mutations
Our WES- and targeted sequencing approach has revealed deleterious heterozygous 
germline variants in the DNA glycosylase genes MBD4, MPG, NEIL1, NTHL1, OGG1, SMUG1 and 
UNG in polyposis patients (Chapter 4 en Chapter 6). However, the clinical relevance of these 
heterozygous variants remains uncertain since MAP and NAP are inherited in an autosomal 
recessive manner.
Possibly, the second hit in the other allele was not detected in the patients who carried 
a heterozygous deleterious variant in one of the DNA glycosylase genes. Due to the applied 
sequencing approach, mutations or CNVs outside the exonic regions on the wild-type allele of 
these patients may have been missed and, therefore, these patients may in fact be compound 
heterozygous carriers. An example of such a scenario was recently reported in Burn-McKeown 
Syndrome [76]. To test this hypothesis, haplotype analysis on multiple apparent heterozygotes 
could be performed, or (targeted) sequencing or copy number analyses on individual cases. 
Alternatively, the remaining wild-type allele may carry expression quantitative traits with 
expression levels in the affected individuals below a certain threshold, giving rise to a BER 
defect. A similar scenario was also reported recently in congenital scoliosis patients [77]. Again, 
haplotype analysis or sequencing of the entire locus in multiple apparent heterozygotes may 
lead to the identification of these aberrations.
Nevertheless, we cannot exclude that germline mutations in some DNA glycosylase 
genes may predispose to the development of polyposis and CRC in an autosomal dominant 
manner. In fact, a low-penetrant CRC predisposing role of the p.G308E variant in OGG1 in 
a dominant manner has already been reported [68] and several studies have reported that 
monoallelic carriers of pathogenic germline variants in MUTYH have a (slightly) increased life-
time risk to develop CRC [78-83]. However, the CRC predisposing role of the p.G308E variant 
in OGG1 could not be substantiated in a well-powered patient-control cohort study [84]. In 
addition, major concerns have been raised regarding data interpretation of the possible CRC 
predisposing effect of monoallelic pathogenic germline variants in MUTYH [85], and these 
conclusions should thus be considered premature based on the available data [86]. In addition, 
data have been reported arguing against an increased CRC risk for monoallelic pathogenic 
variant carriers in MUTYH [86-88]. Perhaps, the BER pathway is less sensitive to somatic second 
hit mutations in DNA glycosylase genes since some overlap exists between these glycosylases 
regarding the recognized substrates, and the encoded proteins may function independently of 
each other (as discussed above). Based on the recessive inheritance of MAP and NAP and the 
lack of strong data supporting a possible polyposis and CRC predisposing role of monoallelic 
pathogenic germline variants in DNA glycosylase genes, we anticipate that the effect of 
heterozygous pathogenic germline variants in DNA glycosylase genes will be limited, and that 
the polyposis phenotype in patients may not solely be explained by the heterozygous nonsense 
variants found in DNA glycosylase genes (chapter 4, chapter 5 and chapter 6).
It has now been established that tumors derived from both MAP and NAP patients 
exhibit a somatic mutation spectrum strongly reflecting a BER defect [35, 89]. Therefore, the 
somatic mutation pattern of a tumor can provide valuable information on whether a BER 
defect has contributed to the development of polyps/CRC in patients who carry a heterozygous 
pathogenic variant in one of the DNA glycosylase genes. For example, OGG1 is required for 
the excision of 8-oxoguanine [90] and an accumulation of 8-oxoguanine in the DNA, known 
to mismatch with an adenine residue, would probably result in an increase of C:G to A:T 
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transversions. Therefore, we hypothesize that a bias towards C:G to A:T transversions is observed 
in carcinomas derived from heterozygous carriers of pathogenic mutations in OGG1. Possibly, 
the somatic mutation spectra of polyps and carcinomas derived from monoallelic carriers of a 
pathogenic germline aberration in one of the DNA glycosylase genes may also reveal whether 
heterozygous aberrations in other DNA glycosylase genes can drive tumorigenesis.
DNA repair defects and the somatic mutation spectra in tumors
 It has been firmly established that germline aberrations that compromise genome 
stability may contribute to the somatic mutation spectra encountered in the respective 
tumors [91, 92]. Characteristic mutation spectra related to somatically acquired defects in 
DNA mismatch repair genes or proofreading domains of DNA polymerase genes have been 
observed, both in sporadic and hereditary CRC cases [91, 93]. If one of the DNA mismatch repair 
proteins, i.e. MLH1, MSH2, MSH6 or PMS2, is not properly expressed, cells will accumulate 
small insertions and deletions in repetitive genomic regions, including microsatellite repeats, 
resulting in the development of tumors with a MSI-positive phenotype (reviewed in [94]). Loss of 
the proofreading capacity of DNA polymerases POLE or POLD1, required to detect and remove 
misincorporated bases in the newly synthesized DNA strand, results in the development of 
tumors with an increased number of somatic base substitutions (i.e., hypermutated tumors) 
[95, 96]. In addition to the previous observations, CMMR-D patients (constitutional mismatch 
repair-deficiency syndrome), who carry biallelic germline defects in one of the MMR genes and 
acquire early somatic driver mutations in POLE or POLD1, develop ultra-hypermutated tumors 
at young age [92]. Similar to these examples, defects in the BER pathway contribute to specific 
somatic mutation spectra in tumors derived from MAP and NAP patients. Here, I will elaborate 
on the differences between the underlying mechanisms in MAP and NAP and how this mutation 
bias may contribute to the identification of novel MAP and NAP patients.
The molecular mechanism underlying the role of MUTYH in the prevention of C:G>A:T 
transversions has been well established. Oxidative DNA damage can produce 8-oxoguanine, 
which has a strong tendency to mispair with adenine [97]. The glycosylase OGG1 can 
recognize, bind and excise 8-oxoguanine if paired with a cytosine [90]. However, if an adenine 
is incorporated opposite to 8-oxoguanine after the first replication step, MUTYH can remove the 
adenine from the DNA backbone [98] to prevent a G-to-T transversion during the subsequent 
DNA replication step (reviewed in [99]). Therefore, MAP patients who do not express functional 
MUTYH, develop polyps and tumors that are highly enriched for somatic C:G>A:T transversions, 
especially in the CRC driver genes APC [42, 89] and KRAS [100].
In contrast to the well defined mechanism underlying the accumulation of C:G>A:T 
transversions in MAP, the molecular mechanism underlying the observed enrichment of somatic 
C:G>T:A transitions in tumors derived from NAP patients has not been elucidated yet. This 
enrichment may result from oxidative damage to a cytosine or guanine base that has not 
been corrected properly due to the absence of functional NTHL1. The absence of C:G>A:T 
transversions in tumors derived from NAP patients may possibly be explained by the fact that 
8-oxoguanine can still be removed from the DNA since OGG1 is still functionally expressed 
[101]. In contrast, candidate NTHL1 targets are 5-hydroxycytosine and 5-hydroxyuracil, both 
products of oxidized cytosine, which are mutagenic and predominantly induce C>T transitions 
in vitro [72, 102]. Future experiments are required to obtain a complete understanding of this 
particular mutation phenotype in tumors derived from NAP patients. 
Irrespective of the mechanism involved, the observed difference between tumors from 
NAP and MAP patients is striking, and opens up possibilities for diagnostic applications with 
respect to recognition and identification of hereditary CRC. The use of mutation spectra in 
diagnostics has already been exploited to identify Lynch syndrome patients [103]. The mutation 
spectra of tumors derived from MAP and NAP patients are possibly less pronounced than 
the MSI-positive characteristics of tumors derived from Lynch syndrome patients, but similar 
approaches may be applied to identify MAP and NAP patients, based on the development of 
tumors enriched for C:G>A:T transversions and C:G>T:A transitions, respectively. MAP patients 
have already successfully been identified using such approaches [104], but the identification of 
NAP patients may be more challenging, since a bias towards C:G>T:A transitions is observed in 
sporadic CRCs as well [95].
Two strategies may be applied to detect NAP patients based on a somatic mutation 
bias towards C:G>T:A transitions in the tumor. First, we found that the bias towards C:G>T:A 
transitions in tumors derived from NAP patients was most pronounced in the CRC driver 
genes APC, KRAS, TP53 and PIK3CA [35]. Similarly, the bias towards C:G>A:T transversions 
in MAP patients has primarily been observed in the APC [42, 89] and KRAS [100] genes. So, 
the respective mutation spectra may be more pronounced in CRC driver genes known to be 
involved in the adenoma-to-carcinoma sequence and targeted sequencing approaches can be 
performed to detect these driver mutations (chapter 1). Second, genome-wide sequencing 
approaches, including WES and WGS, can be performed to simultaneously reveal a larger 
number of somatic mutations per tumor. Possibly, the bias towards C:G>A:T transversions 
(MAP) and C:G>T:A transitions (NAP) will be more pronounced when large numbers of somatic 
mutations are available per tumor. At this moment, the latter approach is more expensive and 
laborious, but is expected to enable a better estimation of the somatic mutation spectrum of 
the tumor. Consequently, the sensitivity and specificity to detect MAP and NAP patients will be 
improved using these approaches compared to targeted sequencing approaches.
Targeted and genome-wide sequencing of tumors may be a valuable approach 
since polyposis and CRC syndromes can appear sporadic in (small) families, especially when 
autosomal recessive syndromes like MAP and NAP are involved. In these cases, a heritable cause 
is not anticipated and, therefore, germline testing for known polyposis and CRC susceptibility 
genes may not be considered. Therefore, genome-wide NGS sequencing data from tumors, 
performed to reveal genetic mechanisms underlying CRC development or to identify druggable 
targets [105], could potentially also identify patients with germline mutations and, as such, 
novel individuals and families at risk.
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From bench to clinic
 One of the aims of the work described in this thesis was to gain information for 
improvement of the diagnosis and clinical management of polyposis and CRC patients. We have 
provided genetic and functional data to consider BUB1, BUB3 and FOCAD as bona fide novel CRC 
predisposing candidate genes. So far, however, the predisposing impact of aberrations in these 
genes has not been established sufficiently, which makes its use in a clinical setting currently 
premature. In contrast, we were already able to provide sufficient data to consider NTHL1 as 
a novel high-penetrant adenomatous polyposis and CRC predisposing gene. Co-segregation 
analyses were performed revealing a full co-segregation of the homozygous NTHL1 p.Q90* 
variant with the development of polyposis within families. Based on the well-documented role of 
NTHL1 in the BER pathway, we were able to show that tumors derived from NAP patients exhibit 
a tumor spectrum reflecting a germline defect in the BER pathway (Chapter 4). Subsequently, 
we confirmed our initial findings by the identification of a fourth NAP family (Chapter 6). Based 
on our data, it is recommended to screen adenomatous polyposis patients with an attenuated 
polyposis phenotype (<100 polyps at diagnosis), but without a strong dominant inheritance 
pattern of polyposis development, for germline aberrations in the NTHL1 gene. Although we 
only identified patients who carried the p.Q90* variant in a homozygous state, we do not favor 
screening on this specific variant alone since other pathogenic variants may be involved as well, 
particularly in patients of different ethnic backgrounds. Once sufficient NAP families have been 
identified, the life-time risk and full spectrum of cancer development can be established. Based 
on its similarities with MAP, we currently recommend to provide regular colonoscopies to these 
patients with the same age limits and frequencies as for MAP.
The future of polyposis and CRC predisposition
After the hypothesis was postulated that heritable factors may underlie the development 
of multiple adenomas [106], the genetic cause for the increased life time risk to develop 
polyposis and CRC remained unknown for several decades. Around the turn of the century, 
however, several high-penetrant predisposing genes were successfully identified, but the limited 
resolution of the available technologies hampered the identification of all predisposing germline 
aberrations. The subsequent introduction of novel genome-wide techniques such as microarray-
based CNV detection and WES provided the opportunity to expand the list of polyposis and CRC 
predisposing genes (this thesis). In spite of the progress made, a subset of the polyposis and 
CRC cases still remains unexplained. I anticipate that in the near future the list of moderate- to 
high-penetrant predisposing genes will continue to grow with the introduction and use of novel 
sequencing techniques, including WGS. WGS enables the detection of germline aberrations in 
non-coding regions and the identification and demarcation of complex genomic rearrangements. 
In conjunction with well-defined patient cohorts and families with multiple affected members, 
novel polyposis and CRC predisposing germline aberrations are on the verge to be identified. 
The ongoing identification of novel polyposis and CRC predisposing germline 
aberrations, like NTHL1, FOCAD, BUB1 and BUB3 (this thesis), is gradually revealing the genetic 
nature of polyposis and CRC predisposition. When this genetic nature of polyposis and CRC 
predisposition has been established, the lifetime risk to develop CRC can be precisely estimated 
per individual. Subsequently, proper clinical management strategies can be implemented for 
individuals at risk. Therefore, I anticipate (and sincerely hope) that the results described in this 
thesis will, ultimately, contribute to significantly reduced CRC-related mortality rates worldwide.
Figure 1) Identification of adenomatous polyposis and colorectal cancer predisposing syndromes. 
The x-axis represent the year the causative gene underlying the corresponding syndrome was identified. The 
future identification of other rare predisposing genes, possibly other base excision repair genes, is anticipated. 
We expect that the incidence of these new syndromes will be rare compared to the those already known, 
which hampers their discovery. FAP: familial adenomatous polyposis (APC, autosomal dominant). MAP: 
MUTYH-associated polyposis (MUTYH, autosomal recessive). PPAP: Polymerase proofreading-associated 
polyposis (POLE and POLD1, autosomal dominant). NAP: NTHL1-associated polyposis (NTHL1, autosomal 
recessive). BER: base excision repair.
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Figure 2) Correlation between the frequency of a deleterious allele in the population and the 
corresponding relative colorectal cancer risk. High-penetrant risk factors, for example predisposing to 
familial adenomatous polyposis, MUTYH-associated polyposis and Lynch Syndrome, are rare in the general 
population (low allele frequency, x-axis). In contrast, risk factors that are more commonly observed in the 
population, have a lower relative risk (effect size, y-axis). Adapted from references [48, 49]. 
Figure 3) DNA damage repair by the base excision repair pathway. The damaged nucleotide (X) is 
removed by a mono- or bifunctional glycosylase and the gap is processed by an AP endonuclease. One (short-
patch) or multiple nucleotides (long-patch, grey) are incorporated by a polymerase and a ligase seals the 
remaining nick to complete the DNA repair process. Italic: the eleven glycosylase genes identified in humans.
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Figure 4) Frequency of predicted pathogenic variants in glycosylase genes in the ExAC exome 
database. Represented dots are all nonsense-, frameshift-, canonical splicesite- and predicted pathogenic 
missense variants in the BER glycosylase genes, obtained from the publicly accessible Exome Aggregation 
Consortium (ExAC) database [24]. Insertions and deletions in homopolymer stretches of ≥5 consecutive 
bases were excluded. Only highly conserved missense variants (PhyloP ≥3) [38] which are predicted 
damaging in silico (CADD score: ≥15 [107], PolyPhen: probably damaging [108], SIFT: deleterious [109], 
AlignGVGD: Class ≠ C0 [110, 111]) were selected. Alterations at protein/cDNA level are only depicted 
for variants frequently encountered (MAF >0.0005). Note: the depicted mutations in MUTYH are indeed 
confirmed to be pathogenic and are the major contributors to the development of MAP. Similarly, the 
p.Gln90* variant in NTHL1 predisposes to NAP. The deleterious effect of the other depicted variants has not 
been established yet.
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Summary
 The hypothesis that heritable germline factors can predispose to the development 
of polyposis and colorectal cancer (CRC) was stated several decades before the first polyposis 
and CRC predisposing gene was identified. However, without knowledge of the genetic cause, 
individual cancer risk assessments can only be made based on the family history of polyposis or 
CRC, which is challenging and highly inaccurate. The rapidly evolving field of human genetics, 
particularly since the 1990s, provided the genetic and molecular tools to identify causative 
germline aberrations which contribute to an increased lifetime risk to develop polyposis and 
CRC. The identification of these causative germline aberrations significantly improved clinical 
management of individuals at risk of polyposis or CRC and, as a consequence, mortality rates 
of heritable CRC decreased. Unfortunately, a significant subset of polyposis and CRC patients 
are not explained by germline aberrations in known polyposis or CRC predisposing genes. 
Consequently, lifetime risk assessment and proper clinical management of these patients and 
their relatives is severely hampered. With the recent introduction of genome-wide profiling- 
and sequencing techniques, novel genetic research tools became available to search for these 
causative germline defects in novel polyposis and CRC predisposing genes (chapter 1). In this 
thesis, we used these techniques to search for novel causative germline defects to explain the 
(possible) heritability of polyposis and CRC in these so far unexplained families.
 One of the potential polyposis and CRC predisposing germline aberrations we identified 
affects the tumor suppressor gene FOCAD, in which we found heterozygous germline deletions 
in three patients with multiple polyps (chapter 2). The first deletion affecting this genomic locus 
was identified in an earlier study in our group using high-resolution genomic profiling of 41 
CRC patients suspected of a hereditary cause. We subsequently performed an extensive copy 
number and mutation screening of additional polyposis and CRC patients, and identified two 
additional patients. Deletions affecting the genomic locus of FOCAD were significantly enriched 
in polyposis and CRC patients compared to these controls (P=0.0067). In line with a potential 
role in colorectal tumorigenesis, we found that FOCAD is expressed in the epithelial cells of the 
colonic crypt, the site of tumor initiation. The lack of somatic second hit mutations in FOCAD 
in polyps and tumors derived from deletion carriers and the observed expression of FOCAD in 
sporadic colorectal carcinomas suggests that complete loss of expression of FOCAD is not a 
common event in CRC tumorigenesis. Co-segregation analysis revealed that not all carriers of a 
germline deletion affecting FOCAD developed polyps or CRC and, therefore, we concluded that 
heterozygous germline deletions affecting the FOCAD locus may act as moderate-penetrant 
polyposis and CRC predisposing germline aberrations.
 A second high-resolution genomic profiling approach was performed on a different 
cohort of 39 patients who were diagnosed with non-polyposis, mismatch-repair proficient CRC 
at young age (≤40y) (Chapter 3). This approach substantiated the potential CRC predisposing 
role of genes involved in the spindle assembly checkpoint genes, illustrated by the identification 
of a heterozygous germline deletion affecting the genomic locus of BUB1 in one of these 
patients. The spindle assembly checkpoint is required for proper chromosome segregation 
during mitosis and previous studies have already shown that disturbances in the spindle 
assembly checkpoint result in aneuploidies, a hallmark of cancer. Indeed, such aneuploidies 
were observed in a significant proportion of lymphocytes and primary skin fibroblasts of the 
index patient. To provide further evidence that haploinsufficiency of BUB1 was responsible for 
the observed increased incidence of aneuplodies, we generated an isogenic mono-allelic BUB1 
knockout cell line and we, indeed, observed a significantly increased number of chromosomal 
gains and losses compared to the maternal cell line. In addition, whole-exome sequencing (WES) 
and targeted copy number- and mutation screening of an additional cohort of early-onset CRC 
patients revealed two truncating germline variants in BUB1 and three highly-conserved germline 
missense mutations in BUB3. Since not all individuals with mutations or deletions in these genes 
developed CRC, it is likely that germline aberrations affecting genes involved in the spindle 
assembly checkpoint predispose to the development of CRC in a moderate-penetrant manner. 
 In chapter 4, we describe the identification of a novel high-penetrant adenomatous 
polyposis and CRC predisposing gene: the base excision repair gene NTHL1. We revealed, based 
on co-segregation analysis in three unrelated families, that individuals who carry a germline 
nonsense mutation, p.Q90*, in NTHL1 in a homozygous state are predisposed to develop 
polyposis and CRC in a high-penetrant manner. Colorectal carcinomas derived from these 
patients are significantly enriched for somatic C:G to T:A transitions, which supports the role 
of a germline defect in the BER pathway (i.e. NTHL1) on the development of these tumors. We 
also noticed that all females who carried the p.Q90* variant in NTHL1 in a homozygous state 
developed (pre-)cancerous lesions in the endometrium, suggesting that the tumor spectrum 
may also include other carcinomas next to CRC. The identification of a novel high-penetrant 
adenomatous polyposis and CRC predisposing syndrome is remarkable, since, prior to our work, 
only three high-penetrant adenomatous polyposis predisposing syndromes had been identified 
so far (i.e. FAP, MAP and PPAP). With the work described in this chapter, a subset of polyposis 
and CRC patients can now be explained and clinical management of these patients and their 
relatives will be improved. We have proposed the name NTHL1-associated polyposis (NAP) for 
this novel condition.
 Although this WES approach led to the successful discovery of NTHL1 mutations, 
a subset of this cohort was not explained yet. Therefore, we applied extensive analyses on 
this dataset to screen for germline aberrations which may explain the remaining unexplained 
adenomatous polyposis cases in this cohort (n = 47) (chapter 5). First, we screened for germline 
mutations in known polyposis and CRC predisposing genes and revealed that two patients 
carried a possibly pathogenic germline variant in the proofreading domain of POLE or POLD1, 
the causative genes for polymerase proofreading-associated polyposis. In addition, several 
interesting novel adenomatous polyposis predisposing candidate genes were identified. For 
example, we noticed that two patients carried a frameshift mutation in ATM, which encodes 
a serine/threonine kinase which is involved in DNA repair. Screening of large adenomatous 
polyposis cohorts and co-segregation analyses in affected families is required to establish the 
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putative predisposing role of these variants.
 Whereas there are no doubts that the homozygous nonsense mutation in NTHL1 explains 
the development of polyposis and CRC in the previously described three families, several questions 
remained. One of these questions relates to the prevalence of NTHL1 -associated polyposis. 
Furthermore, the finding of a second base excision repair gene, next to MUTYH, raises the question 
whether biallelic germline aberrations in other DNA glycosylases (i.e. MBD4, MPG, NEIL1, NEIL2, 
NEIL3, OGG1, SMUG1, TDG and UNG) predispose to the development of polyposis and CRC as 
well. These questions were addressed in chapter 6. Our targeted sequencing approach, applied 
on a cohort of 701 polyposis patients, revealed one patient who carried the p.Q90* variant in 
NTHL1 in a homozygous state and subsequent co-segregation analysis revealed a fourth NTHL1-
associated polyposis family. These results indicate that NTHL1-associated polyposis is rare, but 
recurrently encountered in cohorts of unexplained polyposis patients. Homozygous or compound 
heterozygous deleterious variants were not encountered in the other DNA glycosylase genes and, 
therefore, it could not be established if these genes also underlie the development of polyposis 
and CRC in an autosomal recessive manner. Heterozygous truncating variants were encountered 
in MBD4, NEIL1, OGG1 and UNG, but their clinical significance remained unexplained. Large 
future screenings of well-selected patient cohorts are required to define the exact role of the 
various DNA glycosylase genes in adenomatous polyposis and colorectal cancer predisposition.
 In chapter 7, we investigated another subtype of polyposis: serrated polyposis syndrome. 
In contrast to adenomatous polyposis, no high-penetrant germline aberrations predisposing to the 
development of serrated polyposis have been identified. To identify germline aberrations which 
predispose to the development of serrated polyposis, WES was applied to six relatives from a 
large family which exhibits an autosomal dominant inheritance pattern of serrated polyposis. 
The causative germline aberration in this family was not identified, but it was established that 
a germline nonsense mutation in PIF1, previously associated with the development of serrated 
polyps, actually represents a common (minor allele frequency >0.01) SNP in the Dutch population. 
Therefore, although WES has proven to be a successful approach, it should be anticipated that a 
subset of heritable polyposis cases cannot be explained using this method. The recent introduction 
of whole-genome sequencing may provide the research tool which is required to explain this family 
and should be considered for future research to identify novel causative germline aberrations.
 This thesis not only describes the identification of novel moderate- to high-penetrant 
polyposis and CRC predisposing genes, but also illustrates that a significant number of polyposis 
and CRC patients, despite the introduction of novel sequencing techniques like WES, remains 
unexplained. Bottlenecks which may have hampered the elucidation of novel polyposis and CRC 
predisposing genes are the heterogeneous nature of CRC, the role of rare/private variants and 
the contribution of low-to moderate-penetrant germline aberrations. In chapter 8, I extensively 
discuss our obtained results presented in this thesis and elaborate on my future expectations 
regarding the identification of novel moderate- to high-penetrant polyposis and CRC predisposing 
genes. 
Samenvatting
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Samenvatting
 De hypothese dat kiembaan mutaties ten grondslag kunnen liggen aan de ontwikkeling 
van polyposis en darmkanker werd reeds enkele tientallen jaren vóór de identificatie van het 
eerste predispositie gen gesteld. De oorzakelijke genen bleven echter lang onbekend, wat het 
bepalen van het daadwerkelijke risico op polyposis en darmkanker en het treffen van eventuele 
preventieve maatregelen aanzienlijk bemoeilijkte. Vanaf de jaren 90 van de vorige eeuw 
kwamen nieuwe technieken beschikbaar voor het efficiënt detecteren van DNA afwijkingen. 
Deze technieken hebben het opsporen van ziekte veroorzakende kiembaan mutaties aanzienlijk 
vergemakkelijkt, wat o.a. heeft geleid tot de identificatie van nieuwe genetische oorzaken voor 
polyposis en darmkanker. In families waarin zo’n genetische oorzaak bekend is kan vervolgens 
bepaald worden welke leden daadwerkelijk een verhoogd risico hebben op polyposis en 
darmkanker. De mortaliteit ten gevolge van darmkanker kan dan worden gereduceerd door 
intensieve controle. Echter, nog steeds geldt dat in veel gevallen een familiaire aanleg wel wordt 
vermoed, maar dat deze niet kan worden bevestigd aan de hand van een causatieve mutatie 
in één van de bekende polyposis en/of darmkanker predisponerende genen. Met de recente 
introductie van zogenaamde genoom-brede DNA profilering en sequencing technieken is de 
zoektocht naar nieuwe oorzakelijke genen in een stroomversnelling geraakt, waardoor ook 
meer zeldzame en minder penetrante genetische factoren kunnen worden geïdentificeerd 
(Hoofdstuk 1). In dit proefschrift wordt beschreven hoe wij, met behulp van de hierboven 
genoemde technieken, op zoek zijn gegaan naar nieuwe kiembaan mutaties die de aanleg voor 
polyposis en darmkanker in een aantal van de tot dusver onopgehelderde patiënten en families 
zouden kunnen verklaren.
 Dit werk heeft onder andere geleid tot de identificatie van heterozygote kiembaan 
deleties in het tumor suppressor gen FOCAD. Verschillende, gedeeltelijk overlappende, deleties 
werden gedetecteerd in drie patiënten die meerdere darmpoliepen hadden ontwikkeld 
(Hoofdstuk 2). De eerste deletie werd eerder geïdentificeerd en beschreven door onze 
onderzoeksgroep, waarbij met behulp van ‘high-resolution genomic profiling’ werd gezocht 
naar potentieel causatieve kiembaan mutaties in 41 onverklaarde jonge darmkankerpatiënten. 
Met de vondst van twee additionele patiënten met een kiembaan deletie in het FOCAD gen kon 
worden vastgesteld dat dergelijke kiembaan deleties significant vaker voorkomen in polyposis 
en darmkanker patiënten dan in de gezonde controle populatie (P=0.0067). Hoewel eerdere 
studies hadden laten zien dat FOCAD vooral in hersenweefsel tot expressie komt, toonden wij 
in onze studie aan dat FOCAD ook tot expressie komt in epitheelcellen in de crypten van de 
darm. Dit is in overeenstemming met een potentiële rol in de ontwikkeling van darmpoliepen 
en darmtumoren die ontstaan in de crypten. Zowel het ontbreken van somatische ‘second-hit’ 
FOCAD mutaties in darmpoliepen en darmtumoren afkomstig van patiënten met een kiembaan 
deletie, als ook de expressie van FOCAD in sporadische darmtumoren suggereert dat totaal 
verlies van FOCAD expressie niet gerelateerd is aan de ontwikkeling van dergelijke tumoren. 
Cosegregatie analyses toonden verder aan dat niet alle dragers van kiembaan deleties in FOCAD 
darmpoliepen en/of darmtumoren ontwikkelden. Uit dit werk hebben wij geconcludeerd dat 
dragers van een kiembaan deletie in FOCAD waarschijnlijk een matig verhoogd risico hebben 
op het ontwikkelen van darmpoliepen en darmtumoren.
 In Hoofdstuk 3 beschrijven we een zoektocht naar mogelijk causatieve kiembaan 
mutaties in een tweede cohort van patiënten. Dit cohort bestond uit 39 relatief jonge 
darmkankerpatiënten zonder polyposis, maar met tumoren zonder een DNA mismatch repair 
defect (de grootste subgroep van darmtumoren). Hierbij troffen we een kiembaan deletie aan 
in het BUB1 gen in één van de patiënten. BUB1 speelt een belangrijke rol in de controle van de 
celdeling, het zogenaamde ‘spindle assembly checkpoint’ (SAC). SAC is vereist voor een correcte 
segregatie van chromosomen gedurende de mitose en eerdere studies hebben aangetoond 
dat verstoring van de correcte werking van SAC kan leiden tot een onjuiste verdeling van 
chromosomen over de dochtercellen, hetgeen kan resulteren in aneuploidieën. Aneuploidieën 
zijn een belangrijk kenmerk van kanker, en deze werden inderdaad significant vaker dan 
normaal aangetroffen in lymfocyten en primaire huidbiopten afkomstig van de patiënt met 
de BUB1 deletie. Om te bepalen of deze toename van aneuploidieën volledig kan worden 
toegeschreven aan een kiembaan defect in BUB1 werd een isogene cellijn gemaakt met een 
mono-allelische deletie in BUB1. In deze cellijn werd vervolgens, zoals verwacht, een significante 
toename van aneuploidieën waargenomen ten opzichte van de maternale cellijn. Met behulp 
van ‘whole-exome sequencing’ (WES) en locus-gerichte ‘copy number’ en mutatie screening in 
een additioneel cohort van jonge darmkankerpatiënten werden vervolgens twee truncerende 
kiembaan mutaties in BUB1 en drie geconserveerde kiembaan missense mutaties in BUB3 
gevonden. De daarop volgende cosegregatie analyses lieten zien dat niet alle dragers van een 
pathogene mutatie in BUB1 of BUB3 daadwerkelijk darmkanker ontwikkelden. Hieruit hebben 
wij geconcludeerd dat, vergelijkbaar met dragers van een FOCAD deletie, ook dragers van een 
kiembaan mutatie in een SAC gen een matig verhoogd risico hebben op het ontwikkelen van 
darmkanker.
 Onze zoektocht heeft tevens geleid tot de identificatie van een genetische afwijking 
die leidt tot een sterk verhoogd (hoog penetrant) risico op adenomateuze polyposis en 
darmkanker. De ontdekking van het betrokken gen, het ‘base excision repair’ (BER) gen NTHL1, 
wordt beschreven in Hoofdstuk 4. Met behulp van ‘whole-exome sequencing’ vonden we 
een homozygote stop mutatie (p.Q90*) in dit gen in 4 individuen uit 3 onafhankelijke families. 
Cosegregatie analyse in deze families toonde aan dat alle familieleden waarbij deze NTHL1 
kiembaan mutatie homozygoot aanwezig was adenomateuze darmpoliepen ontwikkelden. 
Het merendeel van deze patiënten had tevens een darmtumor ontwikkeld. De darmtumoren 
die nader konden worden onderzocht bleken significant verrijkt voor somatische C:G naar T:A 
transities, wat overeenkomt met een defect in de BER pathway. Opvallend was bovendien dat 
alle vrouwelijke dragers van de homozygote p.Q90* NTHL1 mutatie een (pre)maligne vorm 
van endometrium laesies hadden ontwikkeld. Dit suggereert dat deze patiënten niet alleen een 
verhoogd risico hebben op het ontwikkelen van darmkanker, maar mogelijk ook andere vormen 
van kanker. Onze studie heeft directe klinische relevantie omdat de oorzaak voor een deel van 
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de eerder onverklaarde polyposis en darmkanker patiënten nu opgehelderd is en daarmee de 
klinische begeleiding van zowel deze patiënten als hun familieleden mogelijk is geworden. In 
analogie met de eerder beschreven polyposis syndromen hebben we voor dit subtype de naam 
NTHL1-associated polyposis (NAP) voorgesteld.
 Ondanks de ontdekking van NAP bleef een deel van het door ons bestudeerde 
cohort van 47 adenomateuze polyposis patiënten nog steeds onverklaard. Om na te gaan of 
we additionele causatieve kiembaan mutaties zouden kunnen detecteren in deze onverklaarde 
groep werd een gedetailleerde data analyse uitgevoerd (Hoofdstuk 5). Allereerst werd 
nagegaan of we potentieel pathogene varianten in bekende polyposis en darmkanker 
predispositie genen konden identificeren. In twee patiënten werden inderdaad mogelijk 
pathogene varianten gevonden in de ‘proofreading’ domeinen van de POLE en POLD1 genen. 
Pathogene mutaties in deze genen leiden tot PPAP. Verder beschrijven wij in dit hoofdstuk 
de identificatie van verschillende kandidaat genen voor de ontwikkeling van adenomateuze 
polyposis en darmkanker. In twee patiënten werd een ‘frameshift’ mutatie gevonden in ATM, 
een gen dat codeert voor een serine/threonine kinase betrokken bij DNA reparatie (‘repair’). Er 
zijn echter grootschalige vervolgstudies nodig om te bevestigen of mutaties in deze kandidaat 
genen inderdaad een rol spelen in de ontwikkeling van adenomateuze darmpoliepen en 
darmtumoren.
 Onze ontdekking dat de homozygote p.Q90* nonsense mutatie in NTHL1 leidt tot 
het ontwikkelen van adenomateuze darmpoliepen en darmtumoren riep ook enkele nieuwe 
vragen op. Naast het feit dat de prevalentie van NAP nog nader dient te worden bepaald, dringt 
zich de vraag op of kiembaan defecten in andere BER genen ook resulteren in de ontwikkeling 
van adenomateuze darmpoliepen en darmtumoren. Naast NTHL1 en MUTYH zijn immers nog 
negen andere BER (DNA glycosylase) genen beschreven, te weten MBD4, MPG, NEIL1, NEIL2, 
NEIL3, OGG1, SMUG1, TDG en UNG. In Hoofdstuk 6 wordt beschreven dat door middel van 
‘targeted sequencing’ met behulp van ‘molecular inversion probes’ (MIPs) is gezocht naar 
kiembaan afwijkingen in deze BER genen in een cohort van 701 polyposis patiënten. Deze 
zoektocht heeft geresulteerd in de identificatie van één patiënt waarbij de p.Q90* mutatie 
in NTHL1, wederom homozygoot, aanwezig was in de kiembaan. Cosegregatie analyse in 
de bijbehorende familie heeft geresulteerd in de identificatie van een onafhankelijke vierde 
NAP familie. Gebaseerd op deze resultaten kan geconcludeerd worden dat NAP weliswaar 
relatief zeldzaam is, maar desalniettemin meerdere malen werd aangetroffen in cohorten van 
onverklaarde polyposis patiënten. In tegenstelling tot NTHL1 werden er geen samengesteld 
heterozygote of homozygote pathogene kiembaan varianten aangetroffen in de andere BER 
genen in het cohort van 701 patiënten. Heterozygote truncerende varianten werden wel 
aangetroffen in de MBD4, NEIL1, OGG1 en UNG genen, maar de klinische relevantie van deze 
varianten is op dit moment nog niet duidelijk. Vervolgstudies waarbij nog grotere cohorten 
onverklaarde polyposis patiënten worden gescreend op het voorkomen van kiembaan mutaties 
in de verschillende BER genen zijn nodig om de potentiële rol van deze genen op het ontstaan 
van darmpoliepen en darmtumoren definitief vast te stellen. 
 In Hoofdstuk 7 wordt een familie beschreven waarin een andere histologische 
subklasse van darmpoliepen voorkomt, zogenaamde ‘serrated’ poliepen. De ontwikkeling van 
deze poliepen staat bekend als het serrated polyposis syndroom. Voor het serrated polyposis 
syndroom zijn, in tegenstelling tot de adenomateuze polyposis syndromen, tot nu toe geen 
hoog penetrante causatieve kiembaan mutaties beschreven. Wij hebben WES uitgevoerd 
op DNA van zes aangedane leden uit deze familie met een duidelijk autosomaal dominant 
overervingpatroon. Op basis hiervan werd geen causatieve kiembaan mutatie gevonden die de 
autosomaal dominante overerving van serrated polyposis in deze familie zou kunnen verklaren. 
Wel toonden wij aan dat een eerder beschreven kiembaan variant die werd geassocieerd met 
het ontwikkelen van serrated poliepen, een nonsense mutatie in het PIF1 gen, een benigne 
variant betreft die veelvuldig wordt aangetroffen in de Nederlandse populatie (‘minor allele 
frequency’ > 0.01). Deze studie laat zien dat WES, hoewel succesvol toegepast in de identificatie 
van NTHL1, niet altijd zal leiden tot de identificatie van de causatieve kiembaan mutatie in 
onverklaarde polyposis patiënten en/of families. De recente introductie van ‘whole-genome 
sequencing’ (WGS) biedt wellicht wel de mogelijkheid om de causatieve kiembaan mutatie in 
deze familie te identificeren. Verwacht wordt dat deze techniek in de nabije toekomst breed 
ingezet zal kunnen worden om kiembaan defecten te identificeren die een belangrijke rol spelen 
bij het ontstaan van darmpoliepen en darmtumoren.
 In dit proefschrift wordt de identificatie van nieuwe genen met een matige tot hoge 
penetrantie voor het ontwikkelen van darmpoliepen en darmtumoren beschreven. Ondanks de 
introductie van genoom-brede sequencing technieken zoals WES blijft een significant deel van 
de polyposis en darmkanker patiënten toch nog onverklaard. Belangrijke oorzaken hiervan zijn 
het heterogene karakter van darmkanker, de verwachtte betrokkenheid van (extreem) zeldzame 
kiembaan varianten en de bijdrage van laag tot gematigd penetrante kiembaan varianten. In 
Hoofdstuk 8 geef ik een uitgebreide uiteenzetting van de resultaten die gepresenteerd zijn in 
dit proefschrift en spreek ik mijn verwachtingen uit over de identificatie van nieuwe genen die 
ten grondslag liggen aan een matig tot sterk verhoogd risico op het ontwikkelen van polyposis 
en darmkanker.
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Aangekomen bij het afronden van mijn proefschrift is dit het ideale moment om alle 
personen te bedanken die een (significante) bijdrage hebben geleverd aan het tot stand komen 
van dit proefschrift. Hieronder volgt een summiere opsomming van personen die ik graag 
persoonlijk wil bedanken. 
Dit proefschrift was natuurlijk nooit tot stand gekomen zonder de waardevolle input 
en begeleiding van mijn promotoren en co-promotoren. 
Roland. Jij bent de eerste die ik hier wil bedanken voor een onvergetelijke bijdrage 
aan dit proefschrift. Niet alleen heb je mij de kans geboden om als PhD student aan de slag te 
gaan, je was gedurende deze jaren ook een fantastische begeleider met een enorm gevoel voor 
(werk-gerelateerde) humor. Door de manier waarop jij sturing gaf aan de invulling van mijn 
PhD traject heb ik niet alleen enorm veel geleerd gedurende deze periode, ik kijk er ook met 
bijzonder veel plezier op terug. Ik wil je verder ook graag nog bedanken voor het feit dat je altijd 
bereikbaar was voor vragen; wat was het prettig dat die deur altijd open stond (en natuurlijk dat 
je echt altijd bereikbaar bent via e-mail). Ik ben blij dat ons werk niet alleen heeft geresulteerd in 
een alleraardigste publicatie in Nature Genetics, maar vooral ook heeft bijgedragen aan nieuwe 
mogelijkheden voor het onderzoek naar erfelijke polyposis en darmkanker. 
Ad. Wat zou iedere PhD student gebaat zijn met een promotor die zijn rol invult zoals 
jij dat hebt gedaan. Soms met oog voor details, maar nog vaker met de focus op het grotere 
geheel. Bewonderenswaardig was de wijze waarop je altijd snel en kundig feedback gaf op 
mijn manuscripten (inclusief de leermomentjes). Ook bij jou stond de deur altijd open voor 
vragen. Of het nu op een kort gesprekje ging of voor werkgerelateerde meetings, altijd was 
het leerzaam en gezellig. Uiteraard dien ik in mijn dankwoord, zoals het een promovendus van 
jou betaamt, ook te vermelden dat ik uitkijk naar het moment dat ik daadwerkelijk toetreed tot 
jouw eregalerij van gepromoveerden.
Nicoline. Met een meer dan gezonde dosis enthousiasme en een enorm hartelijk 
karakter heb je een grote rol gespeeld in mijn periode als PhD student. Natuurlijk wil ik je graag 
expliciet bedanken voor jouw rol in het polyposis project; wat een prachtige selectie patiënten 
en wat fijn dat er additionele mogelijkheden waren voor dit project. De beloning mocht er dan 
ook zeker zijn! Meermaals had ik het genoegen om een verscheidenheid aan onderwerpen 
met je te mogen bespreken; wat vooral prettig was is dat we het uiteindelijk eigenlijk altijd wel 
met elkaar eens waren (behalve dan over voetbal). Bedankt voor de belangrijke rol die je hebt 
gespeeld gedurende deze jaren en alle leerzame, maar vooral leuke, momenten.
Marjolijn. Ik heb jou de afgelopen jaren leren kennen als een bijzonder aardige en 
integere co-promoter. Bewonderenswaardig was altijd hoe je een enorm scherp oog voor detail 
hebt; je hebt me meermaals weten te verbazen met de details die je vaak nog wist te verbeteren 
in manuscripten. Zelfs de supplementaire data was niet veilig voor deze correctierondes. 
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Buiten het feit dat je een bijzonder deskundige professional bent, heb je ook aandacht voor 
mijn persoonlijke ontwikkeling. Dat laatste heb ik altijd enorm gewaardeerd en waardeer ik, 
uiteraard, nog steeds. Natuurlijk wil ik je bedanken voor jouw bijdrage aan dit proefschrift, maar 
tevens ook voor de mogelijkheid die je me geboden hebt om na mijn PhD bij jou aan de slag te 
gaan als postdoc.
De volgende twee personen, welke niet geheel toevallig de rol van paranimf toegewezen 
hebben gekregen, zou ik graag willen bedanken voor hun belangrijke bijdrage gedurende de 
laatste jaren. Michael. Wellicht wat onverwacht, maar ik wil ook jou graag eerst bedanken 
voor een daadwerkelijk werk gerelateerde bijdrage gedurende mijn PhD periode: bedankt dat 
je zelfs in het weekend nog terug kwam naar de afdeling om meerdere IonTorrent runs voor 
mij in te zetten, dat heb ik echt enorm gewaardeerd. Wat iets minder onverwacht zal zijn is dat 
ik je ook graag wil bedanken voor de sociale inbreng die je hebt geleverd gedurende mijn tijd 
als PhD student. Alsof de overwinningen op al die fabelachtig interessante frivole avonden nog 
niet voldoende waren, konden we vaak ook eindeloos van gedachten wisselen over vergeten 
pareltjes uit de moderne muziekgeschiedenis. Prachtig waren de momenten dat we per ongeluk 
in Lent eindigden, het leedvermaak tijdens voetbalpotjes in het park en alle gesprekken zonder 
inhoud die we hebben gehad. Helaas schrijft het protocol voor dat je tijdelijke functie wordt 
omschreven als paranimf, anders was het natuurlijk gewoon Baas geworden. Eveline. Wat was 
het prettig en handig dat je in de laatste periode van mijn PhD (lees: ruim twee jaar) bij mijn 
projecten werd betrokken. Hoewel ik me kan voorstellen dat het voor jou even wennen was 
(celkweek), niet alle experimenten even succesvol waren (comet assay) en ik nou eenmaal graag 
flauwe grapjes maak (sorry!), je bleef altijd opvallend opgewekt. Sterker nog, de talloze praatjes 
op het lab en, vooral, alle keren buiten lunchen waren enorm gezellig. Mijns inziens is het ook 
een bijzonder knappe prestatie hoe we de gezellige momenten zo goed wisten te combineren 
met werk-gerelateerde zaken (zoals de zoektocht naar Nootjes, Tijgernootjes, Heartbreakers en 
Lolly’s in de supermarkt).
Ik had vast en zeker niet zo veel plezier beleefd aan mijn periode als PhD student 
zonder alle leden van onze Oncogenetica groep of andere personen welke werkzaam waren 
aan het erfelijke darmkanker project. Richarda. Wat was het fijn dat jij als postdoc op het CRC 
project werkte. Behulpzaam, gezellig maar ook vaak tijd voor (iets) serieuzere gesprekken. De 
beloning voor alle momenten waarop we samen hebben gewerkt aan verscheidene projecten 
betaalde zich niet alleen uit in verscheidene co-auteurschappen op meerdere papers, maar 
heeft me ook meer dan eens chocolade (Toblerone) en andere versnaperingen opgeleverd 
(bijvoorbeeld de bubbels in Wenen voor de NTHL1 paper). Ik wil je dan ook graag bedanken 
voor de fijne samenwerking en alle leuke en gezellige momenten. Lilian. Wat had ik toch een 
geluk dat jij mijn buurvrouw werd op het lab. Vooral in mijn eerste PhD jaren, toen FOCAD nog 
gewoon KIAA1797 heette, heb je me enorm vaak geholpen. Bedankt voor alle hulp, ik denk 
ook zeker namens mijn stagiaires, en de gezellige praatjes op het lab. Marc. Bedankt voor 
de leuke gesprekken, vooral op het lab als het weer eens laat werd en er nog net dat laatste 
experiment ingezet moest worden. Met de afronding van jouw PhD traject in zicht komt er ook 
voor jou een mooie afronding van een tijdperk aan! Ram. Uiteraard wil ik jou bedanken voor 
het grondwerk wat je verricht hebt waaruit uiteindelijk onze FOCAD paper is voortgekomen. 
Maar ook heb ik met je kunnen lachen, bijvoorbeeld op weg naar de Rolduc Genetica Retraite 
(mijn eerste meeting als PhD student) en tijdens jouw vrijgezellenfeestje. Junxiao. I would like 
to thank you for your valuable contributions to the CRC projects. Although no NAP patients 
have been identified in China yet, I am sure that your efforts have resolved and will resolve a 
large number of unexplained polyposis and CRC patients due to germline mutations in known 
and novel predisposing genes. Marjolijn J. Bedankt voor de belangrijke klinische input die 
je hebt geleverd. Specifiek wil ik je nogmaals bedanken voor de assertieve manier waarop je 
additionele informatie hebt verkregen van een NAP familie; hiermee werd de co-segregatie 
volledig in kaart gebracht en werd het NTHL1 manuscript nog sterker. Asiye. Thank you for 
your enthusiasm regarding the base excision repair project. It was really nice to meet you during 
your stay in the Netherlands and I really enjoyed our talks. Yasmijn. Wat was het leuk om 
samen te werken aan Familie de Groot (waarvan niet bij iedereen direct duidelijk was dat het 
hier, uiteraard, een fictieve naam betrof). Hoewel we de causatieve kiembaan variant helaas niet 
hebben kunnen ontdekken, beschouw ik deze samenwerking tussen MDL en Genetica zeker als 
zeer succesvol. Het was enorm leerzaam om samen te werken met iemand die vanuit een ander 
(klinisch) perspectief naar onderzoeksvragen kijkt, vooral ook omdat het altijd gezellig was.
Gelukkig is de Oncogenetica groep nog iets groter dan alleen bovenstaande personen 
die werken aan het erfelijke darmkanker project. Ondanks dat het onderwerp afwijkend is, 
hebben onderstaande personen (in)direct bijgedragen aan mijn proefschrift. Simon. Wat heb 
ik kunnen lachen met je op het lab, vooral ook wanneer je merkte dat het voor omstanders 
wellicht enigszins ongemakkelijk of onduidelijk werd. Hoewel de meeste opmerkingen en 
grappen wellicht het beste passen bij de vrijdagmiddag, ben ik blij dat je ze de hele week 
door maakte. Hopelijk heb je me die nooit gegeven housewarming enigszins kunnen vergeven, 
de gordijnen zijn wel echt prachtig geworden trouwens. Esmé. Ondanks de verschillende 
onderwerpen waaraan we werkten, hebben we bijzonder interessante gesprekken gehad over 
het leven van de onderzoeker. Echter wil ik je natuurlijk ook zeker bedanken voor alle andere 
leuke gesprekken die we gedurende de laatste jaren gehad hebben. Jiangyan. I really enjoyed 
your positive attitude during the last years. I would like to thank you for all the laughs and I am 
quite happy that you knew how to recognize the moments I was just kidding. Zeljko. Of course I 
would like to thank you for the extensive amount of time that we have shared in the same office 
(approximately four weeks?). In addition, I would like to thank you for the nice conversations 
we had during the last year. Anke en Diederik. Hoewel jullie officieel natuurlijk alweer even 
weg zijn uit onze Oncogenetica groep, zijn jullie wat mij betreft nooit echt vertrokken. Gelukkig 
hebben we af en toe nog tijd om even bij te kletsen.
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Enkele (voormalige) collegae bleken over dezelfde hobby te beschikken en hebben, 
daarmee, niet alleen op het werk maar ook daarbuiten een belangrijke rol gespeeld. Joep. 
Fantastisch waren de werk gerelateerde uitstapjes zoals de jaarlijkse PhD retreat. Immer deelde 
je met ons jouw bijzonder interessante gedachten en theorieën; het maakt voetbal kijken zo 
veel spannender als doelpunten van enkele spelers gewoon niet tellen. Favoriet zullen ze nooit 
worden, maar je hebt ons zelfs kennis laten maken met de vegetarische (pizza) keuken. Als 
ik nu terugkijk op de afgelopen jaren, dan lijkt een bedankje me hier zeker op zijn plaats. 
Eugène. Ten eerste wil ik je graag bedanken voor alle momenten dat je me hebt geholpen 
met het beantwoorden van mijn vragen op het gebied van de bio-informatica. Hoewel het 
voor mij af en toe overkwam als goochelen, was ik altijd blij als je de juiste toverspreuk weer 
uitgesproken had. Verder heeft jouw sociale karakter bijgedragen aan het plezier wat ik aan 
mijn PhD periode heb beleefd. Als de ongeëvenaarde Mr. President heb je de nodige voetbal 
partijtjes weten te regelen. Toen we vervolgens besloten het voetbal een fysiek minder actief 
karakter te geven regelde jij vaak de locatie en de versnaperingen. Bedankt! Djie. Gelukkig 
ben jij, in tegenstelling tot Joep en Eugene, als enige echte bio-informaticus (sorry Michael) van 
dit besloten gezelschap nog werkzaam in het Radboudumc. Fijn dat jij nog altijd bereid bent 
om direct antwoord te geven op vragen op het gebied van de bio-informatica. Bart. Zonder 
jouw inbreng waren vele avonden vast wat anders verlopen. Bedankt voor de rust die je altijd 
uitstraalde en de hartverwarmende dialogen die we, mede dankzij jou, hebben kunnen voeren.
Gedurende mijn periode als PhD student is, naast het lab, ook mijn werkplek het terrein 
geweest waar ik de nodige uurtjes achter de computer heb doorgebracht. De personen met wie 
ik mijn kamer deelde hebben daardoor ook een belangrijke rol gespeeld gedurende de laatste 
jaren. Ingrid. Kamergenootje vanaf het eerste uur. Vanaf mijn eerste werkdag tot en met het 
moment dat je vertrok uit Nijmegen hebben we dezelfde kantoorruimte gedeeld. Wat hebben 
we vaak kunnen lachen (variërend van de PhD comics, muziekkeuzes, het quotelijstje tot en met 
de grootste flauwekul). Ik kan natuurlijk niet anders dan je ook bedanken voor alle koffie die 
je voor me hebt gehaald; gelukkig heb ik vrij snel na jouw vertrek ontdekt waar de automaat 
staat. Bedankt voor de leuke, roze-gekleurde en gezellige momenten. Arjen en Bastiaan. Wat 
was het fijn om met jullie een kamer te delen toen ik startte met mijn PhD. Met jullie uitgebreide 
kennis over de genetica en pathologie konden jullie meermaals mijn vragen beantwoorden. 
Heleen. Bedankt voor de gezellige gesprekken en het inzicht dat je ons altijd hebt verschaft in 
de diagnostiek. Zo was het wel bijzonder leuk om te zien hoe snel een project van mijn bureau 
(identificatie NTHL1; research) kon leiden tot nieuwe aanvragen op jouw bureau (NTHL1 als te 
testen causatief gen voor polyposis en CRC; diagnostiek). Riki. Als meest recente aanwinst op 
mijn lijstje van kamergenoten heb jij je nu al bewezen als leuke en gezellige kamergenoot. Ik wil 
je graag bedanken voor de oprechte interesse die je altijd toont.
Werken bij de afdeling Genetica is een echte teamsport. Zo wordt er meegedacht met 
fraaie wetenschappelijke hypotheses tot gevolg, staan vele personen binnen de genetica voor 
je klaar om je te helpen om problemen op te lossen en wordt er ook tijd vrijgemaakt voor het 
minstens zo belangrijke sociale aspect (bv. Aesculaaf, borrels, etc.). De volgende personen wil 
ik graag bedanken voor het vervullen van een belangrijke rol bij minimaal één van hierboven 
beschreven onderwerpen. Ten eerste wil ik bij deze de epigenetica groep, bestaande uit Armen, 
Sabrina, Renske en Marcel, graag bedanken. Dit proefschrift zou verder niet mogelijk zijn 
geweest zonder de waardevolle hulp en input van bio-informatici: Christian, Maartje, Jayne, 
Nienke en Stefan, bedankt! Ten slotte wil ik graag Ineke, Doménique, Miranda, Han, Joris, 
Chella, Bjorn, Rocío, Petra (monsieur Robert blijft prima klinken), Marloes, Irene, Konny, 
Peer(ke) (dat biertje in Jan van Hoek moeten we echt nog eens regelen), Thessa, Lisenka en 
Alex bedanken.
Gedurende mijn periode als PhD student heb ik de eer gehad om supervisie te geven 
aan drie getalenteerde stagiaires. Erik. Wat had ik een geluk dat mijn eerste stagiair iemand 
was met een enorme hoeveelheid ervaring op het lab. Bedankt voor jouw meer dan succesvolle 
bijdrage in het opzetten van het HR project; de HCT116 cellijn is van grote waarde geweest voor 
het BUB project. Caro. Wat was het fijn dat jij zo zelfstandig en kundig op het lab kon werken. 
Hoewel het project niet de doorbraak heeft opgeleverd waar we op hoopten, heb jij je wel 
degelijk weten te bewijzen als een aanwinst voor ieder lab. Sigrid. Het enthousiasme waarmee 
jij stage hebt gelopen bij de afdeling Genetica is bewonderenswaardig. Het (ambitieuze) 
resultaat waar we op hoopten is misschien nog niet behaald, maar ik denk dat we toch echt 
wel kunnen spreken van een geslaagde stage.
Natuurlijk zijn er ook meerdere personen uit andere (onderzoeks)groepen en 
afdelingen die mij ondersteund hebben gedurende bepaalde projecten of op een andere manier 
een belangrijke bijdrage hebben geleverd. Ondanks dat het ondoenlijk is iedereen te noemen, 
wil ik hier toch graag Lisette, Erwin en Stef (o.a. Gateway cloneren), Mieke (celkweek), 
Elisa (FOCAD IHC), Shannon (DNA isolatie poliepen/tumoren), Hicham (diagnostiek), Neeltje 
(diagnostiek) en Annemiek (CCP sequencing) expliciet bedanken. Tevens wil ik graag Erik-
Jan bedanken; zijn enthousiaste en kundige begeleiding gedurende mijn masterstage heeft 
een belangrijke rol gespeeld bij mijn uiteindelijke keuze om promotieonderzoek op de afdeling 
Genetica uit te gaan voeren.
Uiteraard zijn er nog vele collegae die ik zou willen bedanken voor zijn of haar bijdrage 
gedurende de afgelopen jaren. Echter, zoals hierboven aangegeven, is het praktisch ondoenlijk 
hier iedereen bij naam te noemen. Voor diegene die ik ten onrechte niet heb genoemd: bij deze 
wil ik jou persoonlijk bedanken voor jouw significante bijdrage aan het tot stand komen van 
dit proefschrift.
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De bijdrage van mijn ouders, Henk en Joke, op het ontstaan van dit proefschrift is 
met geen woorden uit te drukken. Zonder jullie onvoorwaardelijke steun, liefde en vertrouwen 
was ik nooit de persoon geworden die ik vandaag de dag ben en was dit proefschrift er nooit 
gekomen. Jullie mogen enorm trots zijn op de wijze waarop jullie mij, Ramon en Jochem 
hebben laten opgroeien en daarmee een zeer stabiele basis voor de toekomst hebben gegeven. 
Natuurlijk ben ik trots op dit proefschrift, maar ik ben nog vele malen trotser op jullie en het feit 
dat ik jullie zoon ben.
Tenslotte, zoals beloofd als laatste, wil ik graag mijn lieve Carlijn bedanken. Nimmer 
was het een probleem als ik weer eens (veel te) laat vanuit mijn werk naar huis kwam, nog 
“even” aan het werk moest in het weekend of dat we in Nijmegen gingen wonen. Dankzij 
jou is deze periode, die we met dit boekje af gaan sluiten, een prachtige periode in mijn leven 
geworden. Terugkijkend hebben we al een fantastische periode achter de rug samen, echter 
ben ik er van overtuigd dat onze (gehuwde) toekomst minimaal net zo mooi wordt. Bij deze wil 
ik je dus niet alleen bedanken voor jouw bijdrage aan het tot stand komen van dit proefschrift, 
maar vooral voor al het geluk dat jij in mijn leven brengt.
Verder wil ik bij deze vrienden en familie bedanken die, soms op de achtergrond, een 
bijzonder grote rol hebben gespeeld. 
Ten eerste wil ik de vrienden bedanken die ik heb leren kennen tijdens mijn tijd in 
Nijmegen; Nick, Jeroen, Sasha en Robin. Ik heb genoten van alle mooie momenten in het 
cultuurcafé, Barca café en gedurende de verjaardagsfeestjes. Uiteraard wil ik ook graag mijn 
vrienden bedanken waarmee ik reeds sinds de middelbare school veel mooie momenten heb 
beleefd: Ken (ik kijk nog altijd met enorm veel plezier terug op onze gezamenlijk studietijd), 
Joost, René, Machiel en Twan. 
Emmy, Freek, Evelien, Rob, Laura en Jeroen, bedankt voor alle interesse gedurende 
de afgelopen jaren; dat was echt een enorme steun in de rug. Bedankt dat jullie mij steeds maar 
weer lieten vertellen over hetgeen waarmee ik bezig was (hoewel het presenteren van mijn 
ESHG presentatie wellicht net wat te veel van het goede was). Ik ben blij dat ik jullie heb leren 
kennen en ben jullie dan ook echt als mijn vrienden gaan beschouwen. Hopelijk begrijpen jullie 
na vandaag nog iets beter waarmee ik mij de afgelopen jaren heb beziggehouden (hint: iets 
met DNA en celletjes).
Natuurlijk wil ik alle familieleden bedanken voor alle interesse en steun. In het bijzonder 
wil ik Wim bedanken voor de interesse in mijn promotietraject. Verder wil ik hier nog graag 
expliciet mijn peettante Ine bedanken voor de oprechte interesse gedurende de afgelopen 
jaren. Ik vind het bijzonder fijn en lovenswaardig dat je nog altijd op de hoogte blijft en wilt 
blijven van hetgeen waarmee ik bezig ben.
Als laatste wil ik graag de personen bedanken die zeer dicht bij me staan. Om te 
beginnen wil ik graag mijn toekomstige schoonouders Jan en Kitty bedanken. Niet alleen voel 
ik me altijd welkom en gewaardeerd en hadden jullie immer interesse in de voortgang van mijn 
PhD traject, maar ook is dankzij jullie Carlijn in mijn leven; daar ben ik jullie uiteraard het meeste 
dankbaar voor. 
Jochem en Ramon, Elske, Veerle en Dex, iedere keer als we elkaar zien is het 
weer gezellig en vertrouwd. Dat soort momenten maakt iedere keer weer duidelijk wat echt 
belangrijk is in het leven. Jochem en Ramon, als broers spelen jullie natuurlijk al sinds lange tijd 
een bijzonder belangrijke rol in mijn leven. Of ik zo lang ben blijven studeren omdat we vroeger 
altijd schooltje (moesten) spelen weet ik niet zeker (we voetbalden immers ook veel; maar een 
professionele voetbalcarrière is er ook nooit van gekomen), maar een feit is wel dat jullie een 
belangrijke rol hebben gespeeld in het ontstaan van dit proefschrift. Hopelijk blijft het contact 
altijd zo goed als dat het nu is en blijven jullie, naast mijn broers, ook mijn beste vrienden. 
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Robbert Weren werd geboren op 13 december 1985 te Heythuysen. Na het behalen 
van zijn VWO diploma aan het St.-Willibrord Gymnasium te Deurne in 2004 is hij gestart 
met de studie medische biologie aan de Radboud Universiteit Nijmegen. Als onderdeel van 
deze studie heeft hij twee masterstages voltooid. Tijdens zijn eerste masterstage, uitgevoerd 
op de afdelingen Genetica (Radboudumc, Nijmegen) en Fysiology (RIMLS, Nijmegen), heeft 
hij gewerkt aan de functionele karakterisering van kiembaan mutaties in het CLCNKB gen 
welke zouden kunnen leiden tot de ontwikkeling van Barrter Syndroom type III. Zijn tweede 
masterstage werd voltooid op de afdeling Celbiologie (FNWI, Radboud Universiteit) waarbij de 
ligand geïnduceerde internalisatie van de tyrosine kinase receptor ERBB4 werd bestudeerd. Na 
het afronden van zijn universitaire studie is hij gestart als onderzoeker in opleiding (PhD student) 
op de afdeling Genetica (Radboudumc, Nijmegen). Onder supervisie van dr. R.P. Kuiper, Prof. 
dr. A. Geurts van Kessel, Prof. dr. N. Hoogerbrugge en dr. M.J.L. Ligtenberg heeft hij onderzoek 
gedaan naar de identificatie van kiembaan mutaties die ten grondslag kunnen liggen aan het 
ontstaan van darmpoliepen en darmtumoren. 
Gedurende zijn PhD periode won hij een prijs voor de beste laptop presentatie tijdens 
de Radboudumc Oncology Science Day (2014), een prijs voor de beste publicatie van het 
Radboudumc onderzoeksthema Gastrointestinale tumoren (2016) en de RIMLS ‘breakthrough’ 
paper prijs 2015. Tevens mocht hij een plenaire presentatie geven in de ‘highlight’ sessie van 
de European Human Genetics Conference 2015 (Glasgow, Schotland) en werd hij aldaar 
genomineerd voor de Young Investigator Award.
 Sinds juli 2015 is Robbert werkzaam als wetenschappelijk onderzoeker (postdoc) op 
de afdeling Genetica (Radboudumc, Nijmegen) onder supervisie van dr. M.J.L. Ligtenberg.
